A Phase 2/3 interventional study of BNT162b1 and BNT162b2 in SARS-CoV-2 Infection and COVID-19, sponsored by BioNTech SE. Completed at 175 sites in 6 countries. Open to participants aged 12 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-25.
Sponsored by BioNTech SE · Phase 2/3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing BNT162 Vaccine in COVID-19 — 4 open to participants now, 6 under way, 1 of them phase 3. BNT162 Vaccine · COVID-19.
Among the 54 studies testing BNT162 Vaccine in COVID-19, this one has the largest enrollment, is one of 5 that started in 2020, is one of 5 in phase 2/3, and was the 1st registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →4 of the 54 studies testing BNT162 Vaccine in COVID-19 are open now, in 6 countries. Recruiting first, the newest first:
BioNTech SE · Sites in United States
Ages 5+ · Healthy volunteers
BioNTech SE · Sites in United States
Ages 18–64 · Healthy volunteers
Technical University of Munich · Sites in Austria, Belgium, Germany and 2 more countries
Ages 3 mo–4 mo · Healthy volunteers
PharmaJet, Inc. · Sites in United States
Ages 18–50 · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 12 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 24 · Phase 3 23 · Phase 4 11
First in 2020; this study’s year is marked. 5 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 46,969 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 575 across the 54 interventional studies. Of the 39 that completed or were terminated, 28 (72%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 54 have an industry lead sponsor. The 10 most frequent:
BioNTech SE is the lead sponsor of 76 studies on the registry; 25 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 26 (79%) have results posted.
35 studies in COVID-19 by BioNTech SE: 2 open now, 2 under way, 1 of them phase 3. Of 31 finished, 25 (81%) have results posted.
Among the 35 studies in COVID-19 by BioNTech SE, this one has the largest enrollment, is one of 10 that started in 2020, is one of 5 in phase 2/3, and was the 1st registered.
BioNTech SE’s COVID-19 studies by the year they started, since 2020.
3 of the studies testing BNT162 Vaccine in COVID-19 that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-21 |
| NCT07730450BioNTech SEA Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age | 2027-08-20 |
| NCT06452654Technical University of MunichAnti-viral Action Against Type 1 Diabetes Autoimmunity | 2027-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 54 studies testing BNT162 Vaccine in COVID-19, from their registry updates:
Among BioNTech SE’s 35 in COVID-19:
This tab as a report to print or save as PDF → With an account.
This is a Phase 1/2/3, randomized, placebo-controlled, observer-blind, dose-finding, vaccine candidate-selection, and efficacy study in healthy individuals.
The study consists of 2 parts: Phase 1: to identify preferred vaccine candidate(s) and dose level(s); Phase 2/3: an expanded cohort and efficacy part.
The study will evaluate the safety, tolerability, and immunogenicity of 3 different SARS-CoV-2 RNA vaccine candidates against COVID-19 and the efficacy of 1 candidate:
The candidate selected for efficacy evaluation in Phase 2/3 is BNT162b2 at a dose of 30 µg.
Participants who originally received placebo will be offered the opportunity to receive BNT162b2 at defined points as part of the study.
In order to describe the boostability of BNT162, and potential heterologous protection against emerging SARS-CoV-2 VOCs, an additional dose of BNT162b2 at 30 µg will be given to Phase 1 participants approximately 6 to 12 months after their second dose of BNT162b1 or BNT162b2. This will provide an early assessment of the safety of a third dose of BNT162, as well as its immunogenicity.
The assessment of boostability will be further expanded in a subset of Phase 3 participants at selected sites in the US who will receive a third dose of BNT162b2 at 30 µg or a third and potentially a fourth dose of prototype BNT162b2VOC at 30 µg (BNT162b2s01, based upon the South African variant and hereafter referred to as BNT162b2SA). A further subset of Phase 3 participants will receive a third, lower, dose of BNT162b2 at 5 or 10 µg.
To further describe potential homologous and heterologous protection against emerging SARS-CoV-2 VOCs, a new cohort of participants will be enrolled who are COVID-19 vaccine-naïve (ie, BNT162b2-naïve) and have not experienced COVID-19. They will receive BNT162b2SA given as a 2-dose series, separated by 21 days.
To reflect current and anticipated recommendations for COVID 19 vaccine boosters, participants in C4591001 who meet specified recommendations and have not already received one, will be offered a third dose of BNT162b2 after their second dose of BNT162.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Newly enrolled participants enrolled to receive 2 doses of BNT162b2SA; male or female participants between the ages of 18 and 55 years, inclusive, at enrollment.
Existing participants enrolled to receive a third dose of BNT162b2 at 5 or 10 µg; male or female participants ≥18 years at rerandomization.
Note that participants \<18 years of age cannot be enrolled in the EU.
Exclusion Criteria:
Phase 1 only: Individuals at high risk for severe COVID-19, including those with any of the following risk factors:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: BNT162b1 · Biological: BNT162b2
Biological: BNT162b1 · Biological: BNT162b2
Biological: BNT162b1 · Biological: BNT162b2
Biological: BNT162b1 · Biological: BNT162b2
Biological: BNT162b1 · Biological: BNT162b2
Biological: BNT162b1 · Biological: BNT162b2
Biological: BNT162b2
Other: Placebo
Other: Placebo
Other: Placebo
Biological: BNT162b1
Participants ≥16 years of age who originally received placebo and are eligible for COVID-19 vaccination following any local or national recommendations will be offered the opportunity to receive BNT162b2 as part of the study.
Biological: BNT162b2
Participants ≥16 years of age who originally received placebo will be offered the opportunity to receive BNT162b2 at defined points as part of the study.
Biological: BNT162b2
Biological: BNT162b2
Biological: BNT162b2
Biological: BNT162b2SA
Biological: BNT162b2SA
Biological: BNT162b2SA
Biological: BNT162b2
Biological: BNT162b2
Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Phase 1
Local reactions included redness, swelling and, pain at the injection site, recorded by participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 centimeter (cm). Redness and swelling were graded as mild (greater than \[\>\] 2.0 to 5.0 cm), moderate (\> 5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), severe (prevents daily activity) and Grade 4 (emergency room visit or hospitalization for severe pain).
Time frame: Within 7 days after Dose 1
Percentage of Participants With Local Reactions Within 7 Days After Dose 2: Phase 1
Local reactions included redness, swelling and, pain at the injection site, recorded by participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\> 2.0 to 5.0 cm), moderate (\> 5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), severe (prevents daily activity) and Grade 4 (emergency room visit or hospitalization for severe pain).
Time frame: Within 7 days after Dose 2
Percentage of Participants With Systemic Events Within 7 Days After Dose 1: Phase 1
Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, new or worsened joint pain recorded by participants or parents/legal guardians of participants using e-diary. Fever=temperature \>=38.0 deg C categorized as \>=38.0 to 38.4, \>38.4 to 38.9, \>38.9 to 40.0 and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain graded as mild (does not interfere with activity), moderate (some interference with activity), severe (prevents daily routine activity), Grade 4 (Emergency room visit/hospitalization). Vomiting: mild (1-2 times in 24 hours\[h\]), moderate (\>2 times in 24 h), severe (requires IV hydration), Grade 4 (emergency room visit/hospitalization for hypotensive shock). Diarrhea: mild (2-3 loose stools in 24h), moderate (4-5 loose stools in 24 h), severe (\>=6 loose stools in 24 h) and Grade 4 (emergency room visit/hospitalization).
Time frame: Within 7 days after Dose 1
Percentage of Participants With Systemic Events Within 7 Days After Dose 2: Phase 1
Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, new or worsened joint pain recorded by participants or parents/legal guardians of participants using e-diary. Fever=temperature \>=38.0 deg C categorized as \>=38.0 to 38.4, \>38.4 to 38.9, \>38.9 to 40.0 and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain graded as mild (does not interfere with activity), moderate (some interference with activity), severe (prevents daily routine activity), Grade 4 (Emergency room visit/hospitalization). Vomiting: mild (1-2 times in 24 h), moderate (\>2 times in 24 h), severe (requires IV hydration), Grade 4 (emergency room visit/hospitalization for hypotensive shock). Diarrhea: mild (2-3 loose stools in 24h), moderate (4-5 loose stools in 24 h), severe (\>=6 loose stools in 24 h) and Grade 4 (emergency room visit/hospitalization).
Time frame: Within 7 days after Dose 2
Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: Phase 1
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. For BNT162b1 100 mcg, participants received one dose of 100 mcg, followed by one dose of 10 mcg.
Time frame: From Dose 1 to 1 Month After Dose 2
Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: Phase 1
An SAE was any untoward medical occurrence that occurred, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect and other important medical events. For BNT162b1 100 mcg, participants received one dose of 100 mcg, followed by one dose of 10 mcg.
Time frame: From Dose 1 to 6 Months After Dose 2
Percentage of Participants With Abnormalities in Hematology Parameters 1 Day After Dose 1: Phase 1
Hematology parameters that were assessed included hemoglobin, hematocrit, erythrocytes, Ery. mean corpuscular volume, Ery. mean corpuscular hemoglobin, Ery. mean corpuscular HGB concentration, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils and monocytes. Abnormal parameters were determined by following criteria: Hemoglobin : \<0.8x lower limit of normal (LLN), Hematocrit : \<0.8x LLN, Erythrocytes : \<0.8x LLN, Ery. Mean Corpuscular Volume: \<0.9x LLN, Ery. Mean Corpuscular Hemoglobin : \<0.9x LLN Ery. Mean Corpuscular HGB Concentration : \<0.9x LLN, Platelets : \<0.5x LLN, Leukocytes : \<0.6x LLN, Lymphocytes : \<0.8x LLN, Neutrophils : \<0.8x LLN, Basophils: \>1.2x upper limit of normal (ULN), Eosinophils \>1.2x ULN, Monocytes \>1.2x ULN. Only parameters with abnormal values were reported in this outcome measure.
Time frame: 1 Day After Dose 1
Percentage of Participants With Abnormalities in Hematology Parameters 7 Days After Dose 1: Phase 1
Hematology parameters that were assessed included hemoglobin, hematocrit, erythrocytes, Ery. mean corpuscular volume, Ery. mean corpuscular hemoglobin, Ery. mean corpuscular HGB concentration, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils and monocytes. Abnormal parameters were determined by following criteria: Hemoglobin : \<0.8x LLN, Hematocrit : \<0.8x LLN, Erythrocytes : \<0.8x LLN, Ery. Mean Corpuscular Volume: \<0.9x LLN, Ery. Mean Corpuscular Hemoglobin : \<0.9x LLN Ery. Mean Corpuscular HGB Concentration : \<0.9x LLN, Platelets : \<0.5x LLN, Leukocytes : \<0.6x LLN, Lymphocytes : \<0.8x LLN, Neutrophils : \<0.8x LLN, Basophils: \>1.2x ULN, Eosinophils \>1.2x ULN, Monocytes \>1.2x ULN. Only parameters with abnormal values were reported in this outcome measure.
Time frame: 7 Days After Dose 1
Percentage of Participants With Abnormalities in Hematology Parameters Before Dose 2: Phase 1
Hematology parameters that were assessed included hemoglobin, hematocrit, erythrocytes, Ery. mean corpuscular volume, Ery. mean corpuscular hemoglobin, Ery. mean corpuscular HGB concentration, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils and monocytes. Abnormal parameters were determined by following criteria: Hemoglobin : \<0.8x LLN, Hematocrit : \<0.8x LLN, Erythrocytes : \<0.8x LLN, Ery. Mean Corpuscular Volume: \<0.9x LLN, Ery. Mean Corpuscular Hemoglobin : \<0.9x LLN Ery. Mean Corpuscular HGB Concentration : \<0.9x LLN, Platelets : \<0.5x LLN, Leukocytes : \<0.6x LLN, Lymphocytes : \<0.8x LLN, Neutrophils : \<0.8x LLN, Basophils: \>1.2x ULN, Eosinophils \>1.2x ULN, Monocytes \>1.2x ULN. Only parameters with abnormal values were reported in this outcome measure.
Time frame: Before Dose 2
Percentage of Participants With Abnormalities in Hematology Parameters 7 Days After Dose 2: Phase 1
Hematology parameters that were assessed included hemoglobin, hematocrit, erythrocytes, Ery. mean corpuscular volume, Ery. mean corpuscular hemoglobin, Ery. mean corpuscular HGB concentration, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils and monocytes. Abnormal parameters were determined by following criteria: Hemoglobin : \<0.8x LLN, Hematocrit : \<0.8x LLN, Erythrocytes : \<0.8x LLN, Ery. Mean Corpuscular Volume: \<0.9x LLN, Ery. Mean Corpuscular Hemoglobin : \<0.9x LLN Ery. Mean Corpuscular HGB Concentration : \<0.9x LLN, Platelets : \<0.5x LLN, Leukocytes : \<0.6x LLN, Lymphocytes : \<0.8x LLN, Neutrophils : \<0.8x LLN, Basophils: \>1.2x ULN, Eosinophils \>1.2x ULN, Monocytes \>1.2x ULN. Only parameters with abnormal values were reported in this outcome measure.
Time frame: 7 Days After Dose 2
Percentage of Participants With Abnormalities in Chemistry Parameters 1 Day After Dose 1: Phase 1
Chemistry parameters that were assessed included bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), urea nitrogen, creatinine. Abnormal parameters were determined by following criteria: bilirubin: \>1.5x ULN, AST: \>3.0x ULN, ALT: \>3.0x ULN, ALP: \>3.0x ULN, urea nitrogen: \>1.3x ULN, creatinine: \>1.3x ULN. Abnormal values reported for this outcome measure are for bilirubin.
Time frame: 1 Day After Dose 1
Percentage of Participants With Abnormalities in Chemistry Parameters 7 Days After Dose 1: Phase 1
Chemistry parameters that were assessed included bilirubin, AST, ALT, ALP, urea nitrogen, creatinine. Abnormal parameters were determined by following criteria: bilirubin: \>1.5x ULN, AST: \>3.0x ULN, ALT: \>3.0x ULN, ALP: \>3.0x ULN, urea nitrogen: \>1.3x ULN, creatinine: \>1.3x ULN. Abnormal values reported for this outcome measure are for bilirubin.
Time frame: 7 Days After Dose 1
Percentage of Participants With Abnormalities in Chemistry Parameters Before Dose 2: Phase 1
Chemistry parameters that were assessed included bilirubin, AST, ALT, ALP, urea nitrogen, creatinine. Abnormal parameters were determined by following criteria: bilirubin: \>1.5x ULN, AST: \>3.0x ULN, ALT: \>3.0x ULN, ALP: \>3.0x ULN, urea nitrogen: \>1.3x ULN, creatinine: \>1.3x ULN. Abnormal values reported for this outcome measure are for bilirubin.
Time frame: Before Dose 2
Percentage of Participants With Abnormalities in Chemistry Parameters 7 Days After Dose 2: Phase 1
Chemistry parameters that were assessed included bilirubin, AST, ALT, ALP, urea nitrogen, creatinine. Abnormal parameters were determined by following criteria: bilirubin: \>1.5x ULN, AST: \>3.0x ULN, ALT: \>3.0x ULN, ALP: \>3.0x ULN, urea nitrogen: \>1.3x ULN, creatinine: \>1.3x ULN. Abnormal values reported for this outcome measure are for bilirubin.
Time frame: 7 Days After Dose 2
Percentage of Participants With Grade Shift in Hematology Parameters 1 Day After Dose 1: Phase 1
Percentage of participants with grade shift in hematology parameters reported in this outcome measure. Grade(G)1: Mild, G2:Moderate, G3:Severe, G4:potentially life threatening. Hemoglobin(Female): G1: 11.0 - 12.0grams per deciliter(g/dL), G2: 9.5 - 10.9, G3: 8.0 - 9.4, G4: \<8.0. Hemoglobin(Male): G1: 12.5 - 13.5, G2: 10.5 - 12.4, G3: 8.5 - 10.4, G4: \<8.5. WBC decrease(cells/mm3):G1: 2,500 - 3,500, G2: 1,500 - 2,499, G3: 1,000 - 1,499, G4: \<1,000 Lymphocytes decrease(cells/mm3): G1: 750 - 1,000, G2: 500 - 749, G3: 250 - 499, G4: \<250. Eosinophils(cells/mm3):G1: 650 - 1500, G2: 1501 - 5000, G3: \>5000, G4:Hypereosinophilic. Platelets decreased(cells/mm3): G1: 125,000 - 140,000, G2: 100,000 - 124,000, G3: 25,000 - 99,000, G4: \<25,000. Urea Nitrogen (mg/dl): G1: 23-26; G2:27-31; G3: \>31; G4: requires dialysis. Only parameters where grade shift was observed were reported.
Time frame: 1 Day After Dose 1
Percentage of Participants With Grade Shift in Hematology Parameters 7 Days After Dose 1: Phase 1
Percentage of participants with grade shift in hematology parameters reported in this outcome measure. Grade(G)1: Mild, G2:Moderate, G3:Severe, G4:potentially life threatening. Hemoglobin(Female): G1: 11.0 - 12.0grams per deciliter(g/dL), G2: 9.5 - 10.9, G3: 8.0 - 9.4, G4: \<8.0. Hemoglobin(Male): G1: 12.5 - 13.5, G2: 10.5 - 12.4, G3: 8.5 - 10.4, G4: \<8.5. WBC decrease(cells/mm3):G1: 2,500 - 3,500, G2: 1,500 - 2,499, G3: 1,000 - 1,499, G4: \<1,000 Lymphocytes decrease(cells/mm3): G1: 750 - 1,000, G2: 500 - 749, G3: 250 - 499, G4: \<250. Eosinophils(cells/mm3):G1: 650 - 1500, G2: 1501 - 5000, G3: \>5000, G4:Hypereosinophilic. Platelets decreased(cells/mm3): G1: 125,000 - 140,000, G2: 100,000 - 124,000, G3: 25,000 - 99,000, G4: \<25,000. Urea Nitrogen (mg/dl): G1: 23-26; G2:27-31; G3: \>31; G4: requires dialysis. Only parameters where grade shift was observed were reported.
Time frame: 7 Days After Dose 1
Percentage of Participants With Grade Shift in Hematology Parameters Before Dose 2: Phase 1
Percentage of participants with grade shift in hematology parameters reported in this outcome measure. Grade(G)1: Mild, G2:Moderate, G3:Severe, G4:potentially life threatening. Hemoglobin(Female): G1: 11.0 - 12.0grams per deciliter(g/dL), G2: 9.5 - 10.9, G3: 8.0 - 9.4, G4: \<8.0. Hemoglobin(Male): G1: 12.5 - 13.5, G2: 10.5 - 12.4, G3: 8.5 - 10.4, G4: \<8.5. WBC decrease(cells/mm3):G1: 2,500 - 3,500, G2: 1,500 - 2,499, G3: 1,000 - 1,499, G4: \<1,000 Lymphocytes decrease(cells/mm3): G1: 750 - 1,000, G2: 500 - 749, G3: 250 - 499, G4: \<250. Eosinophils(cells/mm3):G1: 650 - 1500, G2: 1501 - 5000, G3: \>5000, G4:Hypereosinophilic. Platelets decreased(cells/mm3): G1: 125,000 - 140,000, G2: 100,000 - 124,000, G3: 25,000 - 99,000, G4: \<25,000. Urea Nitrogen (mg/dl): G1: 23-26; G2:27-31; G3: \>31; G4: requires dialysis. Only parameters where grade shift was observed were reported.
Time frame: Before Dose 2
Percentage of Participants With Grade Shift in Hematology Parameters 7 Days After Dose 2: Phase 1
Percentage of participants with grade shift in hematology parameters reported in this outcome measure. Grade(G)1: Mild, G2:Moderate, G3:Severe, G4:potentially life threatening. Hemoglobin(Female): G1: 11.0 - 12.0grams per deciliter(g/dL), G2: 9.5 - 10.9, G3: 8.0 - 9.4, G4: \<8.0. Hemoglobin(Male): G1: 12.5 - 13.5, G2: 10.5 - 12.4, G3: 8.5 - 10.4, G4: \<8.5. WBC decrease(cells/mm3):G1: 2,500 - 3,500, G2: 1,500 - 2,499, G3: 1,000 - 1,499, G4: \<1,000 Lymphocytes decrease(cells/mm3): G1: 750 - 1,000, G2: 500 - 749, G3: 250 - 499, G4: \<250. Eosinophils(cells/mm3):G1: 650 - 1500, G2: 1501 - 5000, G3: \>5000, G4:Hypereosinophilic. Platelets decreased(cells/mm3): G1: 125,000 - 140,000, G2: 100,000 - 124,000, G3: 25,000 - 99,000, G4: \<25,000. Urea Nitrogen (mg/dl): G1: 23-26; G2:27-31; G3: \>31; G4: requires dialysis. Only parameters where grade shift was observed were reported.
Time frame: 7 Days After Dose 2
Percentage of Participants With Grade Shift in Chemistry Parameters 1 Day After Dose 1: Phase 1
Percentage of participants with grade shift in chemistry were reported in this outcome measure. G1: Mild, G2: Moderate, G3: Severe, G4: potentially life threatening. BUN(milligram per deciliter \[mg/dL\]): G1: 23 - 26, G2: 27 - 31, G3: \>31, G4: required dialysis. Creatinine(mg/dL): G1: 1.5 - 1.7, G2: 1.8 - 2.0, G3: 2.1 - 2.5, G4: \> 2.5 or required dialysis. Alkaline phosphate(increase by factor): G1: 1.1 - 2.0 x ULN G2: 2.1 - 3.0 x ULN G3: 3.1 -10 x ULN, G4: \>10 x ULN. Liver function tests(ALT, AST increase by factor): G1: 1.1 - 2.5 x ULN G2: 2.6 - 5.0 x ULN G3: 5.1 - 10 x ULN, G4: \>10 x ULN. Bilirubin(when accompanied by any increase in liver function test - increase by factor): G1: 1.1 - 1.25 x ULN G2: 1.26 - 1.5 x ULN G3: 1.51 - 1.75 x ULN, G4: \>1.75 x ULN. Bilirubin(when liver function test is normal - increase by factor): G1: 1.1 - 1.5 x ULN, G2: 1.6 - 2.0 x ULN, G3: 2.0 - 3.0 x ULN, G4: \>3.0 x ULN. Only parameters where grade shift was observed were reported.
Time frame: 1 Day After Dose 1
Percentage of Participants With Grade Shift in Chemistry Parameters 7 Days After Dose 1: Phase 1
Percentage of participants with grade shift in chemistry were reported in this outcome measure. G1: Mild, G2: Moderate, G3: Severe, G4: potentially life threatening. BUN(mg/dL): G1: 23 - 26, G2: 27 - 31, G3: \>31, G4: required dialysis. Creatinine(mg/dL): G1: 1.5 - 1.7, G2: 1.8 - 2.0, G3: 2.1 - 2.5, G4: \> 2.5 or required dialysis. Alkaline phosphate(increase by factor): G1: 1.1 - 2.0 x ULN G2: 2.1 - 3.0 x ULN G3: 3.1 -10 x ULN, G4: \>10 x ULN. Liver function tests(ALT, AST increase by factor): G1: 1.1 - 2.5 x ULN G2: 2.6 - 5.0 x ULN G3: 5.1 - 10 x ULN, G4: \>10 x ULN. Bilirubin(when accompanied by any increase in liver function test - increase by factor): G1: 1.1 - 1.25 x ULN G2: 1.26 - 1.5 x ULN G3: 1.51 - 1.75 x ULN, G4: \>1.75 x ULN. Bilirubin(when liver function test is normal - increase by factor): G1: 1.1 - 1.5 x ULN, G2: 1.6 - 2.0 x ULN, G3: 2.0 - 3.0 x ULN, G4: \>3.0 x ULN. Only parameters where grade shift was observed were reported.
Time frame: 7 Days After Dose 1
Percentage of Participants With Grade Shift in Chemistry Parameters Before Dose 2: Phase 1
Percentage of participants with grade shift in chemistry were reported in this outcome measure. G1: Mild, G2: Moderate, G3: Severe, G4: potentially life threatening. BUN(mg/dL): G1: 23 - 26, G2: 27 - 31, G3: \>31, G4: required dialysis. Creatinine(mg/dL): G1: 1.5 - 1.7, G2: 1.8 - 2.0, G3: 2.1 - 2.5, G4: \> 2.5 or required dialysis. Alkaline phosphate(increase by factor): G1: 1.1 - 2.0 x ULN G2: 2.1 - 3.0 x ULN G3: 3.1 -10 x ULN, G4: \>10 x ULN. Liver function tests(ALT, AST increase by factor): G1: 1.1 - 2.5 x ULN G2: 2.6 - 5.0 x ULN G3: 5.1 - 10 x ULN, G4: \>10 x ULN. Bilirubin(when accompanied by any increase in liver function test - increase by factor): G1: 1.1 - 1.25 x ULN G2: 1.26 - 1.5 x ULN G3: 1.51 - 1.75 x ULN, G4: \>1.75 x ULN. Bilirubin(when liver function test is normal - increase by factor): G1: 1.1 - 1.5 x ULN, G2: 1.6 - 2.0 x ULN, G3: 2.0 - 3.0 x ULN, G4: \>3.0 x ULN. Only parameters where grade shift was observed were reported.
Time frame: Before Dose 2
Percentage of Participants With Grade Shift in Chemistry Parameters 7 Days After Dose 2: Phase 1
Percentage of participants with grade shift in chemistry were reported in this outcome measure. G1: Mild, G2: Moderate, G3: Severe, G4: potentially life threatening. BUN(mg/dL): G1: 23 - 26, G2: 27 - 31, G3: \>31, G4: required dialysis. Creatinine(mg/dL): G1: 1.5 - 1.7, G2: 1.8 - 2.0, G3: 2.1 - 2.5, G4: \> 2.5 or required dialysis. Alkaline phosphate(increase by factor): G1: 1.1 - 2.0 x ULN G2: 2.1 - 3.0 x ULN G3: 3.1 -10 x ULN, G4: \>10 x ULN. Liver function tests(ALT, AST increase by factor): G1: 1.1 - 2.5 x ULN G2: 2.6 - 5.0 x ULN G3: 5.1 - 10 x ULN, G4: \>10 x ULN. Bilirubin(when accompanied by any increase in liver function test - increase by factor): G1: 1.1 - 1.25 x ULN G2: 1.26 - 1.5 x ULN G3: 1.51 - 1.75 x ULN, G4: \>1.75 x ULN. Bilirubin(when liver function test is normal - increase by factor): G1: 1.1 - 1.5 x ULN, G2: 1.6 - 2.0 x ULN, G3: 2.0 - 3.0 x ULN, G4: \>3.0 x ULN. Only parameters where grade shift was observed were reported.
Time frame: 7 Days After Dose 2
Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Phase 2/3
Local reactions included redness, swelling and, pain at the injection site, recorded by participants or parents/legal guardians in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\> 2.0 to 5.0 cm), moderate (\> 5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), severe (prevents daily activity) and Grade 4 (emergency room visit or hospitalization for severe pain).
Time frame: Within 7 Days after Dose 1
Percentage of Participants With Local Reactions Within 7 Days After Dose 2: Phase 2/3
Local reactions included redness, swelling and, pain at the injection site, recorded by participants or parents/legal guardians in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\> 2.0 to 5.0 cm), moderate (\> 5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), severe (prevents daily activity) and Grade 4 (emergency room visit or hospitalization for severe pain).
Time frame: Within 7 Days after Dose 2
Percentage of Participants With Systemic Events Within 7 Days After Dose 1: Phase 2/3
Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, new or worsened joint pain recorded by participants or parents/legal guardians of participants using e-diary. Fever=temperature \>=38.0 deg C categorized as \>=38.0 to 38.4, \>38.4 to 38.9, \>38.9 to 40.0 and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain graded as mild (does not interfere with activity), moderate (some interference with activity), severe (prevents daily routine activity), Grade 4 (Emergency room visit/hospitalization). Vomiting: mild (1-2 times in 24 h), moderate (\>2 times in 24 h), severe (requires IV hydration), Grade 4 (emergency room visit/hospitalization for hypotensive shock). Diarrhea: mild (2-3 loose stools in 24h), moderate (4-5 loose stools in 24 h), severe (\>=6 loose stools in 24 h) and Grade 4 (emergency room visit/hospitalization).
Time frame: Within 7 Days after Dose 1
Percentage of Participants With Systemic Events Within 7 Days After Dose 2: Phase 2/3
Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, new or worsened joint pain recorded by participants or parents/legal guardians of participants using e-diary. Fever=temperature \>=38.0 deg C categorized as \>=38.0 to 38.4, \>38.4 to 38.9, \>38.9 to 40.0 and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain graded as mild (does not interfere with activity), moderate (some interference with activity), severe (prevents daily routine activity), Grade 4 (Emergency room visit/hospitalization). Vomiting: mild (1-2 times in 24 h), moderate (\>2 times in 24 h), severe (requires IV hydration), Grade 4 (emergency room visit/hospitalization for hypotensive shock). Diarrhea: mild (2-3 loose stools in 24h), moderate (4-5 loose stools in 24 h), severe (\>=6 loose stools in 24 h) and Grade 4 (emergency room visit/hospitalization).
Time frame: Within 7 Days after Dose 2
Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: Phase 2/3
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. HIV positive participants were excluded from this analysis.
Time frame: From Dose 1 to 1 Month After Dose 2
Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: Phase 2/3
An SAE was any untoward medical occurrence that occurred, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect and other important medical events. HIV positive participants were excluded from this analysis.
Time frame: From Dose 1 to 6 Months After Dose 2
Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Phase 2
Local reactions included redness, swelling and, pain at the injection site, recorded by participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\> 2.0 to 5.0 cm), moderate (\> 5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), severe (prevents daily activity) and Grade 4 (emergency room visit or hospitalization for severe pain).
Time frame: Within 7 Days after Dose 1
Percentage of Participants With Local Reactions Within 7 Days After Dose 2: Phase 2
Local reactions included redness, swelling and, pain at the injection site, recorded by participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\> 2.0 to 5.0 cm), moderate (\> 5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), severe (prevents daily activity) and Grade 4 (emergency room visit or hospitalization for severe pain).
Time frame: Within 7 Days after Dose 2
Percentage of Participants With Systemic Events Within 7 Days After Dose 1: Phase 2
Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, new or worsened joint pain recorded by participants or parents/legal guardians of participants using e-diary. Fever=temperature \>=38.0 deg C categorized as \>=38.0 to 38.4, \>38.4 to 38.9, \>38.9 to 40.0 and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain graded as mild (does not interfere with activity), moderate (some interference with activity), severe (prevents daily routine activity), Grade 4 (Emergency room visit/hospitalization). Vomiting: mild (1-2 times in 24 h), moderate (\>2 times in 24 h), severe (requires IV hydration), Grade 4 (emergency room visit/hospitalization for hypotensive shock). Diarrhea: mild (2-3 loose stools in 24h), moderate (4-5 loose stools in 24 h), severe (\>=6 loose stools in 24 h) and Grade 4 (emergency room visit/hospitalization).
Time frame: Within 7 Days after Dose 1
Percentage of Participants With Systemic Events Within 7 Days After Dose 2: Phase 2
Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, new or worsened joint pain recorded by participants or parents/legal guardians of participants using e-diary. Fever=temperature \>=38.0 deg C categorized as \>=38.0 to 38.4, \>38.4 to 38.9, \>38.9 to 40.0 and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain graded as mild (does not interfere with activity), moderate (some interference with activity), severe (prevents daily routine activity), Grade 4 (Emergency room visit/hospitalization). Vomiting: mild (1-2 times in 24 h), moderate (\>2 times in 24 h), severe (requires IV hydration), Grade 4 (emergency room visit/hospitalization for hypotensive shock). Diarrhea: mild (2-3 loose stools in 24h), moderate (4-5 loose stools in 24 h), severe (\>=6 loose stools in 24 h) and Grade 4 (emergency room visit/hospitalization).
Time frame: Within 7 Days After Dose 2
Percentage of Participants Reporting Adverse Events From Dose 1 to 7 Days After Dose 2: Phase 2
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.
Time frame: From Dose 1 to 7 Days After Dose 2
Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 7 Days After Dose 2: Phase 2
A SAE was any untoward medical occurrence that occurred, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect and other important medical events.
Time frame: From Dose 1 to 7 Days After Dose 2
Percentage of Participants With Local Reactions Within 7 Days After Booster Dose: BNT162b2 Experienced Participants Who Were Rerandomized to Receive 1 Booster Dose
Local reactions included redness, swelling and, pain at the injection site, recorded by participants or parents/legal guardians in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\> 2.0 to 5.0 cm), moderate (\> 5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), severe (prevents daily activity) and Grade 4 (emergency room visit or hospitalization for severe pain). HIV positive participants were excluded.
Time frame: Within 7 Days After Booster Dose
Percentage of Participants With Systemic Events Within 7 Days After Booster Dose 1: BNT162b2 Experienced Participants Who Were Rerandomized to Receive 1 Booster Dose
Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, new or worsened joint pain recorded by participants or parents/legal guardians of participants using e-diary. Fever=temperature \>=38.0 deg C categorized as \>=38.0 to 38.4, \>38.4 to 38.9, \>38.9 to 40.0 and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain graded as mild (does not interfere with activity), moderate (some interference with activity), severe (prevents daily routine activity), Grade 4 (Emergency room visit/hospitalization). Vomiting: mild (1-2 times in 24 h), moderate (\>2 times in 24 h), severe (requires IV hydration), Grade 4 (emergency room visit/hospitalization for hypotensive shock). Diarrhea: mild (2-3 loose stools in 24h), moderate (4-5 loose stools in 24 h), severe (\>=6 loose stools in 24 h) and Grade 4 (emergency room visit/hospitalization). HIV positive participants were excluded.
Time frame: Within 7 Days After Booster Dose
Percentage of Participants Reporting Adverse Events From First Booster Dose to 1 Month After Booster Dose: BNT162b2 Experienced Participants Who Were Rerandomized to Receive 1 Booster Dose
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. HIV positive participants were excluded.
Time frame: From First Booster Dose to 1 Month After Booster Dose
Percentage of Participants Reporting Serious Adverse Events From First Booster Dose to 6 Months After Booster Dose: BNT162b2 Experienced Participants Who Were Rerandomized to Receive 1 Booster Dose
A SAE was any untoward medical occurrence that occurred, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect and other important medical events. HIV positive participants were excluded.
Time frame: From First Booster Dose to 6 Months After Booster Dose
Percentage of Participants With Local Reactions Within 7 Days After Booster Dose 1: BNT162b2 Experienced Participants Assigned to Receive 2 Booster Doses of BNT162b2SA
Local reactions included redness, swelling and, pain at the injection site, recorded by participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\> 2.0 to 5.0 cm), moderate (\> 5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), severe (prevents daily activity) and Grade 4 (emergency room visit or hospitalization for severe pain). HIV positive participants were excluded from this analysis.
Time frame: Within 7 Days After Booster Dose 1
Percentage of Participants With Local Reactions Within 7 Days After Booster Dose 2: BNT162b2 Experienced Participants Assigned to Receive 2 Booster Doses of BNT162b2SA
Local reactions included redness, swelling and, pain at the injection site, recorded by participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\> 2.0 to 5.0 cm), moderate (\> 5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), severe (prevents daily activity) and Grade 4 (emergency room visit or hospitalization for severe pain). HIV positive participants were excluded from this analysis.
Time frame: Within 7 Days after Booster Dose 2
Percentage of Participants With Systemic Events Within 7 Days After Booster Dose 1: BNT162b2 Experienced Participants Assigned to Receive 2 Booster Doses of BNT162b2SA
Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, new or worsened joint pain recorded by participants or parents/legal guardians of participants using e-diary. Fever=temperature \>=38.0 deg C categorized as \>=38.0 to 38.4, \>38.4 to 38.9, \>38.9 to 40.0 and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain graded as mild (does not interfere with activity), moderate (some interference with activity), severe (prevents daily routine activity), Grade 4 (Emergency room visit/hospitalization). Vomiting: mild (1-2 times in 24 h), moderate (\>2 times in 24 h), severe (requires IV hydration), Grade 4 (emergency room visit/hospitalization for hypotensive shock). Diarrhea: mild (2-3 loose stools in 24h), moderate (4-5 loose stools in 24 h), severe (\>=6 loose stools in 24 h) and Grade 4 (emergency room visit/hospitalization). HIV positive participants excluded.
Time frame: Within 7 Days After Booster Dose 1
Percentage of Participants With Systemic Events Within 7 Days After Booster Dose 2: BNT162b2 Experienced Participants Assigned to Receive 2 Booster Doses of BNT162b2SA
Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, new or worsened joint pain recorded by participants or parents/legal guardians of participants using e-diary. Fever=temperature \>=38.0 deg C categorized as \>=38.0 to 38.4, \>38.4 to 38.9, \>38.9 to 40.0 and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain graded as mild (does not interfere with activity), moderate (some interference with activity), severe (prevents daily routine activity), Grade 4 (Emergency room visit/hospitalization). Vomiting: mild (1-2 times in 24 h), moderate (\>2 times in 24 h), severe (requires IV hydration), Grade 4 (emergency room visit/hospitalization for hypotensive shock). Diarrhea: mild (2-3 loose stools in 24h), moderate (4-5 loose stools in 24 h), severe (\>=6 loose stools in 24 h) and Grade 4 (emergency room visit/hospitalization). HIV positive participants excluded.
Time frame: Within 7 Days After Booster Dose 2
Percentage of Participants Reporting Adverse Events From First Booster Dose to 1 Month After Second Booster Dose: BNT162b2 Experienced Participants Assigned to Receive 2 Booster Doses of BNT162b2SA
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. HIV positive participants were excluded.
Time frame: From First Booster Dose to 1 Month After Second Booster Dose
Percentage of Participants Reporting Serious Adverse Events From First Booster Dose to 5 Months After Second Booster Dose: BNT162b2 Experienced Participants Assigned to Receive 2 Booster Doses of BNT162b2SA
An SAE was any untoward medical occurrence that occurred, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect and other important medical events. HIV positive participants were excluded.
Time frame: From First Booster Dose to 5 Months After Second Booster Dose
Percentage of Participants With Local Reactions Within 7 Days After Dose 1: BNT162b2 Naive Participants Who Were Enrolled to Receive BNT162b2SA
Local reactions included redness, swelling and, pain at the injection site, recorded by participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\> 2.0 to 5.0 cm), moderate (\> 5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), severe (prevents daily activity) and Grade 4 (emergency room visit or hospitalization for severe pain). HIV positive participants were excluded.
Time frame: Within 7 Days After Dose 1
Percentage of Participants With Local Reactions Within 7 Days After Dose 2: BNT162b2 Naive Participants Who Were Enrolled to Receive BNT162b2SA
Local reactions included redness, swelling and, pain at the injection site, recorded by participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\> 2.0 to 5.0 cm), moderate (\> 5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), severe (prevents daily activity) and Grade 4 (emergency room visit or hospitalization for severe pain). HIV positive participants were excluded.
Time frame: Within 7 Days After Dose 2
Percentage of Participants With Systemic Events Within 7 Days After Dose 1: BNT162b2 Naive Participants Who Were Enrolled to Receive BNT162b2SA
Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, new or worsened joint pain recorded by participants or parents/legal guardians of participants using e-diary. Fever=temperature \>=38.0 deg C categorized as \>=38.0 to 38.4, \>38.4 to 38.9, \>38.9 to 40.0 and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain graded as mild (does not interfere with activity), moderate (some interference with activity), severe (prevents daily routine activity), Grade 4 (Emergency room visit/hospitalization). Vomiting: mild (1-2 times in 24 h), moderate (\>2 times in 24 h), severe (requires IV hydration), Grade 4 (emergency room visit/hospitalization for hypotensive shock). Diarrhea: mild (2-3 loose stools in 24h), moderate (4-5 loose stools in 24 h), severe (\>=6 loose stools in 24 h) and Grade 4 (emergency room visit/hospitalization). HIV positive participants were excluded.
Time frame: Within 7 Days After Dose 1
Percentage of Participants With Systemic Events Within 7 Days After Dose 2: BNT162b2 Naive Participants Who Were Enrolled to Receive BNT162b2SA
Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, new or worsened joint pain recorded by participants or parents/legal guardians of participants using e-diary. Fever=temperature \>=38.0 deg C categorized as \>=38.0 to 38.4, \>38.4 to 38.9, \>38.9 to 40.0 and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain graded as mild (does not interfere with activity), moderate (some interference with activity), severe (prevents daily routine activity), Grade 4 (Emergency room visit/hospitalization). Vomiting: mild (1-2 times in 24 h), moderate (\>2 times in 24 h), severe (requires IV hydration), Grade 4 (emergency room visit/hospitalization for hypotensive shock). Diarrhea: mild (2-3 loose stools in 24h), moderate (4-5 loose stools in 24 h), severe (\>=6 loose stools in 24 h) and Grade 4 (emergency room visit/hospitalization). HIV positive participants were excluded.
Time frame: Within 7 Days After Dose 2
Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: BNT162b2-Naïve Participants Who Were Enrolled to Receive BNT162b2SA
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. HIV positive participants were excluded.
Time frame: From Dose 1 Through 1 Month After Dose 2
Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: BNT162b2-Naïve Participants Who Were Enrolled to Receive BNT162b2SA
A SAE was any untoward medical occurrence that occurred, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect and other important medical events. HIV positive participants were excluded.
Time frame: From Dose 1 to 6 Months After Dose 2
Percentage of Participants With Local Reactions Within 7 Days After Booster Dose: BNT162b2-Experienced Participants Who Were Rerandomized to Receive 1 Booster Dose of BNT162b2 (Lower Dose)
Local reactions included redness, swelling and, pain at the injection site, recorded by participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\> 2.0 to 5.0 cm), moderate (\> 5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), severe (prevents daily activity) and Grade 4 (emergency room visit or hospitalization for severe pain). HIV positive participants were excluded.
Time frame: Within 7 days After Booster Dose
Percentage of Participants With Systemic Events Within 7 Days After Booster Dose: BNT162b2-Experienced Participants Who Were Rerandomized to Receive 1 Booster Dose of BNT162b2 (Lower Dose)
Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, new or worsened joint pain recorded by participants or parents/legal guardians of participants using e-diary. Fever=temperature \>=38.0 deg C categorized as \>=38.0 to 38.4, \>38.4 to 38.9, \>38.9 to 40.0 and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain graded as mild (does not interfere with activity), moderate (some interference with activity), severe (prevents daily routine activity), Grade 4 (Emergency room visit/hospitalization). Vomiting: mild (1-2 times in 24 h), moderate (\>2 times in 24 h), severe (requires IV hydration), Grade 4 (emergency room visit/hospitalization for hypotensive shock). Diarrhea: mild (2-3 loose stools in 24h), moderate (4-5 loose stools in 24 h), severe (\>=6 loose stools in 24 h) and Grade 4 (emergency room visit/hospitalization). HIV positive participants were excluded.
Time frame: Within 7 days After Booster Dose
Percentage of Participants Reporting Adverse Events From Booster Dose to 1 Month After Booster Dose: BNT162b2-Experienced Participants Who Were Rerandomized to Receive 1 Booster Dose of BNT162b2 (Lower Dose)
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. HIV positive participants were excluded.
Time frame: From Booster Dose to 1 Months After Booster Dose
Percentage of Participants Reporting Serious Adverse Events From Booster Dose to 6 Months After Booster Dose: BNT162b2-Experienced Participants Who Were Rerandomized to Receive 1 Booster Dose of BNT162b2 (Lower Dose)
A SAE was any untoward medical occurrence that occurred, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect and other important medical events. HIV positive participants were excluded.
Time frame: From Booster Dose to 6 Months after Booster Dose
COVID-19 Incidence Based on Central Laboratory or Locally Confirmed Nucleic Acid Amplification Test (NAAT) in Participants Without Serological or Virological Evidence: Phase 2/3
Occurrences of first COVID-19 infection in participants followed up based on central laboratory or locally confirmed NAAT in participants, without serological or virological evidence of prior SARS-CoV-2 infection were reported in this outcome measure. HIV positive participants were excluded from this analysis.
Time frame: From 7 days after Dose 2 (Surveillance time [1000 person-years]: BNT162b2 - 6.247, Placebo - 6.003)
COVID-19 Incidence Based on Central Laboratory or Locally Confirmed Nucleic Acid Amplification Test (NAAT) in Participants Without Serological or Virological Evidence: Phase 2/3 (Analysis for EUA)
Occurrences of first COVID-19 infection in participants followed up based on central laboratory or locally confirmed NAAT in participants, without serological or virological evidence of prior SARS-CoV-2 infection (analysis for EUA) were reported in this outcome measure.
Time frame: From 7 days after Dose 2 (Surveillance time [1000 person-years]: BNT162b2 - 2.214, Placebo - 2.222)
COVID-19 Incidence Based on Central Laboratory or Locally Confirmed Nucleic Acid Amplification Test (NAAT) in Participants With or Without Serological or Virological Evidence: Phase 2/3
Occurrences of first COVID-19 infection in participants followed up based on central laboratory or locally confirmed NAAT in participants, with or without serological or virological evidence of prior SARS-CoV-2 infection were reported in this outcome measure.
Time frame: From 7 days after Dose 2 (Surveillance time [1000 person-years]: BNT162b2 - 6.509, Placebo - 6.274)
COVID-19 Incidence Based on Central Laboratory or Locally Confirmed Nucleic Acid Amplification Test (NAAT) in Participants With or Without Serological or Virological Evidence: Phase 2/3 (Analysis for EUA)
Occurrences of first COVID-19 infection in participants followed up based on central laboratory or locally confirmed NAAT in participants, with or without serological or virological evidence (analysis for EUA) of prior SARS-CoV-2 infection were reported in this outcome measure. HIV positive participants were excluded from this analysis.
Time frame: From 7 days after Dose 2 (Surveillance time [1000 person-years]: BNT162b2 - 2.332, Placebo - 2.345)
GMR Based on Geometric Mean Titer (N1a) - Comparison of 1 Month After Dose 2 Between Vaccine Groups: BNT162b2-Naïve Participants Without Evidence of Infection (N1a) up to 1 Month After Dose 2: Phase 3
GMR based on geometric mean titer, comparison of 1 month after dose 2 between vaccine groups: BNT162b2-naive participants without evidence of infection up to 1 month after dose 2 were reported in this outcome measure. HIV positive participants excluded from this analysis.
Time frame: 1 Month After Dose 2
Percentage Difference of Participants Achieving Seroresponse Comparison (N1b) of 1 Month After Dose 2 Between Vaccine Groups: BNT162b2-Naïve Participants Without Evidence of Infection up to 1 Month After Dose 2: Phase 3
Seroresponse was defined as achieving a \>=4-fold rise from baseline (before Dose 1). If the baseline measurement was below the lower limit of quantification (LLOQ), a post vaccination assay result \>=4 × LLOQ was considered a seroresponse. HIV positive participants excluded.
Time frame: 1 Month After Dose 2
GMR of Neutralizing Titers (E1a) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants That Received a Booster Dose of BNT162b2: Phase 3
GMR based on geometric mean titer, comparison of 1 month after booster dose to 1 month after dose 2 for BNT162b2-experienced participants were reported in this outcome measure. HIV positive participants excluded from this analysis.
Time frame: 1 Month After Booster Dose to 1 Month After Dose 2
Percentage Difference of Participants Achieving Seroresponse (E1b) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants That Received a Booster Dose of BNT162b2: Phase 3
Percentage difference of participants achieving seroresponse - comparison of 1 month after booster dose to 1 month after Dose 2 BNT162b2-experienced participants without evidence of infection up to 1 month after booster dose who were rerandomized to receive 1 booster dose were reported in this outcome measure. Seroresponse was defined as achieving a \>=4-fold rise from baseline (before Dose 1). If the baseline measurement was below the LLOQ, a postvaccination assay result \>=4 × LLOQ was considered a seroresponse. HIV positive participants excluded.
Time frame: 1 Month After Booster Dose to 1 Month After Dose 2
GMR of Neutralizing Titers (E2a) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants: Phase 3
GMR of neutralizing titers (E2a) for comparison of 1 month after booster dose to 1 month after dose 2: BNT162b2-experienced participants in Phase 3 were reported in this outcome measure. HIV positive participants were excluded from this analysis.
Time frame: 1 Month After Booster Dose to 1 Month After Dose 2
Percentage Difference of Participants Achieving Seroresponse (E2b) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants: Phase 3
Percentage difference of participants achieving seroresponse - comparison of 1 month after booster dose to 1 month after Dose 2 BNT162b2-experienced participants without evidence of infection up to 1 month after booster dose who were rerandomized to receive 1 booster dose were reported in this outcome measure. Seroresponse was defined as achieving a \>=4-fold rise from baseline (before Dose 1). If the baseline measurement was below the LLOQ, a postvaccination assay result \>=4 × LLOQ was considered a seroresponse. HIV positive participants excluded.
Time frame: 1 Month After Booster Dose to 1 Month After Dose 2
Geometric Mean Titers (GMTs) of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titers: Phase 1
GMTs of severe acute respiratory syndrome coronavirus 2 neutralizing titers were reported in this outcome measure. SARS-CoV-2 neutralization assay - NT50 and SARS-CoV-2 neutralization assay - NT90 were evaluated and reported in this outcome measure.
Time frame: 7, 21 days after Dose 1; 7, 14 days and 1, 6 months after Dose 2
Geometric Mean Concentrations (GMCs) of Severe Acute Respiratory Syndrome Coronavirus 2: S1-binding and RBD-binding IgG Level Assay: Phase 1
GMCs of severe acute respiratory syndrome coronavirus S1-binding and RBD-binding IgG level were reported in this outcome measure.
Time frame: 7, 21 days after Dose 1; 7, 14 days and 1, 6 months after Dose 2
Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Neutralizing Titers: Phase 1
GMFR of SARS-CoV-2 neutralizing titers were reported in this outcome measure. HIV positive participants excluded.
Time frame: 7, 21 days after Dose 1; 7, 14 days and 1, 6 months after Dose 2
Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 S1-binding and RBD-binding IgG Level Assay: Phase 1
GMFR of SARS-CoV-2 S1-binding and RBD-binding IgG level assay in Phase 1 were reported in this outcome measure. HIV positive participants were excluded from this analysis.
Time frame: 7, 21 days after Dose 1; 7, 14 days and 1, 6 months after Dose 2
Percentage of Participants Achieving a >= 4-Fold Rise From Before Vaccination to After Vaccination: Neutralizing Titers: Phase 1
Percentage of participants achieving a \>= 4-fold rise from before vaccination to after vaccination: neutralizing titers in Phase 1 were reported in this outcome measure. HIV positive participants were excluded from this analysis.
Time frame: 7, 21 days after Dose 1; 7, 14 days and 1, 6 months after Dose 2
Percentage of Participants Achieving a >= 4-Fold Rise From Before Vaccination to After Vaccination: S1-binding and RBD-binding IgG Level Assay: Phase 1
Percentage of participants achieving a \>= 4-fold rise from before vaccination to after vaccination: S1-binding and RBD-binding IgG level assay in Phase 1 were reported in this outcome measure. HIV positive participants were excluded from this analysis.
Time frame: From before vaccination to after vaccination
GMR Based on Reference Strain NT - Comparison of Participants 12 to 15 Years of Age to Participants 16 to 25 Years of Age- Participants Without Evidence of Infection up to 1 Month After Dose 2 - Dose 2 Evaluable Immunogenicity Population: Phase2/3
GMR based on reference strain NT, comparison of participants 12 to 15 years of age to participants 16 to 25 years of age of participants without evidence of infection up to 1 month after dose 2 in Phase2/3 were reported in this outcome measure. HIV positive participants were excluded from this analysis.
Time frame: 1 Month After Dose 2
Incidence of Asymptomatic SARS-CoV-2 Infection Per 1000 Person Years Follow-up Without Serological or Virological Evidence (Up to Start of Asymptomatic Surveillance Period) of Past Infection: Phase 3
Incidence of asymptomatic SARS-CoV-2 infection per 1000 person years follow-up without serological or virological evidence (up to start of asymptomatic surveillance period) of past infection were reported in this outcome measure.
Time frame: From start of asymptomatic surveillance (Surveillance time [1000 person-years]: BNT162b2 - 0.383; Placebo - 0.200
Incidence of Asymptomatic SARS-CoV-2 Infection Per 1000 Person Years Follow-up Without Serological or Virological Evidence of Past Infection Based on N-binding Antibody Seroconversion: Phase 3
Incidence of asymptomatic SARS-CoV-2 infection per 1000 person years follow-up without serological or virological evidence of past infection based on N-binding antibody seroconversion were reported in this outcome measure.
Time frame: From Dose 2 to the end of the surveillance period ([1000 person-years]: BNT162b2 - 13.840, Placebo - 6.481)
COVID-19 Incidence Per 1000 Person-Years of Follow-up With or Without Evidence of Infection 7 Days After Second Dose of BNT162b2 Based on CDC-Defined Symptoms (Analysis for EUA): Phase 3
COVID-19 incidence per 1000 person years follow-up with or without the evidence of infection were reported in this outcome measure.
Time frame: From 7 Days After Dose 2 (Surveillance time [1000 person-years]: BNT162b2 - 2.330, Placebo - 2.343)
COVID-19 Incidence Per 1000 Person-Years of Follow-up With or Without Evidence of Infection 14 Days After Second Dose of BNT162b2 Based on CDC-Defined Symptoms (Analysis for EUA): Phase 3
COVID-19 incidence per 1000 person years follow-up with or without the evidence of infection were reported in this outcome measure.
Time frame: From 14 Days After Dose 2 (Surveillance time [1000 person-years]: BNT162b2 - 1.983, Placebo - 1.993)
COVID-19 Incidence Per 1000 Person-Years of Follow-up Without Evidence of Infection: 7 Days After Dose 2 Based on CDC Defined Symptoms (Analysis for EUA): Phase 3
COVID-19 incidence per 1000 person years follow-up without the evidence of infection (analysis for EUA) were reported in this outcome measure.
Time frame: From 7 days after Dose 2 (Surveillance time [1000 person-years]: BNT162b2 - 2.213; Placebo - 2.220)
COVID-19 Incidence Per 1000 Person-Years of Follow-up Without Evidence of Infection: 14 Days After Dose 2 Based on CDC Defined Symptoms (Analysis for EUA): Phase 3
COVID-19 incidence per 1000 person years follow-up without the evidence of infection were reported in this outcome measure.
Time frame: From 14 days after Dose 2 (Surveillance time [1000 person-years]: BNT162b2 - 1.886; Placebo - 1.891)
Severe COVID-19 Incidence Per 1000 Person-Years of Follow-up With or Without Evidence of Infection: 7 Days After Dose 2: Phase 3
Severe COVID-19 incidence per 1000 person years follow-up with or without the evidence of infection were reported in this outcome measure.
Time frame: From 7 days after Dose 2 (Surveillance time [1000 person-years]: BNT162b2 - 6.522; Placebo - 6.404)
Severe COVID-19 Incidence Per 1000 Person-Years of Follow-up With or Without Evidence of Infection: 14 Days After Dose 2 (Analysis for EUA): Phase 3
Severe COVID-19 incidence per 1000 person years follow-up with or without the evidence of infection (analysis for EUA) were reported in this outcome measure.
Time frame: From 14 days after Dose 2 (Surveillance time [1000 person-years]: BNT162b2 - 1.985; Placebo - 2.007)
Severe COVID-19 Incidence Per 1000 Person-Years of Follow-up Without Evidence of Infection: 7 Days After Dose 2: Phase 3
Severe COVID-19 incidence per 1000 person years follow-up without the evidence of infection were reported in this outcome measure.
Time frame: From 7 days after Dose 2 (Surveillance time [1000 person-years]: BNT162b2 - 6.257; Placebo - 6.120)
Severe COVID-19 Incidence Per 1000 Person-Years of Follow-up Without Evidence of Infection: 14 Days After Dose 2 (Analysis for EUA): Phase 3
Severe COVID-19 incidence per 1000 person years follow-up without the evidence of infection (analysis for EUA) were reported in this outcome measure.
Time frame: From 14 days after Dose 2 (Surveillance time [1000 person-years]: BNT162b2 - 1.888; Placebo - 1.901)
COVID-19 Incidence Per 1000 Person-Years of With or Without Evidence of Infection: 14 Days After Dose 2 (EUA Analysis): Phase 3
COVID-19 incidence per 1000 person years follow-up with or without the evidence of infection (analysis for EUA) were reported in this outcome measure.
Time frame: From 14 days after Dose 2 (Surveillance time [1000 person-years]: BNT162b2 - 1.984; Placebo - 1.995)
COVID-19 Incidence Per 1000 Person-Years of Follow-up Without Evidence of Infection: 14 Days After Dose 2 (EUA Analysis): Phase 3
COVID-19 incidence per 1000 person years follow-up without the evidence of infection (analysis for EUA) were reported in this outcome measure.
Time frame: From 14 days after Dose 2 (Surveillance time [1000 person-years]: BNT162b2 - 1.887; Placebo - 1.893)
Percentage Difference of Participants Achieving Seroresponse (Reference Strain) 1 Month After Second Dose in BNT162b2-Naive Participants: Phase 3
Seroresponse was defined as achieving a \>=4-fold rise from baseline (before Dose 1). If the baseline measurement was below the lower limit of quantification (LLOQ), a post vaccination assay result \>=4 × LLOQ was considered a seroresponse. HIV positive participants were excluded from this analysis.
Time frame: 1 Month After Dose 2
GMR Based on Geometric Mean Titer (Reference Strain) 1 Month After Second Dose in BNT162b2-Naive Participants: Phase 3
GMR based on GMT (Reference Strain) 1 month after second dose of BNT162b2SA and 1 month after the second dose of BNT162b2 in BNT162b2-naive participant were reported in this outcome measure.
Time frame: 1 Month After Dose 2
GMR Based on Geometric Mean Titer of SA NT 1 Month After Second Dose of BNT162b2SA to 1 Month After the Second Dose (N2a) of BNT162b2 Naive Participants: Phase 3
GMR based on geometric mean titer of SA NT 1 Month after second dose of BNT162b2SA to 1 Month after the second dose (N2a) of BNT162b2 naive participants of Phase 3 were reported in this outcome measure.
Time frame: 1 month after the second dose
Percentage Difference of Participants Achieving Seroresponse (N2b) Comparison of 1 Month After Dose 2 Between Vaccine Groups: BNT162b2-Naïve Participants Without Evidence of Infection up to 1 Month After Dose 2: Phase 3
Seroresponse was defined as achieving a \>=4-fold rise from baseline (before Dose 1). If the baseline measurement was below the LLOQ, a postvaccination assay result \>=4 × LLOQ was considered a seroresponse.
Time frame: 1 Month After Dose 2
GMR of Neutralizing Titers (E3a) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants That Received a Booster Dose of BNT162b2: Phase 3
GMR of neutralizing titers (E3a) - comparison of 1 month after booster dose to 1 month after dose 2: BNT162b2-experienced participants of Phase 3 were reported in this outcome measure.
Time frame: 1 Month After Booster Dose to 1 Month After Dose 2
Percentage Difference of Participants Achieving Seroresponse (E3b) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants That Received a Booster Dose of BNT162b2: Phase 3
Percentage difference of participants achieving seroresponse (E3b) - comparison of 1 month after booster dose to 1 month after dose 2 BNT162b2-experienced participants without evidence of infection up to 1 month after booster dose who were rerandomized to receive 1 booster dose were reported in this outcome measure.
Time frame: 1 Month After Booster Dose to 1 Month After Dose 2
GMR of Neutralizing Titers (E4a) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants: Phase 3
GMR of neutralizing titers (E4a) - comparison of 1 month after booster dose to 1 month after dose 2: BNT162b2-experienced participants of Phase 3 were reported in this outcome measure.
Time frame: 1 Month After Booster Dose to 1 Month After Dose 2
Percentage Difference of Participants Achieving Seroresponse (E4b) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants: Phase 3
Percentage difference of participants achieving seroresponse (E4b) - comparison of 1 month after booster dose to 1 month after dose 2 BNT162b2-experienced participants without evidence of infection up to 1 month after booster dose who were rerandomized to receive 1 booster dose were reported in this outcome measure.
Time frame: 1 Month After Booster Dose to 1 Month After Dose 2
Percentage Difference of Participants Achieving Seroresponse for SA Variant NT Comparison of 1 Month After Second Booster Dose to 1 Month After Dose 2 of BNT162b2 in Participants Assigned to Receive 2 Booster Doses of BNT162b2SA: Phase 3
Percentage difference of participants achieving seroresponse for SA variant NT comparison of 1 Month after second booster dose to 1 Month after Dose 2 of BNT162b2 in participants assigned to receive 2 booster doses of BNT162b2SA of Phase 3 were reported in this outcome measure.
Time frame: 1 Month after Second Booster Dose to 1 Month After Dose 2 of BNT162b2
GMR of SA Variant NT 1 Month After Second Booster Dose to 1 Month After Dose 2 of BNT162b2 in Participants Assigned to Receive 2 Booster Doses of BNT1612b2SA: Phase 3
GMR of SA variant NT 1 month after second booster dose to 1 month after dose 2 of BNT162b2 in participants assigned to receive 2 booster doses of BNT1612b2SA were reported in this outcome measure.
Time frame: 1 Month After Second Booster Dose to 1 Month After Dose 2 of BNT162b2
Percentage Difference of Participants Achieving Seroresponse for SA Variant NT: BNT162b2-Experienced Participants Without Evidence of Infection up to 1 Month After Booster Dose Who Were Rerandomized to Receive 1 Booster Dose: Phase 3
Percentage difference of participants achieving seroresponse for SA variant NT: BNT162b2-experienced participants without evidence of infection up to 1 month after booster dose who were rerandomized to receive 1 booster dose were reported in this outcome measure.
Time frame: 1 Month After Booster Dose
GMR of SA Variant NT: BNT162b2-Experienced Participants Without Evidence of Infection up to 1 Month After Booster Dose Who Were Rerandomized to Receive 1 Booster Dose: Phase 3
GMR of SA Variant NT: BNT162b2-experienced participants without evidence of infection up to 1 month after booster dose who were rerandomized to receive 1 booster dose were reported in this outcome measure.
Time frame: 1 Month After Booster Dose
| Milestone | Phase 1:BNT162b1 10 mcg Dose: 18-85 Years of Age | Phase 1:BNT162b1 20 mcg Dose:18-85 Years of Age | Phase 1:BNT162b1 30 mcg Dose:18-85 Years of Age | Phase1:BNT162b1 100 mcg Dose:18-55 Years of Age | Phase 1: Placebo: 18-85 Years of Age | Phase 1: BNT162b2: 10 mcg Dose: 18-85 Years of Age | Phase 1: BNT162b2: 20 mcg Dose: 18-85 Years of Age | Phase 1: BNT162b2: 30 mcg Dose: 18-85 Years of Age | Phase 2/3: BNT162b2 30 mcg: 12-15 Years of Age | Phase 2/3: Placebo 12-15 Years of Age | Phase 2/3: BNT162b2 30 mcg: >=16 Years of Age | Phase 2/3: Placebo for >=16 Years of Age | Phase 2/3: BNT162b2 30mcg: 12-15 Years of Age | Phase 2/3: Placebo: 12-15 Years of Age | Phase 2/3: BNT162b2 30 mcg >=16 Years of Age | Phase 2/3: Placebo: >=16 Years of Age | Phase 3: BNT162b2 SA 30 mcg: 18-55 Years of Age |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 24 | 24 | 24 | 12 | 39 | 24 | 24 | 24 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 14 | 18 | 13 | 8 | 23 | 20 | 19 | 16 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 10 | 6 | 11 | 4 | 16 | 4 | 5 | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 5 | 5 | 4 | 2 | 6 | 0 | 3 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: No longer meets eligibility criteria | 5 | 0 | 5 | 1 | 7 | 3 | 1 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Phase 1:BNT162b1 10 mcg Dose: 18-85 Years of Age | Phase 1:BNT162b1 20 mcg Dose:18-85 Years of Age | Phase 1:BNT162b1 30 mcg Dose:18-85 Years of Age | Phase1:BNT162b1 100 mcg Dose:18-55 Years of Age | Phase 1: Placebo: 18-85 Years of Age | Phase 1: BNT162b2: 10 mcg Dose: 18-85 Years of Age | Phase 1: BNT162b2: 20 mcg Dose: 18-85 Years of Age | Phase 1: BNT162b2: 30 mcg Dose: 18-85 Years of Age | Phase 2/3: BNT162b2 30 mcg: 12-15 Years of Age | Phase 2/3: Placebo 12-15 Years of Age | Phase 2/3: BNT162b2 30 mcg: >=16 Years of Age | Phase 2/3: Placebo for >=16 Years of Age | Phase 2/3: BNT162b2 30mcg: 12-15 Years of Age | Phase 2/3: Placebo: 12-15 Years of Age | Phase 2/3: BNT162b2 30 mcg >=16 Years of Age | Phase 2/3: Placebo: >=16 Years of Age | Phase 3: BNT162b2 SA 30 mcg: 18-55 Years of Age |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1134 | 1130 | 22071 | 22071 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 2 | 21 | 37 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1131 | 1128 | 22050 | 22034 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15 | 39 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 7 | 139 | 250 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 2 | 256 | 281 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 7 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 18 | 16 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 9 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Refused further study procedures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Medication error without associated adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: No longer meets eligibility criteria | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 16 | 21 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by parent/guardian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 5 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 33 | 11 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Participants entered open label period | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1119 | 1110 | 21500 | 21351 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Randomized but not vaccinated | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 55 | 48 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Phase 1:BNT162b1 10 mcg Dose: 18-85 Years of Age | Phase 1:BNT162b1 20 mcg Dose:18-85 Years of Age | Phase 1:BNT162b1 30 mcg Dose:18-85 Years of Age | Phase1:BNT162b1 100 mcg Dose:18-55 Years of Age | Phase 1: Placebo: 18-85 Years of Age | Phase 1: BNT162b2: 10 mcg Dose: 18-85 Years of Age | Phase 1: BNT162b2: 20 mcg Dose: 18-85 Years of Age | Phase 1: BNT162b2: 30 mcg Dose: 18-85 Years of Age | Phase 2/3: BNT162b2 30 mcg: 12-15 Years of Age | Phase 2/3: Placebo 12-15 Years of Age | Phase 2/3: BNT162b2 30 mcg: >=16 Years of Age | Phase 2/3: Placebo for >=16 Years of Age | Phase 2/3: BNT162b2 30mcg: 12-15 Years of Age | Phase 2/3: Placebo: 12-15 Years of Age | Phase 2/3: BNT162b2 30 mcg >=16 Years of Age | Phase 2/3: Placebo: >=16 Years of Age | Phase 3: BNT162b2 SA 30 mcg: 18-55 Years of Age |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1119 | 1110 | 21500 | 21351 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 560 | 661 | 6954 | 10428 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 559 | 449 | 14546 | 10923 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 37 | 35 | 1254 | 2422 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 49 | 52 | 1500 | 1792 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 59 | 55 | 1089 | 1402 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 35 | 31 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 67 | 68 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 6 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 |
| Withdrew: Withdrawal by parent/guardian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14 | 19 | 2 | 0 | 0 |
| Withdrew: Refused further study procedure | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 12 | 0 |
| Withdrew: No longer meets eligibility criteria | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 107 | 114 | 940 | 1580 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 293 | 173 | 9647 | 3608 | 0 |
| Milestone | Phase 1:BNT162b1 10 mcg Dose: 18-85 Years of Age | Phase 1:BNT162b1 20 mcg Dose:18-85 Years of Age | Phase 1:BNT162b1 30 mcg Dose:18-85 Years of Age | Phase1:BNT162b1 100 mcg Dose:18-55 Years of Age | Phase 1: Placebo: 18-85 Years of Age | Phase 1: BNT162b2: 10 mcg Dose: 18-85 Years of Age | Phase 1: BNT162b2: 20 mcg Dose: 18-85 Years of Age | Phase 1: BNT162b2: 30 mcg Dose: 18-85 Years of Age | Phase 2/3: BNT162b2 30 mcg: 12-15 Years of Age | Phase 2/3: Placebo 12-15 Years of Age | Phase 2/3: BNT162b2 30 mcg: >=16 Years of Age | Phase 2/3: Placebo for >=16 Years of Age | Phase 2/3: BNT162b2 30mcg: 12-15 Years of Age | Phase 2/3: Placebo: 12-15 Years of Age | Phase 2/3: BNT162b2 30 mcg >=16 Years of Age | Phase 2/3: Placebo: >=16 Years of Age | Phase 3: BNT162b2 SA 30 mcg: 18-55 Years of Age |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 333 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 228 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 105 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 19 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 50 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: No longer meets eligibility criteria | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 24 |
Local reactions included redness, swelling and, pain at the injection site, recorded by participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 centimeter (cm). Redness and swelling were graded as mild (greater than \[\>\] 2.0 to 5.0 cm), moderate (\> 5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), severe (prevents daily activity) and Grade 4 (emergency room visit or hospitalization for severe pain).
| Percentage of participants | BNT162b1 10 mcg Dose: 18-55 Years of Age | BNT162b1 20 mcg Dose: 18-55 Years of Age | BNT162b1 30 mcg Dose: 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b1 | BNT162b1 100 mcg Dose, 18-55 Years of Age | Placebo 18-55 Years of Age for BNT162b1 100 mcg | BNT162b2 10 mcg Dose, 18-55 Years of Age | BNT162b2 20 mcg Dose, 18-55 Years of Age | BNT162b2 30 mcg Dose, 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b2 | BNT162b1 10 mcg Dose, 65-85 Years of Age | BNT162b1 20 mcg Dose, 65-85 Years of Age | BNT162b1 30 mcg Dose, 65-85 Years of Age | Placebo, 65-85 Years of Age for BNT162b1 | BNT162b2 10 mcg Dose, 65-85 Years of Age | BNT162b2 20 mcg Dose, 65-85 Years of Age | BNT162b2 30 mcg Dose, 65-85 Years of Age | Placebo: 65-85 Years of Age for BNT162b2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Redness: Mild | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 16.7 (2.1 to 48.4) | 0 (0.0 to 70.8) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Redness: Moderate | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 16.7 (2.1 to 48.4) | 0 (0.0 to 70.8) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Redness: Severe | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 70.8) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Redness: Grade 4 | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 70.8) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Swelling: Mild | 0 (0.0 to 26.5) | 16.7 (2.1 to 48.4) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 25.0 (5.5 to 57.2) | 0 (0.0 to 70.8) | 16.7 (2.1 to 48.4) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 8.3 (0.2 to 38.5) | 0 (0.0 to 26.5) | 16.7 (2.1 to 48.4) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Swelling: Moderate | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 16.7 (2.1 to 48.4) | 0 (0.0 to 70.8) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Swelling: Severe | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 70.8) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Swelling: Grade 4 | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 70.8) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Pain at injection site: Mild | 58.3 (27.7 to 84.8) | 50.0 (21.1 to 78.9) | 41.7 (15.2 to 72.3) | 0 (0.0 to 33.6) | 33.3 (9.9 to 65.1) | 66.7 (9.4 to 99.2) | 58.3 (27.7 to 84.8) | 50.0 (21.1 to 78.9) | 75.0 (42.8 to 94.5) | 0 (0.0 to 33.6) | 58.3 (27.7 to 84.8) | 83.3 (51.6 to 97.9) | 66.7 (34.9 to 90.1) | 11.1 (0.3 to 48.2) | 33.3 (9.9 to 65.1) | 58.3 (27.7 to 84.8) | 75.0 (42.8 to 94.5) | 0 (0.0 to 33.6) |
| Pain at injection site: Moderate | 0 (0.0 to 26.5) | 25.0 (5.5 to 57.2) | 58.3 (27.7 to 84.8) | 0 (0.0 to 33.6) | 58.3 (27.7 to 84.8) | 0 (0.0 to 70.8) | 8.3 (0.2 to 38.5) | 16.7 (2.1 to 48.4) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 25.0 (5.5 to 57.2) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Pain at injection site: Severe | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 8.3 (0.2 to 38.5) | 0 (0.0 to 70.8) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Pain at injection site: Grade 4 | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 70.8) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
Local reactions included redness, swelling and, pain at the injection site, recorded by participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\> 2.0 to 5.0 cm), moderate (\> 5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), severe (prevents daily activity) and Grade 4 (emergency room visit or hospitalization for severe pain).
| Percentage of participants | BNT162b1 10 mcg Dose: 18-55 Years of Age | BNT162b1 20 mcg Dose: 18-55 Years of Age | BNT162b1 30 mcg Dose: 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b1 | BNT162b2 10 mcg Dose, 18-55 Years of Age | BNT162b2 20 mcg Dose, 18-55 Years of Age | BNT162b2 30 mcg Dose, 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b2 | BNT162b1 10 mcg Dose, 65-85 Years of Age | BNT162b1 20 mcg Dose, 65-85 Years of Age | BNT162b1 30 mcg Dose, 65-85 Years of Age | Placebo, 65-85 Years of Age for BNT162b1 | BNT162b2 10 mcg Dose, 65-85 Years of Age | BNT162b2 20 mcg Dose, 65-85 Years of Age | BNT162b2 30 mcg Dose, 65-85 Years of Age | Placebo: 65-85 Years of Age for BNT162b2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Redness: Mild | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Redness: Moderate | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 16.7 (2.1 to 48.4) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Redness: Severe | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Redness: Grade 4 | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Swelling: Mild | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 16.7 (2.1 to 48.4) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Swelling: Moderate | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.6) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 8.3 (0.2 to 38.5) | 16.7 (2.1 to 48.4) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Swelling: Severe | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Swelling: Grade 4 | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Pain at injection site: Mild | 75.0 (42.8 to 94.5) | 50.0 (21.1 to 78.9) | 66.7 (34.9 to 90.1) | 22.2 (2.8 to 60.0) | 50.0 (21.1 to 78.9) | 58.3 (27.7 to 84.8) | 75.0 (42.8 to 94.5) | 22.2 (2.8 to 60.0) | 50.0 (21.1 to 78.9) | 66.7 (34.9 to 90.1) | 58.3 (27.7 to 84.8) | 0 (0.0 to 33.6) | 25.0 (5.5 to 57.2) | 58.3 (27.7 to 84.8) | 50.0 (34.9 to 90.1) | 11.1 (0.3 to 48.2) |
| Pain at injection site: Moderate | 8.3 (0.2 to 38.5) | 25.0 (5.5 to 57.2) | 33.3 (9.9 to 65.1) | 0 (0.0 to 33.6) | 8.3 (0.2 to 38.5) | 25.0 (5.5 to 27.2) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 16.7 (2.1 to 48.4) | 8.3 (0.2 to 38.5) | 16.7 (2.1 to 48.4) | 0 (0.0 to 33.6) | 8.3 (0.2 to 38.5) | 0 (0.0 to 26.5) | 16.7 (2.1 to 48.4) | 0 (0.0 to 33.6) |
| Pain at injection site: Severe | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Pain at injection site: Grade 4 | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, new or worsened joint pain recorded by participants or parents/legal guardians of participants using e-diary. Fever=temperature \>=38.0 deg C categorized as \>=38.0 to 38.4, \>38.4 to 38.9, \>38.9 to 40.0 and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain graded as mild (does not interfere with activity), moderate (some interference with activity), severe (prevents daily routine activity), Grade 4 (Emergency room visit/hospitalization). Vomiting: mild (1-2 times in 24 hours\[h\]), moderate (\>2 times in 24 h), severe (requires IV hydration), Grade 4 (emergency room visit/hospitalization for hypotensive shock). Diarrhea: mild (2-3 loose stools in 24h), moderate (4-5 loose stools in 24 h), severe (\>=6 loose stools in 24 h) and Grade 4 (emergency room visit/hospitalization).
| Percentage of participants | BNT162b1 10 mcg Dose: 18-55 Years of Age | BNT162b1 20 mcg Dose: 18-55 Years of Age | BNT162b1 30 mcg Dose: 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b1 | BNT162b1 100 mcg Dose, 18-55 Years of Age | Placebo 18-55 Years of Age for BNT162b1 100 mcg | BNT162b2 10 mcg Dose, 18-55 Years of Age | BNT162b2 20 mcg Dose, 18-55 Years of Age | BNT162b2 30 mcg Dose, 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b2 | BNT162b1 10 mcg Dose, 65-85 Years of Age | BNT162b1 20 mcg Dose, 65-85 Years of Age | BNT162b1 30 mcg Dose, 65-85 Years of Age | Placebo, 65-85 Years of Age for BNT162b1 | BNT162b2 10 mcg Dose, 65-85 Years of Age | BNT162b2 20 mcg Dose, 65-85 Years of Age | BNT162b2 30 mcg Dose, 65-85 Years of Age | Placebo: 65-85 Years of Age for BNT162b2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fever: 38.0°C to 38.4°C | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 33.3 (9.9 to 65.1) | 0 (0.0 to 70.8) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 16.7 (2.1 to 48.4) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Fever: >38.4°C to 38.9°C | 8.3 (0.2 to 38.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 16.7 (2.1 to 48.4) | 0 (0.0 to 70.8) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Fever: >38.9°C to 40.0°C | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 70.8) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Fever: >40.0°C | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 70.8) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Fatigue: Mild | 25.0 (5.5 to 57.2) | 41.7 (15.2 to 72.3) | 25.0 (5.5 to 57.2) | 11.1 (0.3 to 48.2) | 16.7 (2.1 to 48.4) | 33.3 (0.8 to 90.6) | 25.0 (5.5 to 57.2) | 33.3 (9.9 to 65.1) | 16.7 (2.1 to 48.4) | 22.2 (2.8 to 60.0) | 16.7 (2.1 to 48.4) | 41.7 (15.2 to 72.3) | 16.7 (2.1 to 48.4) | 33.3 (7.5 to 70.1) | 8.3 (0.2 to 38.5) | 33.3 (9.9 to 65.1) | 16.7 (2.1 to 48.4) | 0 (0.0 to 33.6) |
| Fatigue: Moderate | 8.3 (0.2 to 38.5) | 25.0 (5.5 to 57.2) | 25.0 (5.5 to 57.2) | 11.1 (0.3 to 48.2) | 50.0 (2.1 to 78.9) | 0 (0.0 to 70.8) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 16.7 (2.1 to 48.4) | 11.1 (0.3 to 48.2) | 0 (0.0 to 26.5) | 16.7 (2.1 to 48.4) | 25.0 (5.5 to 57.2) | 11.1 (0.3 to 48.2) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 22.2 (2.8 to 60.0) |
| Fatigue: Severe | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 16.7 (2.1 to 48.4) | 0 (0.0 to 70.8) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Fatigue: Grade 4 | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 70.8) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Headache: Mild | 33.3 (9.9 to 65.1) | 41.7 (15.2 to 72.3) | 16.7 (2.1 to 48.4) | 11.1 (0.3 to 48.2) | 41.7 (15.2 to 72.3) | 66.7 (9.4 to 99.2) | 33.3 (9.9 to 65.1) | 25.0 (5.5 to 57.2) | 25.0 (5.5 to 57.2) | 22.8 (2.8 to 60.0) | 16.7 (2.1 to 48.4) | 16.7 (2.1 to 48.4) | 41.7 (15.2 to 72.3) | 0 (0.0 to 33.6) | 8.3 (0.2 to 38.5) | 16.7 (2.1 to 48.4) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Headache: Moderate | 8.3 (0.2 to 38.5) | 8.3 (0.2 to 38.5) | 33.3 (9.9 to 65.1) | 0. (0.0 to 33.6) | 25.0 (5.5 to 57.2) | 0 (0.0 to 70.8) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 8.3 (0.2 to 38.5) | 11.1 (0.3 to 48.2) | 8.3 (0.2 to 38.5) | 16.7 (2.1 to 48.4) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 26.5) | 11.1 (0.3 to 48.2) |
| Headache: Severe | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 8.3 (0.2 to 38.5) | 0 (0.0 to 70.8) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 16.7 (2.1 to 48.4) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Headache: Grade 4 | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 70.8) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Chills: Mild | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 25.0 (5.5 to 57.2) | 0 (0.0 to 33.6) | 41.7 (15.2 to 72.3) | 0 (0.0 to 70.8) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 16.7 (2.1 to 48.4) | 0 (0.0 to 33.6) | 8.3 (0.2 to 38.5) | 8.3 (0.2 to 38.5) | 8.3 (0.2 to 38.5) | 22.2 (2.8 to 60.0) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Chills: Moderate | 8.3 (0.2 to 38.5) | 16.7 (2.1 to 48.4) | 33.3 (9.9 to 65.1) | 0 (0.0 to 33.6) | 33.3 (9.9 to 65.1) | 0 (0.0 to 70.8) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Chills: Severe | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 8.3 (0.2 to 38.5) | 0 (0.0 to 70.8) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Chills: Grade 4 | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 70.8) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0.0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0. to 026.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Vomiting: Mild | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 70.8) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Vomiting: Moderate | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 70.8) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Vomiting: Severe | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 70.8) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0.0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Vomiting: Grade 4 | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 70.8) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Diarrhea: Mild | 16.7 (2.1 to 48.4) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 33.3 (9.9 to 65.1) | 0 (0.0 to 70.8) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 11.1 (0.3 to 48.2) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 11.1 (0.3 to 48.2) |
| Diarrhea: Moderate | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 70.8) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 0.0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Diarrhea: Severe | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 70.8) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Diarrhea: Grade 4 | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 70.8) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| New or worsened muscle pain: Mild | 8.3 (0.2 to 38.5) | 25.0 (5.5 to 57.2) | 16.7 (2.1 to 48.4) | 0 (0.0 to 33.6) | 41.7 (15.2 to 72.3) | 0 (0.0 to 70.8) | 25.0 (5.5 to 57.2) | 8.3 (0.2 to 38.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 16.7 (2.1 to 48.4) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 8.3 (0.2 to 38.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| New or worsened muscle pain: Moderate | 0.0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 8.3 (0.2 to 38.5) | 0 (0.0 to 70.8) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 16.7 (2.1 to 48.4) | 8.3 (0.2 to 38.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 0.0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 11.1 (0.3 to 48.2) |
| New or worsened muscle pain: Severe | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 8.3 (0.2 to 38.5) | 0 (0.0 to 70.8) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 11.1 (0.3 to 48.2) | 0.0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 11.1 (0.3 to 48.2) |
| New or worsened muscle pain: Grade 4 | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 70.8) | 0 (0.0 to 26.5) | 0.0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0.0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 48.2) |
| New or worsened joint pain: Mild | 16.7 (2.1 to 48.4) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 11.1 (0.3 to 48.2) | 8.3 (0.2 to 38.5) | 0 (0.0 to 70.8) | 8.3 (0.2 to 38.5) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 16.7 (2.1 to 48.4) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0.0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| New or worsened joint pain: Moderate | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 8.3 (0.2 to 38.5) | 0 (0.0 to 70.8) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 8.3 (0.2 to 38.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 11.1 (0.3 to 48.2) |
| New or worsened joint pain: Severe | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 8.3 (0.2 to 38.5) | 0 (0.0 to 70.8) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) |
| New or worsened joint pain: Grade 4 | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 70.8) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 8.3 (0.2 to 38.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, new or worsened joint pain recorded by participants or parents/legal guardians of participants using e-diary. Fever=temperature \>=38.0 deg C categorized as \>=38.0 to 38.4, \>38.4 to 38.9, \>38.9 to 40.0 and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain graded as mild (does not interfere with activity), moderate (some interference with activity), severe (prevents daily routine activity), Grade 4 (Emergency room visit/hospitalization). Vomiting: mild (1-2 times in 24 h), moderate (\>2 times in 24 h), severe (requires IV hydration), Grade 4 (emergency room visit/hospitalization for hypotensive shock). Diarrhea: mild (2-3 loose stools in 24h), moderate (4-5 loose stools in 24 h), severe (\>=6 loose stools in 24 h) and Grade 4 (emergency room visit/hospitalization).
| Percentage of participants | BNT162b1 10 mcg Dose: 18-55 Years of Age | BNT162b1 20 mcg Dose: 18-55 Years of Age | BNT162b1 30 mcg Dose: 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b1 | BNT162b2 10 mcg Dose, 18-55 Years of Age | BNT162b2 20 mcg Dose, 18-55 Years of Age | BNT162b2 30 mcg Dose, 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b2 | BNT162b1 10 mcg Dose, 65-85 Years of Age | BNT162b1 20 mcg Dose, 65-85 Years of Age | BNT162b1 30 mcg Dose, 65-85 Years of Age | Placebo, 65-85 Years of Age for BNT162b1 | BNT162b2 10 mcg Dose, 65-85 Years of Age | BNT162b2 20 mcg Dose, 65-85 Years of Age | BNT162b2 30 mcg Dose, 65-85 Years of Age | Placebo: 65-85 Years of Age for BNT162b2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fever: 38.0°C to 38.4°C | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 16.7 (2.1 to 48.4) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 25.0 (5.5 to 57.2) | 16.7 (2.1 to 48.4) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Fever: >38.4°C to 38.9°C | 8.3 (0.2 to 38.5) | 8.3 (0.2 to 38.5) | 58.3 (27.7 to 84.8) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 25.0 (5.5 to 57.2) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Fever: >38.9°C to 40.0°C | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Fever: >40.0°C | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Fatigue: Mild | 25.0 (5.5 to 57.2) | 50.0 (21.1 to 78.9) | 16.7 (2.1 to 48.4) | 11.1 (0.3 to 48.2) | 25.0 (5.5 to 57.2) | 33.3 (9.9 to 65.1) | 16.7 (2.1 to 48.4) | 22.2 (2.8 to 60.0) | 16.7 (2.1 to 48.4) | 8.3 (0.2 to 38.5) | 25.0 (5.5 to 57.2) | 11.1 (0.3 to 48.2) | 8.3 (0.2 to 38.5) | 33.3 (9.9 to 65.1) | 16.7 (2.1 to 48.4) | 0 (0.0 to 33.6) |
| Fatigue: Moderate | 33.3 (9.9 to 65.1) | 25.0 (5.5 to 57.2) | 66.7 (34.9 to 90.1) | 11.1 (0.3 to 48.2) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 16.7 (2.1 to 48.4) | 11.1 (0.3 to 48.2) | 8.3 (0.2 to 38.5) | 41.7 (15.2 to 72.3) | 33.3 (9.9 to 65.1) | 11.1 (0.3 to 48.2) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 11.1 (0.3 to 48.2) |
| Fatigue: Severe | 8.3 (0.2 to 38.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Fatigue: Grade 4 | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Headache: Mild | 58.3 (27.7 to 84.8) | 50.0 (21.1 to 78.9) | 58.3 (27.7 to 84.8) | 0 (0.0 to 33.6) | 33.3 (9.9 to 65.1) | 25.0 (5.5 to 57.2) | 25.0 (5.5 to 57.2) | 22.8 (2.8 to 60.0) | 33.3 (9.9 to 65.1) | 33.3 (9.9 to 65.1) | 50.0 (2.1 to 78.9) | 11.1 (0.3 to 48.2) | 25.0 (5.5 to 57.2) | 25.0 (5.5 to 57.2) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Headache: Moderate | 25.0 (5.5 to 57.2) | 16.7 (2.1 to 48.4) | 41.7 (15.2 to 72.3) | 0. (0.0 to 33.6) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 8.3 (0.2 to 38.5) | 11.1 (0.3 to 48.2) | 8.3 (0.2 to 38.5) | 33.3 (9.9 to 65.1) | 25.0 (5.5 to 57.2) | 0 (0.0 to 33.6) | 8.3 (0.2 to 38.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 26.5) | 11.1 (0.3 to 48.2) |
| Headache: Severe | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 16.7 (2.1 to 48.4) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Headache: Grade 4 | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Chills: Mild | 0 (0.0 to 26.5) | 16.7 (2.1 to 48.4) | 41.7 (15.2 to 72.3) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 16.7 (2.1 to 48.4) | 0 (0.0 to 33.6) | 16.7 (2.1 to 48.4) | 33.3 (9.9 to 65.1) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 16.7 (2.1 to 48.4) | 8.3 (0.2 to 38.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Chills: Moderate | 25.0 (5.5 to 57.2) | 33.3 (9.9 to 65.1) | 16.7 (2.1 to 48.4) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 8.3 (0.2 to 38.5) | 25.0 (5.5 to 57.2) | 25.0 (5.5 to 57.2) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) |
| Chills: Severe | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Chills: Grade 4 | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0. to 026.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Vomiting: Mild | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Vomiting: Moderate | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Vomiting: Severe | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Vomiting: Grade 4 | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Diarrhea: Mild | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 16.7 (2.1 to 48.4) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 11.1 (0.3 to 48.2) |
| Diarrhea: Moderate | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Diarrhea: Severe | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| Diarrhea: Grade 4 | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| New or worsened muscle pain: Mild | 33.3 (9.9 to 65.1) | 16.7 (2.1 to 48.4) | 16.7 (2.1 to 48.4) | 0 (0.0 to 33.6) | 25.0 (5.5 to 57.2) | 8.3 (0.2 to 38.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 16.7 (2.1 to 48.4) | 8.3 (0.2 to 38.5) | 16.7 (2.1 to 48.4) | 0 (0.0 to 33.6) | 8.3 (0.2 to 38.5) | 8.3 (0.2 to 38.5) | 16.7 (2.1 to 48.4) | 0 (0.0 to 33.6) |
| New or worsened muscle pain: Moderate | 8.3 (0.2 to 38.5) | 58.3 (27.7 to 84.8) | 41.7 (15.2 to 72.3) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 16.7 (2.1 to 48.4) | 25.0 (5.5 to 57.2) | 16.7 (2.1 to 48.4) | 0 (0.0 to 33.6) | 0 (0.0 to 28.5) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 11.1 (0.3 to 48.2) |
| New or worsened muscle pain: Severe | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| New or worsened muscle pain: Grade 4 | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| New or worsened joint pain: Mild | 8.3 (0.2 to 38.5) | 33.3 (9.9 to 65.1) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 8.3 (0.2 to 38.5) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 16.7 (2.1 to 48.4) | 16.7 (2.1 to 48.4) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| New or worsened joint pain: Moderate | 25.0 (5.5 to 57.2) | 16.7 (2.1 to 48.4) | 16.7 (2.1 to 48.4) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 8.3 (0.2 to 38.5) | 8.3 (0.2 to 38.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 11.1 (0.3 to 48.2) |
| New or worsened joint pain: Severe | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
| New or worsened joint pain: Grade 4 | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 26.5) | 0 (0.0 to 33.6) |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. For BNT162b1 100 mcg, participants received one dose of 100 mcg, followed by one dose of 10 mcg.
| Percentage of participants | BNT162b1 10 mcg Dose: 18-55 Years of Age | BNT162b1 20 mcg Dose: 18-55 Years of Age | BNT162b1 30 mcg Dose: 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b1 | BNT162b1 100 mcg Dose, 18-55 Years of Age | Placebo 18-55 Years of Age for BNT162b1 100 mcg | BNT162b2 10 mcg Dose, 18-55 Years of Age | BNT162b2 20 mcg Dose, 18-55 Years of Age | BNT162b2 30 mcg Dose, 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b2 | BNT162b1 10 mcg Dose, 65-85 Years of Age | BNT162b1 20 mcg Dose, 65-85 Years of Age | BNT162b1 30 mcg Dose, 65-85 Years of Age | Placebo, 65-85 Years of Age for BNT162b1 | BNT162b2 10 mcg Dose, 65-85 Years of Age | BNT162b2 20 mcg Dose, 65-85 Years of Age | BNT162b2 30 mcg Dose, 65-85 Years of Age | Placebo: 65-85 Years of Age for BNT162b2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: Phase 1 | 50.0 (21.1 to 78.9) | 41.7 (15.2 to 72.3) | 50.0 (21.1 to 78.9) | 22.2 (2.8 to 60.0) | 66.7 (34.9 to 90.1) | 33.3 (0.8 to 90.6) | 33.3 (9.9 to 65.1) | 41.7 (15.2 to 72.3) | 41.7 (15.2 to 72.3) | 22.2 (2.8 to 60.0) | 50.0 (21.1 to 78.9) | 58.3 (27.7 to 84.8) | 25.0 (5.5 to 57.2) | 44.4 (13.7 to 78.8) | 8.3 (0.2 to 38.5) | 8.3 (0.2 to 38.5) | 25.0 (5.5 to 57.2) | 22.2 (2.8 to 60.0) |
An SAE was any untoward medical occurrence that occurred, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect and other important medical events. For BNT162b1 100 mcg, participants received one dose of 100 mcg, followed by one dose of 10 mcg.
| Percentage of participants | BNT162b1 10 mcg Dose, 18-85 Years of Age | BNT162b1 20 mcg Dose, 18-85 Years of Age | BNT162b1 30 mcg Dose, 18-85 Years of Age | BNT162b1 100 mcg: 18-55 Years of Age | BNT162b2 10 mcg Dose, 18-85 Years of Age | BNT162b2 20 mcg Dose, 18-85 Years of Age | BNT162b2 30 mcg Dose, 18-85 Years of Age | Placebo/BNT162b2 30 mcg: 18-85 Years of Age |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: Phase 1 | 0 (0.0 to 14.2) | 0 (0.0 to 14.2) | 0 (0.0 to 14.2) | 0 (0.0 to 26.5) | 0 (0.0 to 14.2) | 4.2 (0.1 to 21.1) | 4.2 (0.1 to 21.1) | 0 (0.0 to 10.0) |
Hematology parameters that were assessed included hemoglobin, hematocrit, erythrocytes, Ery. mean corpuscular volume, Ery. mean corpuscular hemoglobin, Ery. mean corpuscular HGB concentration, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils and monocytes. Abnormal parameters were determined by following criteria: Hemoglobin : \<0.8x lower limit of normal (LLN), Hematocrit : \<0.8x LLN, Erythrocytes : \<0.8x LLN, Ery. Mean Corpuscular Volume: \<0.9x LLN, Ery. Mean Corpuscular Hemoglobin : \<0.9x LLN Ery. Mean Corpuscular HGB Concentration : \<0.9x LLN, Platelets : \<0.5x LLN, Leukocytes : \<0.6x LLN, Lymphocytes : \<0.8x LLN, Neutrophils : \<0.8x LLN, Basophils: \>1.2x upper limit of normal (ULN), Eosinophils \>1.2x ULN, Monocytes \>1.2x ULN. Only parameters with abnormal values were reported in this outcome measure.
| Percentage of participants | BNT162b1 10 mcg Dose: 18-55 Years of Age | BNT162b1 20 mcg Dose: 18-55 Years of Age | BNT162b1 30 mcg Dose: 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b1 | BNT162b1 100 mcg Dose, 18-55 Years of Age | Placebo 18-55 Years of Age for BNT162b1 100 mcg | BNT162b2 10 mcg Dose, 18-55 Years of Age | BNT162b2 20 mcg Dose, 18-55 Years of Age | BNT162b2 30 mcg Dose, 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b2 | BNT162b1 10 mcg Dose, 65-85 Years of Age | BNT162b1 20 mcg Dose, 65-85 Years of Age | BNT162b1 30 mcg Dose, 65-85 Years of Age | Placebo, 65-85 Years of Age for BNT162b1 | BNT162b2 10 mcg Dose, 65-85 Years of Age | BNT162b2 20 mcg Dose, 65-85 Years of Age | BNT162b2 30 mcg Dose, 65-85 Years of Age | Placebo: 65-85 Years of Age for BNT162b2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lymphocytes | 8.3 | 33.3 | 54.5 | 0 | 75.0 | 75.0 | 0 | 8.3 | 8.3 | 0 | 8.3 | 25.0 | 16.7 | 0 | 8.3 | 8.3 | 8.3 | 0 |
| Neutrophils | 8.3 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 16.7 | 0 | 0 |
| Ery. Mean Corpuscular Hemoglobin | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Hematology parameters that were assessed included hemoglobin, hematocrit, erythrocytes, Ery. mean corpuscular volume, Ery. mean corpuscular hemoglobin, Ery. mean corpuscular HGB concentration, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils and monocytes. Abnormal parameters were determined by following criteria: Hemoglobin : \<0.8x LLN, Hematocrit : \<0.8x LLN, Erythrocytes : \<0.8x LLN, Ery. Mean Corpuscular Volume: \<0.9x LLN, Ery. Mean Corpuscular Hemoglobin : \<0.9x LLN Ery. Mean Corpuscular HGB Concentration : \<0.9x LLN, Platelets : \<0.5x LLN, Leukocytes : \<0.6x LLN, Lymphocytes : \<0.8x LLN, Neutrophils : \<0.8x LLN, Basophils: \>1.2x ULN, Eosinophils \>1.2x ULN, Monocytes \>1.2x ULN. Only parameters with abnormal values were reported in this outcome measure.
| Percentage of participants | BNT162b1 10 mcg Dose: 18-55 Years of Age | BNT162b1 20 mcg Dose: 18-55 Years of Age | BNT162b1 30 mcg Dose: 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b1 | BNT162b1 100 mcg Dose, 18-55 Years of Age | Placebo 18-55 Years of Age for BNT162b1 100 mcg | BNT162b2 10 mcg Dose, 18-55 Years of Age | BNT162b2 20 mcg Dose, 18-55 Years of Age | BNT162b2 30 mcg Dose, 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b2 | BNT162b1 10 mcg Dose, 65-85 Years of Age | BNT162b1 20 mcg Dose, 65-85 Years of Age | BNT162b1 30 mcg Dose, 65-85 Years of Age | Placebo, 65-85 Years of Age for BNT162b1 | BNT162b2 10 mcg Dose, 65-85 Years of Age | BNT162b2 20 mcg Dose, 65-85 Years of Age | BNT162b2 30 mcg Dose, 65-85 Years of Age | Placebo: 65-85 Years of Age for BNT162b2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lymphocytes | 0 | 0 | 0 | 0 | 0 | 11.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 8.3 | 11.1 |
| Neutrophils | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 16.7 | 0 | 0 | 8.3 | 0 | 0 | 0 |
| Ery. Mean Corpuscular Hemoglobin | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Hematology parameters that were assessed included hemoglobin, hematocrit, erythrocytes, Ery. mean corpuscular volume, Ery. mean corpuscular hemoglobin, Ery. mean corpuscular HGB concentration, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils and monocytes. Abnormal parameters were determined by following criteria: Hemoglobin : \<0.8x LLN, Hematocrit : \<0.8x LLN, Erythrocytes : \<0.8x LLN, Ery. Mean Corpuscular Volume: \<0.9x LLN, Ery. Mean Corpuscular Hemoglobin : \<0.9x LLN Ery. Mean Corpuscular HGB Concentration : \<0.9x LLN, Platelets : \<0.5x LLN, Leukocytes : \<0.6x LLN, Lymphocytes : \<0.8x LLN, Neutrophils : \<0.8x LLN, Basophils: \>1.2x ULN, Eosinophils \>1.2x ULN, Monocytes \>1.2x ULN. Only parameters with abnormal values were reported in this outcome measure.
| Percentage of participants | BNT162b1 10 mcg Dose: 18-55 Years of Age | BNT162b1 20 mcg Dose: 18-55 Years of Age | BNT162b1 30 mcg Dose: 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b1 | BNT162b1 100 mcg Dose, 18-55 Years of Age | Placebo 18-55 Years of Age for BNT162b1 100 mcg | BNT162b2 10 mcg Dose, 18-55 Years of Age | BNT162b2 20 mcg Dose, 18-55 Years of Age | BNT162b2 30 mcg Dose, 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b2 | BNT162b1 10 mcg Dose, 65-85 Years of Age | BNT162b1 20 mcg Dose, 65-85 Years of Age | BNT162b1 30 mcg Dose, 65-85 Years of Age | Placebo, 65-85 Years of Age for BNT162b1 | BNT162b2 10 mcg Dose, 65-85 Years of Age | BNT162b2 20 mcg Dose, 65-85 Years of Age | BNT162b2 30 mcg Dose, 65-85 Years of Age | Placebo: 65-85 Years of Age for BNT162b2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ery. Mean Corpuscular Hemoglobin | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophils | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 |
| Lymphocytes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11.1 | 8.3 | 0 | 8.3 | 0 |
| Eosinophils | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 |
Hematology parameters that were assessed included hemoglobin, hematocrit, erythrocytes, Ery. mean corpuscular volume, Ery. mean corpuscular hemoglobin, Ery. mean corpuscular HGB concentration, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils and monocytes. Abnormal parameters were determined by following criteria: Hemoglobin : \<0.8x LLN, Hematocrit : \<0.8x LLN, Erythrocytes : \<0.8x LLN, Ery. Mean Corpuscular Volume: \<0.9x LLN, Ery. Mean Corpuscular Hemoglobin : \<0.9x LLN Ery. Mean Corpuscular HGB Concentration : \<0.9x LLN, Platelets : \<0.5x LLN, Leukocytes : \<0.6x LLN, Lymphocytes : \<0.8x LLN, Neutrophils : \<0.8x LLN, Basophils: \>1.2x ULN, Eosinophils \>1.2x ULN, Monocytes \>1.2x ULN. Only parameters with abnormal values were reported in this outcome measure.
| Percentage of participants | BNT162b1 10 mcg Dose: 18-55 Years of Age | BNT162b1 20 mcg Dose: 18-55 Years of Age | BNT162b1 30 mcg Dose: 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b1 | BNT162b2 10 mcg Dose, 18-55 Years of Age | BNT162b2 20 mcg Dose, 18-55 Years of Age | BNT162b2 30 mcg Dose, 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b2 | BNT162b1 10 mcg Dose, 65-85 Years of Age | BNT162b1 20 mcg Dose, 65-85 Years of Age | BNT162b1 30 mcg Dose, 65-85 Years of Age | Placebo, 65-85 Years of Age for BNT162b1 | BNT162b2 10 mcg Dose, 65-85 Years of Age | BNT162b2 20 mcg Dose, 65-85 Years of Age | BNT162b2 30 mcg Dose, 65-85 Years of Age | Placebo: 65-85 Years of Age for BNT162b2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neutrophils | 8.3 | 0 | 8.3 | 0 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 |
| Monocytes | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 11.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Eosinophils | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocytes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 8.3 | 0 |
| Ery. Mean Corpuscular Hemoglobin | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 | 0 |
Chemistry parameters that were assessed included bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), urea nitrogen, creatinine. Abnormal parameters were determined by following criteria: bilirubin: \>1.5x ULN, AST: \>3.0x ULN, ALT: \>3.0x ULN, ALP: \>3.0x ULN, urea nitrogen: \>1.3x ULN, creatinine: \>1.3x ULN. Abnormal values reported for this outcome measure are for bilirubin.
| Percentage of participants | BNT162b1 10 mcg Dose: 18-55 Years of Age | BNT162b1 20 mcg Dose: 18-55 Years of Age | BNT162b1 30 mcg Dose: 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b1 | BNT162b1 100 mcg Dose, 18-55 Years of Age | Placebo 18-55 Years of Age for BNT162b1 100 mcg | BNT162b2 10 mcg Dose, 18-55 Years of Age | BNT162b2 20 mcg Dose, 18-55 Years of Age | BNT162b2 30 mcg Dose, 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b2 | BNT162b1 10 mcg Dose, 65-85 Years of Age | BNT162b1 20 mcg Dose, 65-85 Years of Age | BNT162b1 30 mcg Dose, 65-85 Years of Age | Placebo, 65-85 Years of Age for BNT162b1 | BNT162b2 10 mcg Dose, 65-85 Years of Age | BNT162b2 20 mcg Dose, 65-85 Years of Age | BNT162b2 30 mcg Dose, 65-85 Years of Age | Placebo: 65-85 Years of Age for BNT162b2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Abnormalities in Chemistry Parameters 1 Day After Dose 1: Phase 1 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Chemistry parameters that were assessed included bilirubin, AST, ALT, ALP, urea nitrogen, creatinine. Abnormal parameters were determined by following criteria: bilirubin: \>1.5x ULN, AST: \>3.0x ULN, ALT: \>3.0x ULN, ALP: \>3.0x ULN, urea nitrogen: \>1.3x ULN, creatinine: \>1.3x ULN. Abnormal values reported for this outcome measure are for bilirubin.
| Percentage of participants | BNT162b1 10 mcg Dose: 18-55 Years of Age | BNT162b1 20 mcg Dose: 18-55 Years of Age | BNT162b1 30 mcg Dose: 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b1 | BNT162b1 100 mcg Dose, 18-55 Years of Age | Placebo 18-55 Years of Age for BNT162b1 100 mcg | BNT162b2 10 mcg Dose, 18-55 Years of Age | BNT162b2 20 mcg Dose, 18-55 Years of Age | BNT162b2 30 mcg Dose, 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b2 | BNT162b1 10 mcg Dose, 65-85 Years of Age | BNT162b1 20 mcg Dose, 65-85 Years of Age | BNT162b1 30 mcg Dose, 65-85 Years of Age | Placebo, 65-85 Years of Age for BNT162b1 | BNT162b2 10 mcg Dose, 65-85 Years of Age | BNT162b2 20 mcg Dose, 65-85 Years of Age | BNT162b2 30 mcg Dose, 65-85 Years of Age | Placebo: 65-85 Years of Age for BNT162b2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Abnormalities in Chemistry Parameters 7 Days After Dose 1: Phase 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Chemistry parameters that were assessed included bilirubin, AST, ALT, ALP, urea nitrogen, creatinine. Abnormal parameters were determined by following criteria: bilirubin: \>1.5x ULN, AST: \>3.0x ULN, ALT: \>3.0x ULN, ALP: \>3.0x ULN, urea nitrogen: \>1.3x ULN, creatinine: \>1.3x ULN. Abnormal values reported for this outcome measure are for bilirubin.
| Percentage of participants | BNT162b1 10 mcg Dose: 18-55 Years of Age | BNT162b1 20 mcg Dose: 18-55 Years of Age | BNT162b1 30 mcg Dose: 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b1 | BNT162b1 100 mcg Dose, 18-55 Years of Age | Placebo 18-55 Years of Age for BNT162b1 100 mcg | BNT162b2 10 mcg Dose, 18-55 Years of Age | BNT162b2 20 mcg Dose, 18-55 Years of Age | BNT162b2 30 mcg Dose, 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b2 | BNT162b1 10 mcg Dose, 65-85 Years of Age | BNT162b1 20 mcg Dose, 65-85 Years of Age | BNT162b1 30 mcg Dose, 65-85 Years of Age | Placebo, 65-85 Years of Age for BNT162b1 | BNT162b2 10 mcg Dose, 65-85 Years of Age | BNT162b2 20 mcg Dose, 65-85 Years of Age | BNT162b2 30 mcg Dose, 65-85 Years of Age | Placebo: 65-85 Years of Age for BNT162b2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Abnormalities in Chemistry Parameters Before Dose 2: Phase 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Chemistry parameters that were assessed included bilirubin, AST, ALT, ALP, urea nitrogen, creatinine. Abnormal parameters were determined by following criteria: bilirubin: \>1.5x ULN, AST: \>3.0x ULN, ALT: \>3.0x ULN, ALP: \>3.0x ULN, urea nitrogen: \>1.3x ULN, creatinine: \>1.3x ULN. Abnormal values reported for this outcome measure are for bilirubin.
| Percentage of participants | BNT162b1 10 mcg Dose: 18-55 Years of Age | BNT162b1 20 mcg Dose: 18-55 Years of Age | BNT162b1 30 mcg Dose: 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b1 | BNT162b2 10 mcg Dose, 18-55 Years of Age | BNT162b2 20 mcg Dose, 18-55 Years of Age | BNT162b2 30 mcg Dose, 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b2 | BNT162b1 10 mcg Dose, 65-85 Years of Age | BNT162b1 20 mcg Dose, 65-85 Years of Age | BNT162b1 30 mcg Dose, 65-85 Years of Age | Placebo, 65-85 Years of Age for BNT162b1 | BNT162b2 10 mcg Dose, 65-85 Years of Age | BNT162b2 20 mcg Dose, 65-85 Years of Age | BNT162b2 30 mcg Dose, 65-85 Years of Age | Placebo: 65-85 Years of Age for BNT162b2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Abnormalities in Chemistry Parameters 7 Days After Dose 2: Phase 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Percentage of participants with grade shift in hematology parameters reported in this outcome measure. Grade(G)1: Mild, G2:Moderate, G3:Severe, G4:potentially life threatening. Hemoglobin(Female): G1: 11.0 - 12.0grams per deciliter(g/dL), G2: 9.5 - 10.9, G3: 8.0 - 9.4, G4: \<8.0. Hemoglobin(Male): G1: 12.5 - 13.5, G2: 10.5 - 12.4, G3: 8.5 - 10.4, G4: \<8.5. WBC decrease(cells/mm3):G1: 2,500 - 3,500, G2: 1,500 - 2,499, G3: 1,000 - 1,499, G4: \<1,000 Lymphocytes decrease(cells/mm3): G1: 750 - 1,000, G2: 500 - 749, G3: 250 - 499, G4: \<250. Eosinophils(cells/mm3):G1: 650 - 1500, G2: 1501 - 5000, G3: \>5000, G4:Hypereosinophilic. Platelets decreased(cells/mm3): G1: 125,000 - 140,000, G2: 100,000 - 124,000, G3: 25,000 - 99,000, G4: \<25,000. Urea Nitrogen (mg/dl): G1: 23-26; G2:27-31; G3: \>31; G4: requires dialysis. Only parameters where grade shift was observed were reported.
| Percentage of participants | BNT162b1 10 mcg Dose: 18-55 Years of Age | BNT162b1 20 mcg Dose: 18-55 Years of Age | BNT162b1 30 mcg Dose: 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b1 | BNT162b1 100 mcg Dose, 18-55 Years of Age | Placebo 18-55 Years of Age for BNT162b1 100 mcg | BNT162b2 10 mcg Dose, 18-55 Years of Age | BNT162b2 20 mcg Dose, 18-55 Years of Age | BNT162b2 30 mcg Dose, 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b2 | BNT162b1 10 mcg Dose, 65-85 Years of Age | BNT162b1 20 mcg Dose, 65-85 Years of Age | BNT162b1 30 mcg Dose, 65-85 Years of Age | Placebo, 65-85 Years of Age for BNT162b1 | BNT162b2 10 mcg Dose, 65-85 Years of Age | BNT162b2 20 mcg Dose, 65-85 Years of Age | BNT162b2 30 mcg Dose, 65-85 Years of Age | Placebo: 65-85 Years of Age for BNT162b2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hemoglobin: Baseline Normal to Normal | 75.0 | 75.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 83.3 | 87.5 | 91.7 | 91.7 | 100.0 | 88.9 | 83.3 | 91.7 | 83.3 | 88.9 |
| Hemoglobin: Normal to Grade 1 | 8.3 | 8.3 | 0 | 0 | 0 | 0 | 0 | 0 | 16.7 | 0 | 0 | 0 | 0 | 11.1 | 8.3 | 0 | 8.3 | 11.1 |
| Hemoglobin: Grade 1 to Normal | 16.7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12.5 | 8.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin: Grade1 to Grade1 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 8.3 | 8.3 | 0 |
| Hemoglobin: Grade1 to Grade2 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Eosinophils: Baseline Normal to Normal | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |
| Lymphocytes: Baseline Normal to Normal | 66.7 | 25.0 | 18.2 | 100.0 | 0 | 100.0 | 75.0 | 75.0 | 58.3 | 100.0 | 33.3 | 16.7 | 41.7 | 100.0 | 75.0 | 33.3 | 66.7 | 88.9 |
| Lymphocytes: Normal to Grade1 | 16.7 | 41.7 | 27.3 | 0 | 16.7 | 0 | 25.0 | 16.7 | 33.3 | 0 | 50.0 | 16.7 | 33.3 | 0 | 16.7 | 50.0 | 25.0 | 0 |
| Lymphocytes: Normal to Grade2 | 8.3 | 16.7 | 45.5 | 0 | 50.0 | 0 | 0 | 8.3 | 8.3 | 0 | 8.3 | 66.7 | 16.7 | 0 | 0 | 16.7 | 0 | 0 |
| Lymphocytes: Normal to Grade3 | 8.3 | 16.7 | 9.1 | 0 | 33.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 8.3 | 0 | 0 | 0 |
| Lymphocytes: Normal to Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocytes: Grade1 to Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11.1 |
| Lymphocytes: Grade 1 to Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 |
| Platelets Decrease: Normal to Normal | 100.0 | 91.7 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 87.5 | 100.0 | 91.7 | 91.7 | 91.7 | 100.0 | 83.3 | 91.7 | 83.3 | 77.8 |
| Platelet Decrease: Normal to Grade 1 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 | 0 | 12.5 | 0 | 0 | 0 | 0 | 0 | 8.3 | 8.3 | 8.3 | 11.1 |
| Platelet Decrease: Normal to Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 8.3 | 0 | 0 | 8.3 | 0 | 8.3 | 0 |
| Platelet decrease: Grade 1 to Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 | 0 | 11.1 |
| Urea Nitrogen: Baseline Normal to Normal | 100.0 | 91.7 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 88.9 | 91.7 | 100.0 | 100.0 | 88.9 | 100.0 | 100.0 | 91.7 | 100.0 |
| Urea Nitrogen: Normal to Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Urea Nitrogen: Normal to Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11.1 | 0 | 0 | 8.3 | 0 |
| Urea Nitrogen: Grade 1 to Normal | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| WBC Decrease: Baseline Normal to Normal | 91.7 | 91.7 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 91.7 | 100.0 | 100.0 | 83.3 | 75.0 | 100.0 | 88.9 | 83.3 | 75.0 | 91.7 | 100.0 |
| WBC Decrease: Baseline normal to Grade 1 | 8.3 | 8.3 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 16.7 | 25.0 | 0 | 11.1 | 8.3 | 8.3 | 0 | 0 |
| WBC Decrease: Normal to Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 16.7 | 0 | 0 |
| WBC Decrease: Grade 1 to Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 |
| WBC Decrease: Grade 1 to Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 |
Percentage of participants with grade shift in hematology parameters reported in this outcome measure. Grade(G)1: Mild, G2:Moderate, G3:Severe, G4:potentially life threatening. Hemoglobin(Female): G1: 11.0 - 12.0grams per deciliter(g/dL), G2: 9.5 - 10.9, G3: 8.0 - 9.4, G4: \<8.0. Hemoglobin(Male): G1: 12.5 - 13.5, G2: 10.5 - 12.4, G3: 8.5 - 10.4, G4: \<8.5. WBC decrease(cells/mm3):G1: 2,500 - 3,500, G2: 1,500 - 2,499, G3: 1,000 - 1,499, G4: \<1,000 Lymphocytes decrease(cells/mm3): G1: 750 - 1,000, G2: 500 - 749, G3: 250 - 499, G4: \<250. Eosinophils(cells/mm3):G1: 650 - 1500, G2: 1501 - 5000, G3: \>5000, G4:Hypereosinophilic. Platelets decreased(cells/mm3): G1: 125,000 - 140,000, G2: 100,000 - 124,000, G3: 25,000 - 99,000, G4: \<25,000. Urea Nitrogen (mg/dl): G1: 23-26; G2:27-31; G3: \>31; G4: requires dialysis. Only parameters where grade shift was observed were reported.
| Percentage of participants | BNT162b1 10 mcg Dose: 18-55 Years of Age | BNT162b1 20 mcg Dose: 18-55 Years of Age | BNT162b1 30 mcg Dose: 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b1 | BNT162b1 100 mcg Dose, 18-55 Years of Age | Placebo 18-55 Years of Age for BNT162b1 100 mcg | BNT162b2 10 mcg Dose, 18-55 Years of Age | BNT162b2 20 mcg Dose, 18-55 Years of Age | BNT162b2 30 mcg Dose, 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b2 | BNT162b1 10 mcg Dose, 65-85 Years of Age | BNT162b1 20 mcg Dose, 65-85 Years of Age | BNT162b1 30 mcg Dose, 65-85 Years of Age | Placebo, 65-85 Years of Age for BNT162b1 | BNT162b2 10 mcg Dose, 65-85 Years of Age | BNT162b2 20 mcg Dose, 65-85 Years of Age | BNT162b2 30 mcg Dose, 65-85 Years of Age | Placebo: 65-85 Years of Age for BNT162b2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hemoglobin: Baseline Normal to Normal | 83.3 | 75.0 | 100.0 | 100.0 | 91.7 | 100.0 | 91.7 | 100.0 | 100.0 | 88.9 | 91.7 | 83.3 | 100.0 | 100.0 | 91.7 | 91.7 | 91.7 | 88.9 |
| Hemoglobin: Grade1 to Normal | 16.7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11.1 | 8.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin: Normal to Grade1 | 0 | 8.3 | 0 | 0 | 8.3 | 0 | 8.3 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 | 11.1 |
| Hemoglobin: Grade1 to Grade1 | 0 | 16.7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 8.3 | 8.3 | 0 |
| Hemoglobin: Grade1 to Grade2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Eosinophils: Baseline Normal to Normal | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |
| Lymphocytes: Baseline Normal to Normal | 100.0 | 91.7 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 91.7 | 77.8 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 91.7 | 91.7 | 88.9 |
| Lymphocytes: Normal to Grade1 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 11.1 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 |
| Lymphocytes: Grade1 to Normal | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11.1 |
| Lymphocytes: Grade 1 to Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 |
| Platelets Decrease: Baseline Normal to Normal | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 91.7 | 91.7 | 90.9 | 100.0 | 90.9 | 100.0 | 100.0 | 77.8 |
| Platelets Decrease: Normal to Grade1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 8.3 | 0 | 0 | 9.1 | 0 | 0 | 11.1 |
| Platelets Decrease: Grade1 to Normal | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9.1 | 0 | 0 | 0 | 0 | 0 |
| Platelets Decrease: Grade 1 to Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11.1 |
| Urea Nitrogen: Baseline Normal to Normal | 100.0 | 91.7 | 100.0 | 100.0 | 100.0 | 100.0 | 91.7 | 100.0 | 100.0 | 88.9 | 91.7 | 91.7 | 91.7 | 88.9 | 100.0 | 91.7 | 83.3 | 88.9 |
| Urea Nitrogen: Grade1 to Normal | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 | 8.3 | 8.3 | 8.3 | 0 | 0 | 8.3 | 0 | 11.1 |
| Urea Nitrogen: Normal to Grade1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11.1 | 0 | 0 | 16.7 | 0 |
| Urea Nitrogen: Grade1 to Grade2 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Urea Nitrogen: Normal to Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11.1 | 0 | 0 | 0 | 11.1 | 0 | 0 | 16.7 | 0 |
| WBC decrease: Baseline Normal to Normal | 100.0 | 91.7 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 83.3 | 100.0 | 100.0 | 83.3 | 100.0 | 91.7 | 88.9 |
| WBC decrease: Normal to Grade1 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 16.7 | 0 | 0 | 8.3 | 0 | 0 | 11.1 |
| WBC Decrease: Grade 1 to Normal | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 |
| WBC Decrease: Grade 1 to Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 |
Percentage of participants with grade shift in hematology parameters reported in this outcome measure. Grade(G)1: Mild, G2:Moderate, G3:Severe, G4:potentially life threatening. Hemoglobin(Female): G1: 11.0 - 12.0grams per deciliter(g/dL), G2: 9.5 - 10.9, G3: 8.0 - 9.4, G4: \<8.0. Hemoglobin(Male): G1: 12.5 - 13.5, G2: 10.5 - 12.4, G3: 8.5 - 10.4, G4: \<8.5. WBC decrease(cells/mm3):G1: 2,500 - 3,500, G2: 1,500 - 2,499, G3: 1,000 - 1,499, G4: \<1,000 Lymphocytes decrease(cells/mm3): G1: 750 - 1,000, G2: 500 - 749, G3: 250 - 499, G4: \<250. Eosinophils(cells/mm3):G1: 650 - 1500, G2: 1501 - 5000, G3: \>5000, G4:Hypereosinophilic. Platelets decreased(cells/mm3): G1: 125,000 - 140,000, G2: 100,000 - 124,000, G3: 25,000 - 99,000, G4: \<25,000. Urea Nitrogen (mg/dl): G1: 23-26; G2:27-31; G3: \>31; G4: requires dialysis. Only parameters where grade shift was observed were reported.
| Percentage of participants | BNT162b1 10 mcg Dose: 18-55 Years of Age | BNT162b1 20 mcg Dose: 18-55 Years of Age | BNT162b1 30 mcg Dose: 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b1 | BNT162b1 100 mcg Dose, 18-55 Years of Age | Placebo 18-55 Years of Age for BNT162b1 100 mcg | BNT162b2 10 mcg Dose, 18-55 Years of Age | BNT162b2 20 mcg Dose, 18-55 Years of Age | BNT162b2 30 mcg Dose, 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b2 | BNT162b1 10 mcg Dose, 65-85 Years of Age | BNT162b1 20 mcg Dose, 65-85 Years of Age | BNT162b1 30 mcg Dose, 65-85 Years of Age | Placebo, 65-85 Years of Age for BNT162b1 | BNT162b2 10 mcg Dose, 65-85 Years of Age | BNT162b2 20 mcg Dose, 65-85 Years of Age | BNT162b2 30 mcg Dose, 65-85 Years of Age | Placebo: 65-85 Years of Age for BNT162b2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hemoglobin: Baseline Normal to Normal | 50.0 | 75.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 83.3 | 88.9 | 91.7 | 83.3 | 100.0 | 100.0 | 91.7 | 91.7 | 83.3 | 100.0 |
| Hemoglobin: Normal to Grade1 | 33.3 | 8.3 | 0 | 0 | 0 | 0 | 0 | 0 | 16.7 | 0 | 0 | 8.3 | 0 | 0 | 0 | 0 | 8.3 | 0 |
| Hemoglobin: Grade1 to Normal | 16.7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11.1 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 |
| Hemoglobin: Grade1 to Grade1 | 0 | 16.7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 | 8.3 | 8.3 | 0 | 0 |
| Hemoglobin: Grade1 to Grade2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Eosinophils: Baseline Normal to Normal | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 91.7 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |
| Eosinophils: Baseline Normal to Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 |
| Lymphocytes: Baseline Normal to Normal | 91.7 | 83.3 | 100.0 | 88.9 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 88.9 | 100.0 | 83.3 | 100.0 | 100.0 | 91.7 | 100.0 | 91.7 | 88.9 |
| Lymphocytes: Normal to Grade1 | 8.3 | 16.7 | 0 | 11.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 16.7 | 0 | 0 | 8.3 | 0 | 0 | 0 |
| Lymphocytes: Grade1 to Grade1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11.1 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 11.1 |
| Platelets Decrease: Baseline Normal to Normal | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 91.7 | 100.0 | 91.7 | 100.0 | 100.0 | 88.9 |
| Platelets Decrease: Grade 1 to Grade1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 |
| Platelets Decrease: Normal to Grade2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 |
| Platelets Decrease: Grade1 to Grade2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11.1 |
| Urea Nitrogen: Baseline Normal to Normal | 100.0 | 91.7 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 91.7 | 88.9 | 91.7 | 100.0 | 100.0 | 77.8 | 100.0 | 100.0 | 83.3 | 100.0 |
| Urea Nitrogen: Normal to Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 | 0 | 22.2 | 0 | 0 | 16.7 | 0 |
| Urea Nitrogen: Normal to Grade2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Urea Nitrogen: Grade1 to Normal | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Urea Nitrogen: Grade 1 to Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| WBC Decrease: Baseline Normal to Normal | 100.0 | 91.7 | 100.0 | 88.9 | 100.0 | 100.0 | 91.7 | 100.0 | 100.0 | 77.8 | 100.0 | 91.7 | 100.0 | 100.0 | 75.0 | 100.0 | 91.7 | 100.0 |
| WBC Decrease: Normal to Grade1 | 0 | 8.3 | 0 | 11.1 | 0 | 0 | 8.3 | 0 | 0 | 22.2 | 0 | 8.3 | 0 | 0 | 16.7 | 0 | 0 | 0 |
| WBC Decrease: Grade1 to Normal | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 |
| WBC Decrease: Grade 1 to Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 |
Percentage of participants with grade shift in hematology parameters reported in this outcome measure. Grade(G)1: Mild, G2:Moderate, G3:Severe, G4:potentially life threatening. Hemoglobin(Female): G1: 11.0 - 12.0grams per deciliter(g/dL), G2: 9.5 - 10.9, G3: 8.0 - 9.4, G4: \<8.0. Hemoglobin(Male): G1: 12.5 - 13.5, G2: 10.5 - 12.4, G3: 8.5 - 10.4, G4: \<8.5. WBC decrease(cells/mm3):G1: 2,500 - 3,500, G2: 1,500 - 2,499, G3: 1,000 - 1,499, G4: \<1,000 Lymphocytes decrease(cells/mm3): G1: 750 - 1,000, G2: 500 - 749, G3: 250 - 499, G4: \<250. Eosinophils(cells/mm3):G1: 650 - 1500, G2: 1501 - 5000, G3: \>5000, G4:Hypereosinophilic. Platelets decreased(cells/mm3): G1: 125,000 - 140,000, G2: 100,000 - 124,000, G3: 25,000 - 99,000, G4: \<25,000. Urea Nitrogen (mg/dl): G1: 23-26; G2:27-31; G3: \>31; G4: requires dialysis. Only parameters where grade shift was observed were reported.
| Percentage of participants | BNT162b1 10 mcg Dose: 18-55 Years of Age | BNT162b1 20 mcg Dose: 18-55 Years of Age | BNT162b1 30 mcg Dose: 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b1 | BNT162b2 10 mcg Dose, 18-55 Years of Age | BNT162b2 20 mcg Dose, 18-55 Years of Age | BNT162b2 30 mcg Dose, 18-55 Years of Age | BNT162b1 10 mcg Dose, 65-85 Years of Age | BNT162b1 20 mcg Dose, 65-85 Years of Age | BNT162b1 30 mcg Dose, 65-85 Years of Age | Placebo, 65-85 Years of Age for BNT162b1 | BNT162b2 10 mcg Dose, 65-85 Years of Age | BNT162b2 20 mcg Dose, 65-85 Years of Age | BNT162b2 30 mcg Dose, 65-85 Years of Age | Placebo: 65-85 Years of Age for BNT162b2 | Placebo: 18-55 Years of Age for BNT162b2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hemoglobin: Baseline Normal to Normal | 58.3 | 66.7 | 91.7 | 88.9 | 91.7 | 100.0 | 66.7 | 88.9 | 83.3 | 83.3 | 83.3 | 88.9 | 83.3 | 91.7 | 91.7 | 100.0 |
| Hemoglobin: Normal to Grade 1 | 8.3 | 8.3 | 8.3 | 11.1 | 8.3 | 0 | 16.7 | 11.1 | 8.3 | 0 | 16.7 | 11.1 | 8.3 | 0 | 0 | 0 |
| Hemoglobin: Grade 1 to Normal | 25.0 | 0 | 0 | 0 | 0 | 0 | 16.7 | 0 | 0 | 8.3 | 0 | 0 | 0 | 0 | 8.3 | 0 |
| Hemoglobin: Grade 1 to Grade 1 | 8.3 | 25.0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 8.3 | 8.3 | 0 | 0 |
| Hemoglobin: Grade 2 to Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Eosinophils: Baseline Normal to Normal | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 91.7 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |
| Eosinophils: Baseline Normal to Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 |
| Eosinophils: Grade 1 to Normal | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocytes: Baseline Normal to Normal | 91.7 | 83.3 | 100.0 | 88.9 | 100.0 | 100.0 | 100.0 | 77.8 | 100.0 | 83.3 | 100.0 | 100.0 | 100.0 | 100.0 | 91.7 | 88.9 |
| Lymphocytes: Normal to Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocytes: Grade 1 to Normal | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11.1 | 0 | 16.7 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocytes: Grade 1 to Grade 1 | 8.3 | 16.7 | 0 | 11.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocytes: Grade 1 to Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 11.1 |
| Platelets Decrease: Baseline Normal to Normal | 100.0 | 100.0 | 91.7 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 88.9 | 100.0 |
| Platelets Decrease: Normal to Grade 1 | 0 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelets Decrease: Grade 1 to Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelets Decrease: Grade 2 to Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11.1 | 0 |
| Urea Nitrogen: Baseline Normal to Normal | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 91.7 | 91.7 | 91.7 | 91.7 | 100.0 | 77.8 | 91.7 | 83.3 | 75.0 | 100.0 | 88.9 |
| Urea Nitrogen: Normal to Grade 1 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 | 8.3 | 16.7 | 8.3 | 0 | 0 |
| Urea Nitrogen: Grade 1 to Normal | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 | 11.1 | 0 | 0 | 0 | 0 | 0 |
| Urea Nitrogen: Grade 2 to Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11.1 |
| Urea Nitrogen: Grade 1 to Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 16.7 | 0 | 0 |
| Urea Nitrogen: Grade 2 to Normal | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Urea Nitrogen: Normal to Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Urea Nitrogen: Grade 1 to Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11.1 | 0 | 0 | 0 | 0 | 0 |
| WBC Decrease: Baseline Normal to Normal | 91.7 | 83.3 | 91.7 | 88.9 | 91.7 | 100.0 | 100.0 | 100.0 | 83.3 | 100.0 | 100.0 | 75.0 | 100.0 | 91.7 | 100.0 | 77.8 |
| WBC Decrease: Normal to Grade 1 | 8.3 | 8.3 | 8.3 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 8.3 | 0 | 0 | 0 | 0 |
| WBC Decrease: Grade 1 to Normal | 0 | 8.3 | 0 | 11.1 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 | 0 | 22.2 |
| WBC Decrease: Grade 1 to Grade 1 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 | 0 | 16.7 | 0 | 8.3 | 0 | 0 |
Percentage of participants with grade shift in chemistry were reported in this outcome measure. G1: Mild, G2: Moderate, G3: Severe, G4: potentially life threatening. BUN(milligram per deciliter \[mg/dL\]): G1: 23 - 26, G2: 27 - 31, G3: \>31, G4: required dialysis. Creatinine(mg/dL): G1: 1.5 - 1.7, G2: 1.8 - 2.0, G3: 2.1 - 2.5, G4: \> 2.5 or required dialysis. Alkaline phosphate(increase by factor): G1: 1.1 - 2.0 x ULN G2: 2.1 - 3.0 x ULN G3: 3.1 -10 x ULN, G4: \>10 x ULN. Liver function tests(ALT, AST increase by factor): G1: 1.1 - 2.5 x ULN G2: 2.6 - 5.0 x ULN G3: 5.1 - 10 x ULN, G4: \>10 x ULN. Bilirubin(when accompanied by any increase in liver function test - increase by factor): G1: 1.1 - 1.25 x ULN G2: 1.26 - 1.5 x ULN G3: 1.51 - 1.75 x ULN, G4: \>1.75 x ULN. Bilirubin(when liver function test is normal - increase by factor): G1: 1.1 - 1.5 x ULN, G2: 1.6 - 2.0 x ULN, G3: 2.0 - 3.0 x ULN, G4: \>3.0 x ULN. Only parameters where grade shift was observed were reported.
| Percentage of participants | BNT162b1 10 mcg Dose: 18-55 Years of Age | BNT162b1 20 mcg Dose: 18-55 Years of Age | BNT162b1 30 mcg Dose: 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b1 | BNT162b1 100 mcg Dose, 18-55 Years of Age | Placebo 18-55 Years of Age for BNT162b1 100 mcg | BNT162b2 10 mcg Dose, 18-55 Years of Age | BNT162b2 20 mcg Dose, 18-55 Years of Age | BNT162b2 30 mcg Dose, 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b2 | BNT162b1 10 mcg Dose, 65-85 Years of Age | BNT162b1 20 mcg Dose, 65-85 Years of Age | BNT162b1 30 mcg Dose, 65-85 Years of Age | Placebo, 65-85 Years of Age for BNT162b1 | BNT162b2 10 mcg Dose, 65-85 Years of Age | BNT162b2 20 mcg Dose, 65-85 Years of Age | BNT162b2 30 mcg Dose, 65-85 Years of Age | Placebo: 65-85 Years of Age for BNT162b2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALT Increased: Baseline Normal to Normal | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 91.7 | 91.7 | 0 | 0 | 0 | 0 | 88.9 | 0 | 0 | 0 | 0 |
| ALT Increased: Normal to Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 | 11.1 | 0 | 0 | 0 | 0 |
| ALT Increased: Grade 1 to Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALP Increased: Baseline Normal to Normal | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 91.7 | 88.9 | 0 | 0 | 0 | 0 |
| ALP Increased: Grade 1 to Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 |
| ALP Increased: Grade 1 to Normal | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11.1 | 0 | 0 | 0 | 0 |
| AST Increased: Baseline Normal to Normal | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 91.7 | 0 |
| AST Increased: Normal to Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 |
| Bilirubin: Baseline Normal to Normal | 0 | 0 | 0 | 0 | 91.7 | 0 | 91.7 | 0 | 0 | 88.9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bilirubin: Grade 2 to Grade 3 | 0 | 0 | 0 | 0 | 8.3 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bilirubin: Grade 1 to Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Percentage of participants with grade shift in chemistry were reported in this outcome measure. G1: Mild, G2: Moderate, G3: Severe, G4: potentially life threatening. BUN(mg/dL): G1: 23 - 26, G2: 27 - 31, G3: \>31, G4: required dialysis. Creatinine(mg/dL): G1: 1.5 - 1.7, G2: 1.8 - 2.0, G3: 2.1 - 2.5, G4: \> 2.5 or required dialysis. Alkaline phosphate(increase by factor): G1: 1.1 - 2.0 x ULN G2: 2.1 - 3.0 x ULN G3: 3.1 -10 x ULN, G4: \>10 x ULN. Liver function tests(ALT, AST increase by factor): G1: 1.1 - 2.5 x ULN G2: 2.6 - 5.0 x ULN G3: 5.1 - 10 x ULN, G4: \>10 x ULN. Bilirubin(when accompanied by any increase in liver function test - increase by factor): G1: 1.1 - 1.25 x ULN G2: 1.26 - 1.5 x ULN G3: 1.51 - 1.75 x ULN, G4: \>1.75 x ULN. Bilirubin(when liver function test is normal - increase by factor): G1: 1.1 - 1.5 x ULN, G2: 1.6 - 2.0 x ULN, G3: 2.0 - 3.0 x ULN, G4: \>3.0 x ULN. Only parameters where grade shift was observed were reported.
| Percentage of participants | BNT162b1 10 mcg Dose: 18-55 Years of Age | BNT162b1 20 mcg Dose: 18-55 Years of Age | BNT162b1 30 mcg Dose: 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b1 | BNT162b1 100 mcg Dose, 18-55 Years of Age | Placebo 18-55 Years of Age for BNT162b1 100 mcg | BNT162b2 10 mcg Dose, 18-55 Years of Age | BNT162b2 20 mcg Dose, 18-55 Years of Age | BNT162b2 30 mcg Dose, 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b2 | BNT162b1 10 mcg Dose, 65-85 Years of Age | BNT162b1 20 mcg Dose, 65-85 Years of Age | BNT162b1 30 mcg Dose, 65-85 Years of Age | Placebo, 65-85 Years of Age for BNT162b1 | BNT162b2 10 mcg Dose, 65-85 Years of Age | BNT162b2 20 mcg Dose, 65-85 Years of Age | BNT162b2 30 mcg Dose, 65-85 Years of Age | Placebo: 65-85 Years of Age for BNT162b2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALT Increased: Baseline Normal to Normal | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 91.7 | 91.7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased: Normal to Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased: Grade 1 to Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALP Increased: Baseline Normal to Normal | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 91.7 | 88.9 | 0 | 0 | 0 | 0 |
| ALP Increased: Grade 1 to Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 11.1 | 0 | 0 | 0 | 0 |
| Bilirubin: Baseline Normal to Normal | 0 | 0 | 91.7 | 0 | 0 | 0 | 91.7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 91.7 | 0 |
| Bilirubin: Normal to Grade 1 | 0 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 |
| Bilirubin: Grade 2 to Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bilirubin: Grade 1 to Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased: Baseline Normal to Normal | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 88.9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased: Normal to Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Percentage of participants with grade shift in chemistry were reported in this outcome measure. G1: Mild, G2: Moderate, G3: Severe, G4: potentially life threatening. BUN(mg/dL): G1: 23 - 26, G2: 27 - 31, G3: \>31, G4: required dialysis. Creatinine(mg/dL): G1: 1.5 - 1.7, G2: 1.8 - 2.0, G3: 2.1 - 2.5, G4: \> 2.5 or required dialysis. Alkaline phosphate(increase by factor): G1: 1.1 - 2.0 x ULN G2: 2.1 - 3.0 x ULN G3: 3.1 -10 x ULN, G4: \>10 x ULN. Liver function tests(ALT, AST increase by factor): G1: 1.1 - 2.5 x ULN G2: 2.6 - 5.0 x ULN G3: 5.1 - 10 x ULN, G4: \>10 x ULN. Bilirubin(when accompanied by any increase in liver function test - increase by factor): G1: 1.1 - 1.25 x ULN G2: 1.26 - 1.5 x ULN G3: 1.51 - 1.75 x ULN, G4: \>1.75 x ULN. Bilirubin(when liver function test is normal - increase by factor): G1: 1.1 - 1.5 x ULN, G2: 1.6 - 2.0 x ULN, G3: 2.0 - 3.0 x ULN, G4: \>3.0 x ULN. Only parameters where grade shift was observed were reported.
| Percentage of participants | BNT162b1 10 mcg Dose: 18-55 Years of Age | BNT162b1 20 mcg Dose: 18-55 Years of Age | BNT162b1 30 mcg Dose: 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b1 | BNT162b1 100 mcg Dose, 18-55 Years of Age | Placebo 18-55 Years of Age for BNT162b1 100 mcg | BNT162b2 10 mcg Dose, 18-55 Years of Age | BNT162b2 20 mcg Dose, 18-55 Years of Age | BNT162b2 30 mcg Dose, 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b2 | BNT162b1 10 mcg Dose, 65-85 Years of Age | BNT162b1 20 mcg Dose, 65-85 Years of Age | BNT162b1 30 mcg Dose, 65-85 Years of Age | Placebo, 65-85 Years of Age for BNT162b1 | BNT162b2 10 mcg Dose, 65-85 Years of Age | BNT162b2 20 mcg Dose, 65-85 Years of Age | BNT162b2 30 mcg Dose, 65-85 Years of Age | Placebo: 65-85 Years of Age for BNT162b2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALT Increased: Baseline Normal to Normal | 0 | 91.7 | 0 | 0 | 0 | 0 | 0 | 91.7 | 91.7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased: Normal to Grade 1 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased: Grade 1 to Normal | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALP Increased: Baseline Normal to Normal | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 91.7 | 88.9 | 0 | 0 | 0 | 0 |
| ALP Increased: Grade 1 to Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 11.1 | 0 | 0 | 0 | 0 |
| AST Increased: Baseline Normal to Normal | 0 | 90.9 | 90.9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 85.7 | 0 | 0 | 0 | 0 |
| AST Increased: Normal to Grade 1 | 0 | 9.1 | 9.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14.3 | 0 | 0 | 0 | 0 |
| Bilirubin: Baseline Normal to Normal | 0 | 0 | 91.7 | 0 | 0 | 0 | 91.7 | 0 | 91.7 | 88.9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bilirubin: Normal to Grade 1 | 0 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bilirubin: Grade 2 to Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bilirubin: Grade 1 to Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased: Baseline Normal to Normal | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 88.9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased: Normal to Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Percentage of participants with grade shift in chemistry were reported in this outcome measure. G1: Mild, G2: Moderate, G3: Severe, G4: potentially life threatening. BUN(mg/dL): G1: 23 - 26, G2: 27 - 31, G3: \>31, G4: required dialysis. Creatinine(mg/dL): G1: 1.5 - 1.7, G2: 1.8 - 2.0, G3: 2.1 - 2.5, G4: \> 2.5 or required dialysis. Alkaline phosphate(increase by factor): G1: 1.1 - 2.0 x ULN G2: 2.1 - 3.0 x ULN G3: 3.1 -10 x ULN, G4: \>10 x ULN. Liver function tests(ALT, AST increase by factor): G1: 1.1 - 2.5 x ULN G2: 2.6 - 5.0 x ULN G3: 5.1 - 10 x ULN, G4: \>10 x ULN. Bilirubin(when accompanied by any increase in liver function test - increase by factor): G1: 1.1 - 1.25 x ULN G2: 1.26 - 1.5 x ULN G3: 1.51 - 1.75 x ULN, G4: \>1.75 x ULN. Bilirubin(when liver function test is normal - increase by factor): G1: 1.1 - 1.5 x ULN, G2: 1.6 - 2.0 x ULN, G3: 2.0 - 3.0 x ULN, G4: \>3.0 x ULN. Only parameters where grade shift was observed were reported.
| Percentage of participants | BNT162b1 10 mcg Dose: 18-55 Years of Age | BNT162b1 20 mcg Dose: 18-55 Years of Age | BNT162b1 30 mcg Dose: 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b1 | BNT162b2 10 mcg Dose, 18-55 Years of Age | BNT162b2 20 mcg Dose, 18-55 Years of Age | BNT162b2 30 mcg Dose, 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b2 | BNT162b1 10 mcg Dose, 65-85 Years of Age | BNT162b1 20 mcg Dose, 65-85 Years of Age | BNT162b1 30 mcg Dose, 65-85 Years of Age | Placebo, 65-85 Years of Age for BNT162b1 | BNT162b2 10 mcg Dose, 65-85 Years of Age | BNT162b2 20 mcg Dose, 65-85 Years of Age | BNT162b2 30 mcg Dose, 65-85 Years of Age | Placebo: 65-85 Years of Age for BNT162b2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALT Increased: Baseline Normal to Normal | 0 | 91.7 | 91.7 | 0 | 0 | 91.7 | 83.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased: Grade 1 to Normal | 0 | 8.3 | 0 | 0 | 0 | 0 | 16.7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased: Normal to Grade 1 | 0 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT Increased: Grade 1 to Grade 1 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALP Increased: Baseline Normal to Normal | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 91.7 | 91.7 | 88.9 | 0 | 0 | 0 | 0 |
| ALP Increased: Normal to Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALP Increased: Grade 1 to Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 11.1 | 0 | 0 | 0 | 0 |
| AST Increased: Baseline Normal to Normal | 0 | 90.9 | 91.7 | 0 | 0 | 0 | 90.9 | 0 | 0 | 0 | 0 | 85.7 | 0 | 0 | 91.7 | 0 |
| AST Increased: Grade 1 to Normal | 0 | 9.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14.3 | 0 | 0 | 0 | 0 |
| AST Increased: Grade 1 to Grade 1 | 0 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST Increased: Normal to Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 9.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 |
| Bilirubin: Baseline Normal to Normal | 0 | 0 | 91.7 | 0 | 91.7 | 0 | 91.7 | 88.9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bilirubin: Grade 1 to Normal | 0 | 0 | 8.3 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bilirubin: Grade 1 to Grade 1 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bilirubin: Grade 1 to Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased: Baseline Normal to Normal | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 88.9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine Increased: Grade 1 to Normal | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Local reactions included redness, swelling and, pain at the injection site, recorded by participants or parents/legal guardians in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\> 2.0 to 5.0 cm), moderate (\> 5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), severe (prevents daily activity) and Grade 4 (emergency room visit or hospitalization for severe pain).
| Percentage of participants | BNT162b2 (30 mcg): 16-55 Years | BNT162b2 (30 mcg): 56-85 Years | Placebo: 16-55 Years | Placebo: 56 to 85 Years | BNT162b2 (30 mcg): 12-15 Years of Age | Placebo: 12-15 Years of Age |
|---|---|---|---|---|---|---|
| Redness: Mild | 3.9 (3.2 to 4.7) | 3.5 (2.8 to 4.4) | 0.7 (0.4 to 1.0) | 0.7 (0.3 to 1.1) | 3.9 (2.9 to 5.2) | 1.0 (0.5 to 1.7) |
| Redness: Moderate | 1.2 (0.9 to 1.7) | 1.5 (1.0 to 2.1) | 0.2 (0.1 to 0.4) | 0.3 (0.1 to 0.6) | 1.8 (1.1 to 2.7) | 0.1 (0.0 to 0.5) |
| Redness: Severe | 0.2 (0.1 to 0.5) | 0.2 (0.1 to 0.6) | 0.1 (0.0 to 0.3) | 0.1 (0.0 to 0.4) | 0.1 (0.0 to 0.5) | 0.0 (0.0 to 0.3) |
| Redness: Grade 4 | 0 (0.0 to 0.1) | 0.0 (0.0 to 0.2) | 0.0 (0.0 to 0.1) | 0.0 (0.0 to 0.2) | 0.0 (0.0 to 0.3) | 0.0 (0.0 to 0.3) |
| Swelling: Mild | 4.3 (3.6 to 5.1) | 4.3 (3.5 to 5.3) | 0.2 (0.1 to 0.4) | 0.6 (0.3 to 1.0) | 4.9 (3.7 to 6.3) | 0.8 (0.4 to 1.5) |
| Swelling: Moderate | 1.9 (1.4 to 2.4) | 2.6 (1.9 to 3.4) | 0.3 (0.1 to 0.5) | 0.6 (0.3 to 1.1) | 2.0 (1.3 to 3.0) | 0.2 (0.0 to 0.6) |
| Swelling: Severe | 0.2 (0.1 to 0.4) | 0.1 (0.0 to 0.4) | 0.1 (0.0 to 0.2) | 0 (0.0 to 0.2) | 0.0 (0.0 to 0.3) | 0.0 (0.0 to 0.3) |
| Swelling: Grade 4 | 0 (0.0 to 0.1) | 0.0 (0.0 to 0.2) | 0 (0.0 to 0.1) | 0 (0.0 to 0.2) | 0.0 (0.0 to 0.3) | 0 (0.0 to 0.3) |
| Pain at injection site: Mild | 50.5 (48.7 to 52.3) | 55.2 (53.0 to 57.4) | 13.4 (12.2 to 14.7) | 8.9 (7.7 to 10.2) | 41.4 (38.5 to 44.4) | 20.1 (17.8 to 22.6) |
| Pain at injection site: Moderate | 31.8 (30.1 to 33.6) | 14.7 (13.2 to 16.4) | 0.7 (0.4 to 1.1) | 0.4 (0.2 to 0.8) | 43.7 (40.8 to 46.7) | 3.2 (2.2 to 4.4) |
| Pain at injection site: Severe | 1.3 (1.0 to 1.8) | 0.2 (0.1 to 0.5) | 0.1 (0.0 to 0.3) | 0.0 (0.0 to 0.2) | 1.0 (0.5 to 1.7) | 0.0 (0.0 to 0.3) |
| Pain at injection site: Grade 4 | 0.0 (0.0 to 0.1) | 0.0 (0.0 to 0.2) | 0.0 (0.0 to 0.1) | 0.0 (0.0 to 0.2) | 0.0 (0.0 to 0.3) | 0.0 (0.0 to 0.3) |
Local reactions included redness, swelling and, pain at the injection site, recorded by participants or parents/legal guardians in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\> 2.0 to 5.0 cm), moderate (\> 5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), severe (prevents daily activity) and Grade 4 (emergency room visit or hospitalization for severe pain).
| Percentage of participants | BNT162b2 (30 mcg): 16-55 Years | BNT162b2 (30 mcg): 56-85 Years | Placebo: 16-55 Years | Placebo: 56 to 85 Years | BNT162b2 (30 mcg): 12-15 Years of Age | Placebo: 12-15 Years of Age |
|---|---|---|---|---|---|---|
| Redness: Mild | 3.4 (2.7 to 4.1) | 3.5 (2.7 to 4.4) | 0.4 (0.2 to 0.8) | 0.5 (0.3 to 1.0) | 2.6 (1.8 to 3.8) | 0.7 (0.3 to 1.5) |
| Redness: Moderate | 1.9 (1.4 to 2.5) | 3.1 (2.4 to 4.0) | 0.2 (0.1 to 0.5) | 0.2 (0.0 to 0.5) | 2.4 (1.6 to 3.5) | 0.2 (0.0 to 0.7) |
| Redness: Severe | 0.4 (0.2 to 0.7) | 0.5 (0.3 to 1.0) | 0.0 (0.0 to 0.1) | 0.1 (0.0 to 0.3) | 0.1 (0.0 to 0.3) | 0.0 (0.0 to 0.3) |
| Redness: Grade 4 | 0 (0.0 to 0.1) | 0.0 (0.0 to 0.2) | 0.0 (0.0 to 0.1) | 0.0 (0.0 to 0.2) | 0.0 (0.0 to 0.3) | 0.0 (0.0 to 0.3) |
| Swelling: Mild | 4.1 (3.4 to 4.9) | 4.3 (3.4 to 5.3) | 0.1 (0.0 to 0.3) | 0.3 (0.1 to 0.6) | 3.3 (2.3 to 4.5) | 0.4 (0.1 to 1.9) |
| Swelling: Moderate | 2.5 (1.9 to 3.1) | 3.3 (2.5 to 4.2) | 0.1 (0.0 to 0.3) | 0.4 (0.2 to 0.8) | 1.6 (1.0 to 2.6) | 0.2 (0.0 to 0.7) |
| Swelling: Severe | 0.3 (0.1 to 0.5) | 0.2 (0.1 to 0.5) | 0.0 (0.0 to 0.1) | 0.1 (0.0 to 0.3) | 0.0 (0.0 to 0.3) | 0.0 (0.0 to 0.3) |
| Swelling: Grade 4 | 0 (0.0 to 0.1) | 0.0 (0.0 to 0.2) | 0 (0.0 to 0.1) | 0 (0.0 to 0.2) | 0.0 (0.0 to 0.3) | 0 (0.0 to 0.3) |
| Pain at injection site: Mild | 47.5 (45.6 to 49.4) | 46.9 (44.6 to 49.2) | 10.6 (9.4 to 11.8) | 7.5 (6.4 to 8.8) | 42.5 (39.5 to 45.5) | 15.2 (13.1 to 17.5) |
| Pain at injection site: Moderate | 29.4 (27.7 to 31.1) | 18.7 (16.9 to 20.5) | 1.0 (0.7 to 1.5) | 0.3 (0.1 to 0.6) | 35.8 (33.0 to 38.7) | 2.7 (1.8 to 3.8) |
| Pain at injection site: Severe | 1.5 (1.0 to 2.0) | 0.5 (0.3 to 1.0) | 0.0 (0.0 to 0.1) | 0.0 (0.0 to 0.2) | 0.6 (0.3 to 1.3) | 0.0 (0.0 to 0.3) |
| Pain at injection site: Grade 4 | 0.0 (0.0 to 0.1) | 0.0 (0.0 to 0.2) | 0.0 (0.0 to 0.1) | 0.0 (0.0 to 0.2) | 0.0 (0.0 to 0.3) | 0.0 (0.0 to 0.3) |
Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, new or worsened joint pain recorded by participants or parents/legal guardians of participants using e-diary. Fever=temperature \>=38.0 deg C categorized as \>=38.0 to 38.4, \>38.4 to 38.9, \>38.9 to 40.0 and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain graded as mild (does not interfere with activity), moderate (some interference with activity), severe (prevents daily routine activity), Grade 4 (Emergency room visit/hospitalization). Vomiting: mild (1-2 times in 24 h), moderate (\>2 times in 24 h), severe (requires IV hydration), Grade 4 (emergency room visit/hospitalization for hypotensive shock). Diarrhea: mild (2-3 loose stools in 24h), moderate (4-5 loose stools in 24 h), severe (\>=6 loose stools in 24 h) and Grade 4 (emergency room visit/hospitalization).
| Percentage of participants | BNT162b2 (30 mcg): 16-55 Years | Placebo: 16-55 Years | BNT162b2 (30 mcg): 56-85 Years | Placebo: 56 to 85 Years | BNT162b2 (30 mcg): 12-15 Years of Age | Placebo: 12-15 Years of Age |
|---|---|---|---|---|---|---|
| Fever: 38.0°C to 38.4°C | 3.0 (2.4 to 3.7) | 0.6 (0.3 to 0.9) | 1.1 (0.7 to 1.7) | 0.4 (0.2 to 0.8) | 6.6 (5.2 to 8.2) | 0.7 (0.3 to 1.4) |
| Fever: >38.4°C to 38.9°C | 0.9 (0.6 to 1.3) | 0.2 (0.1 to 0.4) | 0.1 (0.0 to 0.4) | 0.2 (0.0 to 0.4) | 2.6 (1.7 to 3.7) | 0.2 (0.0 to 0.6) |
| Fever: >38.9°C to 40.0°C | 0.3 (0.1 to 0.5) | 0.1 (0.0 to 0.4) | 0.0 (0.0 to 0.3) | 0.2 (0.0 to 0.4) | 0.9 (0.4 to 1.6) | 0.2 (0.0 to 0.6) |
| Fever: >40.0°C | 0 (0.0 to 0.1) | 0.0 (0.0 to 0.1) | 0.0 (0.0 to 0.2) | 0 (0.0 to 0.2) | 0.1 (0.0 to 0.5) | 0.0 (0.0 to 0.3) |
| Fatigue: Mild | 26.2 (24.6 to 27.9) | 19.6 (18.2 to 21.1) | 20.7 (18.9 to 22.5) | 14.1 (12.6 to 15.7) | 24.7 (22.2 to 27.3) | 22.2 (19.8 to 24.7) |
| Fatigue: Moderate | 21.7 (20.2 to 23.3) | 12.8 (11.6 to 14.1) | 12.9 (11.5 to 14.4) | 8.2 (7.0 to 9.5) | 34.1 (31.3 to 36.9) | 17.7 (15.5 to 20.0) |
| Fatigue: Severe | 1.4 (1.0 to 1.9) | 0.6 (0.4 to 1.0) | 0.1 (0.0 to 0.4) | 0.2 (0.0 to 0.4) | 1.3 (0.7 to 2.2) | 0.7 (0.3 to 1.4) |
| Fatigue: Grade 4 | 0 (0.0 to 0.1) | 0 (0.0 to 0.1) | 0 (0.0 to 0.2) | 0 (0.0 to 0.2) | 0 (0.0 to 0.3) | 0 (0.0 to 0.3) |
| Headache: Mild | 27.1 (25.5 to 28.7) | 21.8 (20.3 to 23.3) | 19.0 (17.3 to 20.8) | 13.4 (12.0 to 15.0) | 32.0 (29.3 to 34.8) | 22.7 (20.3 to 25.3) |
| Headache: Moderate | 15.3 (14.0 to 16.7) | 10.9 (9.8 to 12.1) | 6.0 (5.0 to 7.1) | 4.7 (3.8 to 5.7) | 22.3 (19.9 to 24.8) | 11.6 (9.8 to 13.6) |
| Headache: Severe | 1.1 (0.8 to 1.6) | 0.8 (0.5 to 1.2) | 0.1 (0.0 to 0.4) | 0.2 (0.0 to 0.4) | 1.0 (0.5 to 1.7) | 0.8 (0.4 to 1.5) |
| Headache: Grade 4 | 0.0 (0.0 to 0.1) | 0.0 (0.0 to 0.1) | 0.0 (0.0 to 0.2) | 0.0 (0.0 to 0.2) | 0.0 (0.0 to 0.3) | 0.0 (0.0 to 0.3) |
| Chills: Mild | 11.7 (10.5 to 12.9) | 5.1 (4.3 to 6.0) | 5.1 (4.2 to 6.1) | 2.5 (1.8 to 3.2) | 17.3 (15.1 to 19.6) | 7.3 (5.8 to 9.0) |
| Chills: Moderate | 4.3 (3.6 to 5.2) | 1.7 (1.2 to 2.2) | 1.4 (0.9 to 2.0) | 1.0 (0.6 to 1.5) | 9.8 (8.2 to 11.7) | 2.2 (1.4 to 3.3) |
| Chills: Severe | 0.5 (0.3 to 0.9) | 0.1 (0.0 to 0.2) | 0.0 (0.0 to 0.2) | 0.0 (0.0 to 0.2) | 0.4 (0.1 to 1.0) | 0.2 (0.0 to 0.6) |
| Chills: Grade 4 | 0.0 (0.0 to 0.1) | 0.0 (0.0 to 0.1) | 0.0 (0.0 to 0.2) | 0.0 (0.0 to 0.2) | 0.0 (0.0 to 0.3) | 0.0 (0.0 to 0.3) |
| Vomiting: Mild | 1.0 (0.7 to 1.4) | 1.0 (0.7 to 1.5) | 0.4 (0.2 to 0.8) | 0.5 (0.2 to 0.9) | 2.7 (1.8 to 3.8) | 0.7 (0.3 to 1.4) |
| Vomiting: Moderate | 0.2 (0.1 to 0.4) | 0.2 (0.1 to 0.4) | 0.0 (0.0 to 0.3) | 0.0 (0.0 to 0.2) | 0.0 (0.0 to 0.3) | 0.2 (0.0 to 0.6) |
| Vomiting: Severe | 0.0 (0.0 to 0.1) | 0.0 (0.0 to 0.2) | 0.0 (0.0 to 0.2) | 0.0 (0.0 to 0.2) | 0.1 (0.0 to 0.5) | 0.0 (0.0 to 0.3) |
| Vomiting: Grade 4 | 0.0 (0.0 to 0.1) | 0.0 (0.0 to 0.1) | 0.0 (0.0 to 0.2) | 0.0 (0.0 to 0.2) | 0.0 (0.0 to 0.3) | 0.0 (0.0 to 0.3) |
| Diarrhea: Mild | 8.7 (7.7 to 9.7) | 9.1 (8.1 to 10.2) | 6.8 (5.8 to 8.0) | 5.5 (4.5 to 6.6) | 6.8 (5.4 to 8.5) | 6.4 (5.0 to 8.0) |
| Diarrhea: Moderate | 1.9 (1.4 to 2.5) | 2.0 (1.5 to 2.6) | 1.3 (0.9 to 2.0) | 1.0 (0.6 to 1.5) | 1.2 (0.6 to 2.0) | 0.9 (0.4 to 1.6) |
| Diarrhea: Severe | 0.1 (0.0 to 0.3) | 0.0 (0.0 to 0.2) | 0.2 (0.1 to 0.5) | 0.1 (0.0 to 0.3) | 0.0 (0.0 to 0.3) | 0.0 (0.0 to 0.3) |
| Diarrhea: Grade 4 | 0.0 (0.0 to 0.1) | 0.0 (0.0 to 0.1) | 0.0 (0.0 to 0.2) | 0.0 (0.0 to 0.2) | 0.0 (0.0 to 0.3) | 0.0 (0.0 to 0.3) |
| New or worsened muscle pain: Mild | 12.2 (11.0 to 13.4) | 7.9 (7.0 to 9.0) | 9.1 (7.9 to 10.5) | 5.6 (4.6 to 6.7) | 11.1 (9.3 to 13.1) | 7.8 (6.3 to 9.5) |
| New or worsened muscle pain: Moderate | 10.2 (9.1 to 11.4) | 3.3 (2.7 to 4.0) | 4.5 (3.6 to 5.5) | 2.6 (1.9 to 3.4) | 12.9 (11.0 to 15.0) | 5.3 (4.1 to 6.8) |
| New or worsened muscle pain: Severe | 0.5 (0.3 to 0.9) | 0.1 (0.0 to 0.2) | 0.0 (0.0 to 0.3) | 0.2 (0.0 to 0.4) | 0.2 (0.0 to 0.6) | 0.0 (0.0 to 0.3) |
| New or worsened muscle pain: Grade 4 | 0.0 (0.0 to 0.1) | 0.0 (0.0 to 0.1) | 0.0 (0.0 to 0.2) | 0.0 (0.0 to 0.2) | 0.0 (0.0 to 0.3) | 0.0 (0.0 to 0.3) |
| New or worsened joint pain: Mild | 6.9 (6.0 to 7.9) | 3.9 (3.2 to 4.6) | 5.9 (4.9 to 7.0) | 3.9 (3.1 to 4.9) | 5.9 (4.6 to 7.4) | 4.4 (3.3 to 5.8) |
| New or worsened joint pain: Moderate | 4.7 (4.0 to 5.6) | 1.9 (1.4 to 2.5) | 2.6 (2.0 to 3.4) | 2.3 (1.7 to 3.0) | 3.7 (2.7 to 5.0) | 2.4 (1.6 to 3.5) |
| New or worsened joint pain: Severe | 0.2 (0.1 to 0.4) | 0.0 (0.0 to 0.2) | 0.1 (0.0 to 0.4) | 0.1 (0.0 to 0.3) | 0.1 (0.0 to 0.5) | 0 (0.0 to 0.3) |
| New or worsened joint pain: Grade 4 | 0.0 (0.0 to 0.1) | 0.0 (0.0 to 0.1) | 0.0 (0.0 to 0.2) | 0.0 (0.0 to 0.2) | 0 (0.0 to 0.3) | 0 (0.0 to 0.3) |
Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, new or worsened joint pain recorded by participants or parents/legal guardians of participants using e-diary. Fever=temperature \>=38.0 deg C categorized as \>=38.0 to 38.4, \>38.4 to 38.9, \>38.9 to 40.0 and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain graded as mild (does not interfere with activity), moderate (some interference with activity), severe (prevents daily routine activity), Grade 4 (Emergency room visit/hospitalization). Vomiting: mild (1-2 times in 24 h), moderate (\>2 times in 24 h), severe (requires IV hydration), Grade 4 (emergency room visit/hospitalization for hypotensive shock). Diarrhea: mild (2-3 loose stools in 24h), moderate (4-5 loose stools in 24 h), severe (\>=6 loose stools in 24 h) and Grade 4 (emergency room visit/hospitalization).
| Percentage of participants | BNT162b2 (30 mcg): 16-55 Years | BNT162b2 (30 mcg): 56-85 Years | Placebo: 16-55 Years | Placebo: 56 to 85 Years | BNT162b2 (30 mcg): 12-15 Years of Age | Placebo: 12-15 Years of Age |
|---|---|---|---|---|---|---|
| Fever: 38.0°C to 38.4°C | 9.5 (8.4 to 10.6) | 8.5 (7.3 to 9.9) | 0.2 (0.1 to 0.4) | 0.1 (0.0 to 0.4) | 9.8 (8.1 to 11.7) | 0.5 (0.2 to 1.1) |
| Fever: >38.4°C to 38.9°C | 5.4 (4.6 to 6.4) | 2.9 (2.2 to 3.8) | 0.1 (0.0 to 0.4) | 0.1 (0.0 to 0.3) | 7.6 (6.1 to 9.3) | 0.1 (0.0 to 0.5) |
| Fever: >38.9°C to 40.0°C | 1.5 (1.0 to 2.0) | 0.4 (0.2 to 0.8) | 0.1 (0.0 to 0.3) | 0.0 (0.0 to 0.2) | 2.3 (1.5 to 3.3) | 0.1 (0.0 to 0.5) |
| Fever: >40.0°C | 0.0 (0.0 to 0.2) | 0.0 (0.0 to 0.2) | 0.0 (0.0 to 0.1) | 0 (0.0 to 0.2) | 0.0 (0.0 to 0.3) | 0.0 (0.0 to 0.3) |
| Fatigue: Mild | 20.8 (19.3 to 22.4) | 21.0 (19.2 to 22.9) | 11.8 (10.6 to 13.1) | 10.0 (8.6 to 11.4) | 21.1 (18.8 to 23.7) | 12.3 (10.4 to 14.5) |
| Fatigue: Moderate | 35.4 (33.6 to 37.2) | 26.7 (24.7 to 28.8) | 10.5 (9.4 to 11.8) | 6.6 (5.5 to 7.8) | 42.7 (39.7 to 45.7) | 11.8 (9.9 to 13.9) |
| Fatigue: Severe | 5.3 (4.5 to 6.2) | 3.2 (2.5 to 4.1) | 0.5 (0.3 to 0.9) | 0.1 (0.0 to 0.4) | 2.4 (1.6 to 3.5) | 0.4 (0.1 to 0.9) |
| Fatigue: Grade 4 | 0.0 (0.0 to 0.1) | 0.1 (0.0 to 0.3) | 0.0 (0.0 to 0.1) | 0.0 (0.0 to 0.2) | 0 (0.0 to 0.3) | 0 (0.0 to 0.3) |
| Headache: Mild | 26.1 (24.4 to 27.8) | 24.9 (23.0 to 27.0) | 15.1 (13.7 to 16.5) | 10.3 (9.0 to 11.8) | 27.5 (24.9 to 30.3) | 15.7 (13.6 to 18.0) |
| Headache: Moderate | 24.5 (22.9 to 26.2) | 26.7 (24.7 to 28.8) | 8.6 (7.5 to 9.7) | 3.5 (2.7 to 4.5) | 35.0 (32.2 to 37.9) | 8.6 (7.0 to 10.5) |
| Headache: Severe | 3.4 (2.7 to 4.1) | 3.2 (2.5 to 4.1) | 0.7 (0.4 to 1.1) | 0.3 (0.1 to 0.6) | 2.0 (1.3 to 3.0) | 0.1 (0.0 to 0.5) |
| Headache: Grade 4 | 0.0 (0.0 to 0.1) | 0.1 (0.0 to 0.3) | 0.0 (0.0 to 0.1) | 0.0 (0.0 to 0.2) | 0.0 (0.0 to 0.3) | 0.0 (0.0 to 0.3) |
| Chills: Mild | 17.8 (16.4 to 19.3) | 12.3 (10.9 to 13.9) | 3.3 (2.7 to 4.1) | 2.5 (1.8 to 3.3) | 20.1 (17.8 to 22.6) | 4.8 (3.6 to 6.3) |
| Chills: Moderate | 17.5 (16.1 to 19.0) | 9.9 (8.6 to 11.4) | 0.9 (0.5 to 1.3) | 0.0 (0.0 to 0.2) | 19.5 (17.2 to 22.0) | 1.9 (1.2 to 3.0) |
| Chills: Severe | 2.6 (2.0 to 3.2) | 1.1 (0.7 to 1.7) | 0.1 (0.0 to 0.3) | 0.0 (0.0 to 0.2) | 1.8 (1.1 to 2.8) | 0.0 (0.0 to 0.3) |
| Chills: Grade 4 | 0.0 (0.0 to 0.1) | 0.0 (0.0 to 0.2) | 0.0 (0.0 to 0.1) | 0.0 (0.0 to 0.2) | 0.0 (0.0 to 0.3) | 0.0 (0.0 to 0.3) |
| Vomiting: Mild | 1.6 (1.1 to 2.1) | 0.5 (0.3 to 1.0) | 0.7 (0.5 to 1.1) | 0.3 (0.1 to 0.6) | 2.3 (1.5 to 3.3) | 1.0 (0.5 to 1.8) |
| Vomiting: Moderate | 0.4 (0.2 to 0.8) | 0.1 (0.0 to 0.3) | 0.4 (0.2 to 0.7) | 0.0 (0.0 to 0.2) | 0.4 (0.1 to 1.9) | 0.1 (0.0 to 0.5) |
| Vomiting: Severe | 0.1 (0.0 to 0.4) | 0.1 (0.0 to 0.4) | 0.0 (0.0 to 0.1) | 0.0 (0.0 to 0.2) | 0.0 (0.0 to 0.3) | 0.0 (0.0 to 0.3) |
| Vomiting: Grade 4 | 0.0 (0.0 to 0.1) | 0.0 (0.0 to 0.2) | 0.0 (0.0 to 0.1) | 0.0 (0.0 to 0.2) | 0.0 (0.0 to 0.3) | 0.0 (0.0 to 0.3) |
| Diarrhea: Mild | 8.2 (7.2 to 9.3) | 6.7 (5.6 to 8.0) | 6.3 (5.4 to 7.3) | 4.1 (3.3 to 5.2) | 5.4 (4.1 to 6.9) | 3.5 (2.5 to 4.8) |
| Diarrhea: Moderate | 1.6 (1.2 to 2.2) | 1.3 (0.9 to 2.0) | 1.3 (0.9 to 1.8) | 1.2 (0.8 to 1.8) | 0.5 (0.2 to 1.2) | 0.5 (0.2 to 1.1) |
| Diarrhea: Severe | 0.2 (0.1 to 0.5) | 0.1 (0.1 to 0.4) | 0.0 (0.0 to 0.2) | 0.2 (0.1 to 0.6) | 0.0 (0.0 to 0.3) | 0.0 (0.0 to 0.3) |
| Diarrhea: Grade 4 | 0.0 (0.0 to 0.1) | 0.0 (0.0 to 0.2) | 0.0 (0.0 to 0.1) | 0.0 (0.0 to 0.2) | 0.0 (0.0 to 0.3) | 0.0 (0.0 to 0.3) |
| New or worsened muscle pain: Mild | 16.4 (15.1 to 17.9) | 12.3 (10.9 to 13.9) | 5.6 (4.7 to 6.5) | 3.5 (2.7 to 4.5) | 13.9 (11.9 to 16.0) | 4.7 (3.5 to 6.2) |
| New or worsened muscle pain: Moderate | 20.6 (19.1 to 22.2) | 15.5 (13.9 to 17.2) | 3.1 (2.5 to 3.9) | 1.8 (1.2 to 2.5) | 18.0 (15.7 to 20.4) | 3.4 (2.4 to 4.7) |
| New or worsened muscle pain: Severe | 2.3 (1.8 to 3.0) | 1.1 (0.7 to 1.7) | 0.1 (0.0 to 0.3) | 0.1 (0.0 to 0.3) | 0.5 (0.2 to 1.2) | 0.2 (0.0 to 0.7) |
| New or worsened muscle pain: Grade 4 | 0.0 (0.0 to 0.1) | 0.0 (0.0 to 0.2) | 0.0 (0.0 to 0.1) | 0.0 (0.0 to 0.2) | 0.0 (0.0 to 0.3) | 0.0 (0.0 to 0.3) |
| New or worsened joint pain: Mild | 10.9 (9.7 to 12.1) | 9.8 (8.5 to 11.3) | 3.1 (2.4 to 3.8) | 2.4 (1.7 to 3.2) | 8.3 (6.7 to 10.1) | 2.8 (1.9 to 3.9) |
| New or worsened joint pain: Moderate | 11.9 (10.7 to 13.2) | 8.7 (7.4 to 10.0) | 2.3 (1.7 to 2.9) | 1.5 (1.0 to 2.1) | 7.1 (5.7 to 8.8) | 1.9 (1.2 to 3.0) |
| New or worsened joint pain: Severe | 1.0 (0.7 to 1.5) | 0.5 (0.2 to 0.9) | 0.1 (0.0 to 0.4) | 0.1 (0.0 to 0.3) | 0.4 (0.1 to 0.9) | 0 (0.0 to 0.3) |
| New or worsened joint pain: Grade 4 | 0.0 (0.0 to 0.1) | 0.0 (0.0 to 0.2) | 0.0 (0.0 to 0.1) | 0.0 (0.0 to 0.2) | 0 (0.0 to 0.3) | 0 (0.0 to 0.3) |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. HIV positive participants were excluded from this analysis.
| Percentage of participants | BNT162b2 (30 mcg): >=16 Years of Age | Placebo: >=16 Years of Age | BNT162b2 (30 mcg): 12-15 Years of Age | Placebo: 12-15 Years of Age |
|---|---|---|---|---|
| Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: Phase 2/3 | 30.2 (29.6 to 30.8) | 13.9 (13.4 to 14.4) | 6.0 (4.7 to 7.6) | 5.9 (4.6 to 7.5) |
An SAE was any untoward medical occurrence that occurred, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect and other important medical events. HIV positive participants were excluded from this analysis.
| Percentage of participants | BNT162b2 (30 mcg): 12-15 Years of Age | Placebo/BNT162b2 30 mcg: 12-15 Years of Age | Placebo: 12-15 Years of Age | BNT162b2 30 mcg: >=16 Years of Age | Placebo/BNT162b2 30 mcg: >=16 Years of Age | Placebo: >=16 Years of Age |
|---|---|---|---|---|---|---|
| Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: Phase 2/3 | 1.1 (0.6 to 2.0) | 1.3 (0.7 to 2.2) | 0.2 (0.0 to 0.6) | 2.0 (1.8 to 2.1) | 1.7 (1.6 to 1.9) | 1.3 (1.2 to 1.5) |
Local reactions included redness, swelling and, pain at the injection site, recorded by participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\> 2.0 to 5.0 cm), moderate (\> 5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), severe (prevents daily activity) and Grade 4 (emergency room visit or hospitalization for severe pain).
| Percentage of participants | BNT162b2 (30 mcg): 18-55 Years of Age | Placebo:18-55 Years of Age | BNT162b2 (30 mcg): 56-85 Years of Age | Placebo: 56 to 85 Years of Age |
|---|---|---|---|---|
| Redness: Mild | 1.1 (0.0 to 6.2) | 1.7 (0.3 to 4.8) | 2.2 (0.3 to 7.6) | 0.6 (0.0 to 3.1) |
| Redness: Moderate | 2.3 (0.3 to 8.0) | 2.2 (0.6 to 5.6) | 2.2 (0.3 to 7.6) | 0 (0.0 to 2.0) |
| Redness: Severe | 0 (0.0 to 4.1) | 0 (0.0 to 2.0) | 0 (0.0 to 3.9) | 0 (0.0 to 2.0) |
| Redness: Grade 4 | 0 (0.0 to 4.1) | 0 (0.0 to 2.0) | 0 (0.0 to 3.9) | 0 (0.0 to 2.0) |
| Swelling: Mild | 2.3 (0.3 to 8.0) | 2.2 (0.6 to 5.6) | 2.2 (0.3 to 7.6) | 0 (0.0 to 2.0) |
| Swelling: Moderate | 4.5 (1.3 to 11.2) | 4.4 (1.9 to 8.6) | 4.3 (1.2 to 10.8) | 0 (0.0 to 2.0) |
| Swelling: Severe | 0 (0.0 to 4.1) | 0 (0.0 to 4.1) | 0 (0.0 to 3.9) | 0 (0.0 to 2.0) |
| Swelling: Grade 4 | 0 (0.0 to 4.1) | 0 (0.0 to 4.1) | 0 (0.0 to 3.9) | 0 (0.0 to 2.0) |
| Pain at injection site: Mild | 56.8 (45.8 to 67.3) | 55.0 (47.4 to 62.4) | 53.3 (42.6 to 63.7) | 8.9 (5.2 to 14.0) |
| Pain at injection site: Moderate | 28.4 (19.3 to 39.0) | 22.2 (16.4 to 29.0) | 16.3 (9.4 to 25.5) | 0 (0.0 to 2.0) |
| Pain at injection site: Severe | 0 (0.0 to 4.1) | 0.6 (0.0 to 3.1) | 1.1 (0.0 to 5.9) | 0 (0.0 to 2.0) |
| Pain at injection site: Grade 4 | 0 (0.0 to 4.1) | 0 (0.0 to 2.0) | 0 (0.0 to 3.9) | 0 (0.0 to 2.0) |
Local reactions included redness, swelling and, pain at the injection site, recorded by participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\> 2.0 to 5.0 cm), moderate (\> 5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), severe (prevents daily activity) and Grade 4 (emergency room visit or hospitalization for severe pain).
| Percentage of participants | BNT162b2 (30 mcg): 18-55 Years of Age | Placebo:18-55 Years of Age | BNT162b2 (30 mcg): 56-85 Years of Age | Placebo: 56 to 85 Years of Age |
|---|---|---|---|---|
| Redness: Mild | 2.3 (0.3 to 8.1) | 2.3 (0.6 to 5.7) | 2.2 (0.3 to 7.7) | 0 (0.0 to 2.1) |
| Redness: Moderate | 1.2 (0.0 to 6.3) | 2.8 (0.9 to 6.5) | 4.4 (1.2 to 10.9) | 0 (0.0 to 2.1) |
| Redness: Severe | 0 (0.0 to 4.2) | 0.6 (0.0 to 3.1) | 1.1 (0.0 to 6.0) | 0 (0.0 to 2.1) |
| Redness: Grade 4 | 0 (0.0 to 4.2) | 0 (0.0 to 2.1) | 0 (0.0 to 4.0) | 0 (0.0 to 2.1) |
| Swelling: Mild | 3.5 (0.7 to 9.9) | 4.5 (2.0 to 8.7) | 5.5 (1.8 to 12.4) | 0 (0.0 to 2.1) |
| Swelling: Moderate | 0 (0.0 to 4.2) | 0 (0.0 to 4.2) | 0 (0.0 to 4.2) | 0 (0.0 to 2.1) |
| Swelling: Severe | 0 (0.0 to 4.2) | 0 (0.0 to 2.1) | 0 (0.0 to 4.0) | 0 (0.0 to 2.1) |
| Swelling: Grade 4 | 0 (0.0 to 4.2) | 0 (0.0 to 2.1) | 0 (0.0 to 4.0) | 0 (0.0 to 2.1) |
| Pain at injection site: Mild | 53.5 (42.4 to 64.3) | 54.2 (46.6 to 61.7) | 54.9 (44.2 to 65.4) | 8.5 (4.8 to 13.7) |
| Pain at injection site: Moderate | 25.6 (16.8 to 36.1) | 21.5 (15.7 to 28.3) | 17.6 (10.4 to 27.0) | 1.1 (0.1 to 4.0) |
| Pain at injection site: Severe | 1.2 (0.0 to 6.3) | 0.6 (0.0 to 3.1) | 0 (0.0 to 4.0) | 0 (0.0 to 2.1) |
| Pain at injection site: Grade 4 | 0 (0.0 to 4.2) | 0 (0.0 to 2.1) | 0 (0.0 to 4.0) | 0 (0.0 to 2.1) |
Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, new or worsened joint pain recorded by participants or parents/legal guardians of participants using e-diary. Fever=temperature \>=38.0 deg C categorized as \>=38.0 to 38.4, \>38.4 to 38.9, \>38.9 to 40.0 and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain graded as mild (does not interfere with activity), moderate (some interference with activity), severe (prevents daily routine activity), Grade 4 (Emergency room visit/hospitalization). Vomiting: mild (1-2 times in 24 h), moderate (\>2 times in 24 h), severe (requires IV hydration), Grade 4 (emergency room visit/hospitalization for hypotensive shock). Diarrhea: mild (2-3 loose stools in 24h), moderate (4-5 loose stools in 24 h), severe (\>=6 loose stools in 24 h) and Grade 4 (emergency room visit/hospitalization).
| Percentage of participants | BNT162b2 (30 mcg): 18-55 Years of Age | Placebo: 18-55 Years of Age | BNT162b2 (30 mcg): 56-85 Years of Age | Placebo: 56 to 85 Years of Age |
|---|---|---|---|---|
| Fever: 38.0°C to 38.4°C | 0 (0.0 to 4.1) | 0 (0.0 to 2.0) | 0 (0.0 to 3.9) | 0 (0.0 to 2.0) |
| Fever: >38.4°C to 38.9°C | 3.4 (0.7 to 9.6) | 1.7 (0.3 to 4.8) | 0 (0.0 to 3.9) | 0 (0.0 to 2.0) |
| Fever: >38.9°C to 40.0°C | 0 (0.0 to 4.1) | 0 (0.0 to 2.0) | 0 (0.0 to 3.9) | 0 (0.0 to 2.0) |
| Fever: >40.0°C | 0 (0.0 to 4.1) | 0 (0.0 to 2.0) | 0 (0.0 to 3.9) | 0 (0.0 to 2.0) |
| Fatigue: Mild | 29.5 (20.3 to 40.2) | 23.3 (17.4 to 30.2) | 17.4 (10.3 to 26.7) | 17.8 (12.5 to 24.2) |
| Fatigue: Moderate | 20.5 (12.6 to 30.4) | 19.4 (13.9 to 26.0) | 18.5 (11.1 to 27.9) | 9.4 (5.6 to 14.7) |
| Fatigue: Severe | 0 (0.0 to 4.1) | 0 (0.0 to 2.0) | 0 (0.0 to 3.9) | 0 (0.0 to 2.0) |
| Fatigue: Grade 4 | 0 (0.0 to 4.1) | 0 (0.0 to 2.0) | 0 (0.0 to 3.9) | 0 (0.0 to 2.0) |
| Headache: Mild | 20.5 (12.6 to 30.4) | 21.7 (15.9 to 28.4) | 22.8 (14.7 to 32.8) | 15.6 (10.6 to 21.7) |
| Headache: Moderate | 11.4 (5.6 to 19.9) | 7.8 (4.3 to 12.7) | 4.3 (1.2 to 10.8) | 8.3 (4.7 to 13.4) |
| Headache: Severe | 0 (0.0 to 4.1) | 0 (0.0 to 2.0) | 0 (0.0 to 3.9) | 0.6 (0.0 to 3.1) |
| Headache: Grade 4 | 0 (0.0 to 4.1) | 0 (0.0 to 2.0) | 0 (0.0 to 3.9) | 0 (0.0 to 2.0) |
| Chills: Mild | 6.8 (2.5 to 14.3) | 6.1 (3.1 to 10.7) | 5.4 (1.8 to 12.2) | 3.9 (1.6 to 7.8) |
| Chills: Moderate | 2.3 (0.3 to 8.0) | 2.2 (0.6 to 5.6) | 2.2 (0.3 to 7.6) | 0 (0.0 to 2.0) |
| Chills: Severe | 0 (0.0 to 4.1) | 0 (0.0 to 2.0) | 0 (0.0 to 3.9) | 0 (0.0 to 2.0) |
| Chills: Grade 4 | 0 (0.0 to 4.1) | 0 (0.0 to 2.0) | 0 (0.0 to 3.9) | 0 (0.0 to 2.0) |
| Vomiting: Mild | 0 (0.0 to 4.1) | 0 (0.0 to 2.0) | 0 (0.0 to 3.9) | 0 (0.0 to 2.0) |
| Vomiting: Moderate | 0 (0.0 to 4.1) | 0 (0.0 to 2.0) | 0 (0.0 to 3.9) | 0 (0.0 to 2.0) |
| Vomiting: Severe | 0 (0.0 to 4.1) | 0 (0.0 to 2.0) | 0 (0. to 03.9) | 0 (0.0 to 2.0) |
| Vomiting: Grade 4 | 0 (0.0 to 4.1) | 0 (0.0 to 2.0) | 0 (0.0 to 3.9) | 0 (0.0 to 2.0) |
| Diarrhea: Mild | 10.2 (4.8 to 18.5) | 10.0 (6.0 to 15.3) | 9.8 (4.6 to 17.8) | 10.6 (6.5 to 16.0) |
| Diarrhea: Moderate | 6.8 (2.5 to 14.3) | 4.4 (1.9 to 8.6) | 2.2 (0.3 to 7.6) | 1.7 (0.3 to 4.8) |
| Diarrhea: Severe | 0 (0.0 to 4.1) | 0 (0.0 to 2.0) | 0 (0.0 to 3.9) | 0 (0.0 to 2.0) |
| Diarrhea: Grade 4 | 0 (0.0 to 4.1) | 0 (0.0 to 2.0) | 0 (0.0 to 3.9) | 0 (0.0 to 2.0) |
| New or worsened muscle pain: Mild | 13.6 (7.2 to 22.6) | 11.1 (6.9 to 16.6) | 8.7 (3.8 to 16.4) | 4.4 (1.9 to 8.6) |
| New or worsened muscle pain: Moderate | 10.2 (4.8 to 18.5) | 7.8 (4.3 to 12.7) | 5.4 (1.8 to 12.2) | 1.7 (0.3 to 4.8) |
| New or worsened muscle pain: Severe | 0 (0.0 to 4.1) | 0 (0.0 to 2.0) | 0 (0.0 to 3.9) | 0 (0.0 to 2.0) |
| New or worsened muscle pain: Grade 4 | 0 (0.0 to 4.1) | 0 (0.0 to 2.0) | 0 (0.0 to 3.9) | 0 (0.0 to 2.0) |
| New or worsened joint pain: Mild | 6.8 (2.5 to 14.3) | 5.0 (2.3 to 9.3) | 3.3 (0.7 to 9.2) | 2.2 (0.6 to 5.6) |
| New or worsened joint pain: Moderate | 2.3 (0.3 to 8.0) | 1.7 (0.3 to 4.8) | 1.1 (0.0 to 5.9) | 1.7 (0.3 to 4.8) |
| New or worsened joint pain: Severe | 0 (0.0 to 4.1) | 0 (0.0 to 2.0) | 0 (0.0 to 3.9) | 0 (0.0 to 2.0) |
| New or worsened joint pain: Grade 4 | 0 (0.0 to 4.1) | 0 (0.0 to 2.0) | 0 (0.0 to 3.9) | 0 (0.0 to 2.0) |
Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, new or worsened joint pain recorded by participants or parents/legal guardians of participants using e-diary. Fever=temperature \>=38.0 deg C categorized as \>=38.0 to 38.4, \>38.4 to 38.9, \>38.9 to 40.0 and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain graded as mild (does not interfere with activity), moderate (some interference with activity), severe (prevents daily routine activity), Grade 4 (Emergency room visit/hospitalization). Vomiting: mild (1-2 times in 24 h), moderate (\>2 times in 24 h), severe (requires IV hydration), Grade 4 (emergency room visit/hospitalization for hypotensive shock). Diarrhea: mild (2-3 loose stools in 24h), moderate (4-5 loose stools in 24 h), severe (\>=6 loose stools in 24 h) and Grade 4 (emergency room visit/hospitalization).
| Percentage of participants | BNT162b2 (30 mcg): 18-55 Years of Age | Placebo:18-55 Years of Age | BNT162b2 (30 mcg): 56-85 Years of Age | Placebo: 56 to 85 Years of Age |
|---|---|---|---|---|
| Fever: 38.0°C to 38.4°C | 8.1 (3.3 to 16.1) | 7.9 (4.4 to 12.9) | 7.7 (3.1 to 15.2) | 0 (0.0 to 2.1) |
| Fever: >38.4°C to 38.9°C | 7.0 (2.6 to 14.6) | 5.1 (2.4 to 9.4) | 3.3 (0.7 to 9.3) | 0 (0.0 to 2.1) |
| Fever: >38.9°C to 40.0°C | 2.3 (0.3 to 8.1) | 1.1 (0.1 to 4.0) | 0 (0.0 to 4.0) | 0 (0.0 to 2.1) |
| Fever: >40.0°C | 0 (0.0 to 4.2) | 0 (0.0 to 2.1) | 0 (0.0 to 4.0) | 0 (0.0 to 2.1) |
| Fatigue: Mild | 16.3 (9.2 to 25.8) | 20.3 (14.7 to 27.0) | 24.2 (15.8 to 34.3) | 11.9 (7.5 to 17.7) |
| Fatigue: Moderate | 37.2 (27.0 to 48.3) | 31.6 (24.9 to 39.0) | 26.4 (17.7 to 36.7) | 8.5 (4.8 to 13.7) |
| Fatigue: Severe | 5.8 (1.9 to 13.0) | 4.0 (1.6 to 8.0) | 2.2 (0.3 to 7.7) | 0 (0.0 to 2.1) |
| Fatigue: Grade 4 | 0 (0.0 to 4.2) | 0 (0.0 to 2.1) | 0 (0.0 to 4.0) | 0 (0.0 to 2.1) |
| Headache: Mild | 22.1 (13.9 to 32.3) | 20.9 (15.2 to 27.6) | 19.8 (12.2 to 29.4) | 9.7 (5.7 to 15.0) |
| Headache: Moderate | 24.4 (15.8 to 34.9) | 19.8 (14.2 to 26.4) | 15.4 (8.7 to 24.5) | 6.3 (3.2 to 10.9) |
| Headache: Severe | 4.7 (1.3 to 11.5) | 2.8 (0.9 to 6.5) | 1.1 (0.0 to 6.0) | 0.6 (0.0 to 3.1) |
| Headache: Grade 4 | 0 (0.0 to 4.2) | 0 (0.0 to 2.1) | 0 (0.0 to 4.0) | 0 (0.0 to 2.1) |
| Chills: Mild | 22.1 (13.9 to 32.3) | 15.8 (10.8 to 22.0) | 9.9 (4.6 to 17.9) | 1.7 (0.4 to 4.9) |
| Chills: Moderate | 15.1 (8.3 to 24.5) | 12.4 (8.0 to 18.2) | 9.9 (4.6 to 17.9) | 0.6 (0.0 to 3.1) |
| Chills: Severe | 3.5 (0.7 to 9.9) | 2.3 (0.6 to 5.7) | 1.1 (0.0 to 6.0) | 0 (0.0 to 2.1) |
| Chills: Grade 4 | 0 (0.0 to 4.2) | 0 (0.0 to 2.1) | 0 (0.0 to 4.0) | 0 (0.0 to 2.1) |
| Vomiting: Mild | 2.3 (0.3 to 8.1) | 1.1 (0.1 to 4.0) | 0 (0.0 to 4.0) | 0.6 (0.0 to 3.1) |
| Vomiting: Moderate | 0 (0.0 to 4.2) | 0 (0.0 to 2.1) | 0 (0.0 to 4.0) | 0 (0.0 to 2.1) |
| Vomiting: Severe | 0 (0.0 to 4.2) | 0 (0.0 to 2.1) | 0 (0.0 to 4.0) | 0 (0.0 to 2.1) |
| Vomiting: Grade 4 | 0 (0.0 to 4.2) | 0 (0.0 to 2.1) | 0 (0.0 to 4.0) | 0 (0.0 to 2.1) |
| Diarrhea: Mild | 16.3 (9.2 to 25.8) | 11.3 (7.0 to 16.9) | 6.6 (2.5 to 13.8) | 6.8 (3.6 to 11.6) |
| Diarrhea: Moderate | 3.5 (0.7 to 9.9) | 2.8 (0.9 to 6.5) | 2.2 (0.3 to 7.7) | 1.1 (0.1 to 4.0) |
| Diarrhea: Severe | 0 (0.0 to 4.2) | 0 (0.0 to 2.1) | 0 (0.0 to 4.0) | 0 (0.0 to 2.1) |
| Diarrhea: Grade 4 | 0 (0.0 to 4.2) | 0 (0.0 to 2.1) | 0 (0.0 to 4.0) | 0 (0.0 to 2.1) |
| New or worsened muscle pain: Mild | 20.9 (12.9 to 31.0) | 16.4 (11.3 to 22.7) | 12.1 (6.2 to 20.6) | 2.3 (0.6 to 5.7) |
| New or worsened muscle pain: Moderate | 22.1 (13.9 to 32.3) | 18.6 (13.2 to 25.2) | 15.4 (8.7 to 24.5) | 1.1 (0.1 to 4.0) |
| New or worsened muscle pain: Severe | 0 (0.0 to 4.2) | 1.7 (0.4 to 4.9) | 1.1 (0.0 to 6.0) | 0 (0.0 to 2.1) |
| New or worsened muscle pain: Grade 4 | 0 (0.0 to 4.2) | 0 (0.0 to 2.1) | 0 (0.0 to 4.0) | 0 (0.0 to 2.1) |
| New or worsened joint pain: Mild | 9.3 (4.1 to 17.5) | 9.0 (5.3 to 14.3) | 8.8 (3.9 to 16.6) | 2.3 (0.6 to 5.7) |
| New or worsened joint pain: Moderate | 8.1 (3.3 to 16.1) | 7.9 (4.4 to 12.9) | 7.7 (3.1 to 15.2) | 2.3 (0.6 to 5.7) |
| New or worsened joint pain: Severe | 0 (0.0 to 4.2) | 0 (0.0 to 2.1) | 0 (0.0 to 4.0) | 0 (0.0 to 2.1) |
| New or worsened joint pain: Grade 4 | 0 (0.0 to 4.2) | 0 (0.0 to 2.1) | 0 (0.0 to 4.0) | 0 (0.0 to 2.1) |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.
| Percentage of participants | BNT162b2 (30 mcg): 18-55 Years of Age | Placebo:18-55 Years of Age | BNT162b2 (30 mcg): 56-85 Years of Age | Placebo: 56 to 85 Years of Age |
|---|---|---|---|---|
| Percentage of Participants Reporting Adverse Events From Dose 1 to 7 Days After Dose 2: Phase 2 | 9.1 (4.0 to 17.1) | 6.7 (3.5 to 11.4) | 4.3 (1.2 to 10.8) | 10.0 (6.0 to 15.3) |
A SAE was any untoward medical occurrence that occurred, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect and other important medical events.
| Percentage of participants | BNT162b2 (30 mcg): 18-55 Years of Age | Placebo:18-55 Years of Age | BNT162b2 (30 mcg): 56-85 Years of Age | Placebo: 56 to 85 Years of Age |
|---|---|---|---|---|
| Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 7 Days After Dose 2: Phase 2 | 1.1 (0.0 to 6.2) | 0.6 (0.0 to 3.1) | 0 (0.0 to 3.9) | 0 (0.0 to 2.0) |
Local reactions included redness, swelling and, pain at the injection site, recorded by participants or parents/legal guardians in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\> 2.0 to 5.0 cm), moderate (\> 5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), severe (prevents daily activity) and Grade 4 (emergency room visit or hospitalization for severe pain). HIV positive participants were excluded.
| Percentage of participants | BNT162b2 (30 mcg) | BNT162b2SA (30 mcg) |
|---|---|---|
| Redness: Mild | 3.5 (1.7 to 6.3) | 1.7 (0.5 to 3.9) |
| Redness: Moderate | 2.4 (1.0 to 4.9) | 3.0 (1.4 to 5.7) |
| Redness: Severe | 0 (0.0 to 1.3) | 0.3 (0.0 to 1.9) |
| Redness: Grade 4 | 0 (0.0 to 1.3) | 0 (0.0 to 1.2) |
| Swelling: Mild | 4.5 (2.4 to 7.6) | 4.4 (2.3 to 7.3) |
| Swelling: Moderate | 3.1 (1.4 to 5.8) | 2.0 (0.7 to 4.3) |
| Swelling: Severe | 0.3 (0.0 to 1.9) | 0.3 (0.0 to 1.9) |
| Swelling: Grade 4 | 0 (0.0 to 1.3) | 0 (0.0 to 1.2) |
| Pain at injection site: Mild | 60.2 (54.3 to 65.9) | 53.0 (47.2 to 58.8) |
| Pain at injection site: Moderate | 22.5 (17.8 to 27.7) | 28.9 (23.8 to 34.4) |
| Pain at injection site: Severe | 0.3 (0.0 to 1.9) | 1.0 (0.2 to 2.9) |
| Pain at injection site: Grade 4 | 0 (0.0 to 1.3) | 0 (0.0 to 1.2) |
Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, new or worsened joint pain recorded by participants or parents/legal guardians of participants using e-diary. Fever=temperature \>=38.0 deg C categorized as \>=38.0 to 38.4, \>38.4 to 38.9, \>38.9 to 40.0 and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain graded as mild (does not interfere with activity), moderate (some interference with activity), severe (prevents daily routine activity), Grade 4 (Emergency room visit/hospitalization). Vomiting: mild (1-2 times in 24 h), moderate (\>2 times in 24 h), severe (requires IV hydration), Grade 4 (emergency room visit/hospitalization for hypotensive shock). Diarrhea: mild (2-3 loose stools in 24h), moderate (4-5 loose stools in 24 h), severe (\>=6 loose stools in 24 h) and Grade 4 (emergency room visit/hospitalization). HIV positive participants were excluded.
| Percentage of participants | BNT162b2 (30 mcg) | BNT162b2SA (30 mcg) |
|---|---|---|
| Fever: 38.0°C to 38.4°C | 4.2 (2.2 to 7.1) | 4.0 (2.1 to 6.9) |
| Fever: >38.4°C to 38.9°C | 4.2 (2.2 to 7.1) | 4.0 (2.1 to 6.9) |
| Fever: >38.9°C to 40.0°C | 0.3 (0.0 to 1.9) | 4.0 (2.1 to 6.9) |
| Fever: >40.0°C | 0 (0.0 to 1.3) | 1.3 (0.4 to 3.4) |
| Fatigue: Mild | 23.5 (18.8 to 28.9) | 23.8 (19.1 to 29.1) |
| Fatigue: Moderate | 35.6 (30.1 to 41.5) | 41.3 (35.6 to 47.1) |
| Fatigue: Severe | 4.5 (2.4 to 7.6) | 4.7 (2.6 to 7.8) |
| Fatigue: Grade 4 | 0 (0.0 to 1.3) | 0 (0.0 to 1.2) |
| Headache: Mild | 28.7 (23.6 to 34.3) | 28.2 (23.2 to 33.7) |
| Headache: Moderate | 18.7 (14.4 to 23.7) | 23.5 (18.8 to 28.7) |
| Headache: Severe | 1.0 (0.2 to 3.0) | 2.0 (0.7 to 4.3) |
| Headache: Grade 4 | 0 (0.0 to 1.3) | 0 (0.0 to 1.2) |
| Chills: Mild | 12.8 (9.2 to 17.2) | 18.5 (14.2 to 23.3) |
| Chills: Moderate | 15.2 (11.3 to 19.9) | 16.1 (12.1 to 20.8) |
| Chills: Severe | 1.0 (0.2 to 3.0) | 2.0 (0.7 to 4.3) |
| Chills: Grade 4 | 0 (0.0 to 1.3) | 0 (0.0 to 1.2) |
| Vomiting: Mild | 1.7 (0.6 to 4.0) | 0.7 (0.1 to 2.4) |
| Vomiting: Moderate | 0 (0.0 to 1.3) | 0 (0.0 to 1.2) |
| Vomiting: Severe | 0 (0.0 to 1.3) | 0 (0.0 to 1.2) |
| Vomiting: Grade 4 | 0 (0.0 to 1.3) | 0 (0.0 to 1.2) |
| Diarrhea: Mild | 7.3 (4.6 to 10.9) | 8.1 (5.2 to 11.7) |
| Diarrhea: Moderate | 1.4 (0.4 to 3.5) | 1.3 (0.4 to 3.4) |
| Diarrhea: Severe | 0 (0.0 to 1.3) | 0.3 (0.0 to 1.9) |
| Diarrhea: Grade 4 | 0 (0.0 to 1.3) | 0 (0.0 to 1.2) |
| New or worsened muscle pain: Mild | 18.0 (13.7 to 22.9) | 14.8 (10.9 to 19.3) |
| New or worsened muscle pain: Moderate | 19.7 (15.3 to 24.8) | 21.8 (17.3 to 26.9) |
| New or worsened muscle pain: Severe | 1.4 (0.4 to 3.5) | 2.0 (0.7 to 4.3) |
| New or worsened muscle pain: Grade 4 | 0 (0.0 to 1.3) | 0 (0.0 to 1.2) |
| New or worsened joint pain: Mild | 12.5 (8.9 to 16.8) | 10.4 (7.2 to 14.4) |
| New or worsened joint pain: Moderate | 12.5 (8.9 to 16.8) | 11.4 (8.0 to 15.6) |
| New or worsened joint pain: Severe | 0.3 (0.0 to 1.9) | 0.7 (0.1 to 2.4) |
| New or worsened joint pain: Grade 4 | 0 (0.0 to 1.3) | 0 (0.0 to 1.2) |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. HIV positive participants were excluded.
| Percentage of participants | BNT162b2 (30 mcg) | BNT162b2SA (30 mcg) |
|---|---|---|
| Percentage of Participants Reporting Adverse Events From First Booster Dose to 1 Month After Booster Dose: BNT162b2 Experienced Participants Who Were Rerandomized to Receive 1 Booster Dose | 15.0 (11.2 to 19.5) | 10.8 (7.6 to 14.8) |
A SAE was any untoward medical occurrence that occurred, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect and other important medical events. HIV positive participants were excluded.
| Percentage of participants | BNT162b2 (30 mcg) | BNT162b2SA (30 mcg) |
|---|---|---|
| Percentage of Participants Reporting Serious Adverse Events From First Booster Dose to 6 Months After Booster Dose: BNT162b2 Experienced Participants Who Were Rerandomized to Receive 1 Booster Dose | 0.7 (0.1 to 2.3) | 0.6 (0.1 to 2.3) |
Local reactions included redness, swelling and, pain at the injection site, recorded by participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\> 2.0 to 5.0 cm), moderate (\> 5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), severe (prevents daily activity) and Grade 4 (emergency room visit or hospitalization for severe pain). HIV positive participants were excluded from this analysis.
| Percentage of participants | BNT162b2SA (30 mcg), 2 Doses |
|---|---|
| Redness: Mild | 0 (0.0 to 11.6) |
| Redness: Moderate | 0 (0.0 to 11.6) |
| Redness: Severe | 0 (0.0 to 11.6) |
| Redness: Grade 4 | 0 (0.0 to 11.6) |
| Swelling: Mild | 0 (0.0 to 11.6) |
| Swelling: Moderate | 0 (0.0 to 11.6) |
| Swelling: Severe | 0 (0.0 to 11.6) |
| Swelling: Grade 4 | 0 (0.0 to 11.6) |
| Pain at injection site: Mild | 56.7 (37.4 to 74.5) |
| Pain at injection site: Moderate | 20.0 (7.7 to 38.6) |
| Pain at injection site: Severe | 0 (0.0 to 11.6) |
| Pain at injection site: Grade 4 | 0 (0.0 to 11.6) |
Local reactions included redness, swelling and, pain at the injection site, recorded by participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\> 2.0 to 5.0 cm), moderate (\> 5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), severe (prevents daily activity) and Grade 4 (emergency room visit or hospitalization for severe pain). HIV positive participants were excluded from this analysis.
| Percentage of participants | BNT162b2SA (30 mcg), 2 Doses |
|---|---|
| Redness: Mild | 0 (0.0 to 12.3) |
| Redness: Moderate | 0 (0.0 to 12.3) |
| Redness: Severe | 0 (0.0 to 12.3) |
| Redness: Grade 4 | 0 (0.0 to 12.3) |
| Swelling: Mild | 0 (0.0 to 12.3) |
| Swelling: Moderate | 0 (0.0 to 12.3) |
| Swelling: Severe | 0 (0.0 to 12.3) |
| Swelling: Grade 4 | 0 (0.0 to 12.3) |
| Pain at injection site: Mild | 50.0 (30.6 to 69.4) |
| Pain at injection site: Moderate | 17.9 (6.1 to 36.9) |
| Pain at injection site: Severe | 0 (0.0 to 12.3) |
| Pain at injection site: Grade 4 | 0 (0.0 to 12.3) |
Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, new or worsened joint pain recorded by participants or parents/legal guardians of participants using e-diary. Fever=temperature \>=38.0 deg C categorized as \>=38.0 to 38.4, \>38.4 to 38.9, \>38.9 to 40.0 and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain graded as mild (does not interfere with activity), moderate (some interference with activity), severe (prevents daily routine activity), Grade 4 (Emergency room visit/hospitalization). Vomiting: mild (1-2 times in 24 h), moderate (\>2 times in 24 h), severe (requires IV hydration), Grade 4 (emergency room visit/hospitalization for hypotensive shock). Diarrhea: mild (2-3 loose stools in 24h), moderate (4-5 loose stools in 24 h), severe (\>=6 loose stools in 24 h) and Grade 4 (emergency room visit/hospitalization). HIV positive participants excluded.
| Percentage of participants | BNT162b2SA (30 mcg), 2 Doses |
|---|---|
| Fever: 38.0°C to 38.4°C | 3.3 (0.1 to 17.2) |
| Fever: >38.4°C to 38.9°C | 6.7 (0.8 to 22.1) |
| Fever: >38.9°C to 40.0°C | 0 (0.0 to 11.6) |
| Fever: >40.0°C | 0 (0.0 to 11.6) |
| Fatigue: Mild | 26.7 (12.3 to 45.9) |
| Fatigue: Moderate | 33.3 (17.3 to 52.8) |
| Fatigue: Severe | 3.3 (0.1 to 17.2) |
| Fatigue: Grade 4 | 0 (0.0 to 11.6) |
| Headache: Mild | 3.3 (0.1 to 17.2) |
| Headache: Moderate | 20.0 (7.7 to 38.6) |
| Headache: Severe | 0 (0.0 to 11.6) |
| Headache: Grade 4 | 0 (0.0 to 11.6) |
| Chills: Mild | 13.3 (3.8 to 30.7) |
| Chills: Moderate | 16.7 (5.6 to 34.7) |
| Chills: Severe | 3.3 (0.1 to 17.2) |
| Chills: Grade 4 | 0 (0.0 to 11.6) |
| Vomiting: Mild | 3.3 (0.1 to 17.2) |
| Vomiting: Moderate | 0 (0.0 to 11.6) |
| Vomiting: Severe | 0 (0.0 to 11.6) |
| Vomiting: Grade 4 | 0 (0.0 to 11.6) |
| Diarrhea: Mild | 6.7 (0.8 to 22.1) |
| Diarrhea: Moderate | 3.3 (0.1 to 17.2) |
| Diarrhea: Severe | 0 (0.0 to 11.6) |
| Diarrhea: Grade 4 | 0 (0.0 to 11.6) |
| New or worsened muscle pain: Mild | 20.0 (7.0 to 38.6) |
| New or worsened muscle pain: Moderate | 20.0 (7.0 to 38.6) |
| New or worsened muscle pain: Severe | 0 (0.0 to 11.6) |
| New or worsened muscle pain: Grade 4 | 0 (0.0 to 11.6) |
| New or worsened joint pain: Mild | 13.3 (3.3 to 38.7) |
| New or worsened joint pain: Moderate | 20.0 (7.7 to 38.6) |
| New or worsened joint pain: Severe | 0 (0.0 to 11.6) |
| New or worsened joint pain: Grade 4 | 0 (0.0 to 11.6) |
Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, new or worsened joint pain recorded by participants or parents/legal guardians of participants using e-diary. Fever=temperature \>=38.0 deg C categorized as \>=38.0 to 38.4, \>38.4 to 38.9, \>38.9 to 40.0 and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain graded as mild (does not interfere with activity), moderate (some interference with activity), severe (prevents daily routine activity), Grade 4 (Emergency room visit/hospitalization). Vomiting: mild (1-2 times in 24 h), moderate (\>2 times in 24 h), severe (requires IV hydration), Grade 4 (emergency room visit/hospitalization for hypotensive shock). Diarrhea: mild (2-3 loose stools in 24h), moderate (4-5 loose stools in 24 h), severe (\>=6 loose stools in 24 h) and Grade 4 (emergency room visit/hospitalization). HIV positive participants excluded.
| Percentage of participants | BNT162b2SA (30 mcg), 2 Doses |
|---|---|
| Fever: 38.0°C to 38.4°C | 3.6 (0.1 to 18.3) |
| Fever: >38.4°C to 38.9°C | 3.6 (0.1 to 18.3) |
| Fever: >38.9°C to 40.0°C | 3.6 (0.1 to 18.3) |
| Fever: >40.0°C | 0 (0.0 to 12.3) |
| Fatigue: Mild | 32.1 (15.9 to 52.4) |
| Fatigue: Moderate | 21.4 (8.3 to 41.0) |
| Fatigue: Severe | 0 (0.0 to 12.3) |
| Fatigue: Grade 4 | 0 (0.0 to 12.3) |
| Headache: Mild | 25.0 (10.7 to 44.9) |
| Headache: Moderate | 17.9 (6.1 to 36.9) |
| Headache: Severe | 0 (0.0 to 12.3) |
| Headache: Grade 4 | 0 (0.0 to 12.3) |
| Chills: Mild | 14.3 (4.0 to 32.7) |
| Chills: Moderate | 14.3 (4.0 to 32.7) |
| Chills: Severe | 0 (0.0 to 12.3) |
| Chills: Grade 4 | 0 (0.0 to 12.3) |
| Vomiting: Mild | 0 (0.0 to 12.3) |
| Vomiting: Moderate | 0 (0.0 to 12.3) |
| Vomiting: Severe | 0 (0.0 to 12.3) |
| Vomiting: Grade 4 | 0 (0.0 to 12.3) |
| Diarrhea: Mild | 14.3 (4.0 to 32.7) |
| Diarrhea: Moderate | 0 (0.0 to 12.3) |
| Diarrhea: Severe | 0 (0.0 to 12.3) |
| Diarrhea: Grade 4 | 0 (0.0 to 12.3) |
| New or worsened muscle pain: Mild | 14.3 (4.0 to 32.7) |
| New or worsened muscle pain: Moderate | 21.4 (8.3 to 41.0) |
| New or worsened muscle pain: Severe | 0 (0.0 to 12.3) |
| New or worsened muscle pain: Grade 4 | 0 (0.0 to 12.3) |
| New or worsened joint pain: Mild | 17.9 (6.1 to 36.9) |
| New or worsened joint pain: Moderate | 10.7 (2.3 to 28.2) |
| New or worsened joint pain: Severe | 0 (0.0 to 12.3) |
| New or worsened joint pain: Grade 4 | 0 (0.0 to 12.3) |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. HIV positive participants were excluded.
| Percentage of participants | BNT162b2SA (30 mcg), 2 Doses |
|---|---|
| Percentage of Participants Reporting Adverse Events From First Booster Dose to 1 Month After Second Booster Dose: BNT162b2 Experienced Participants Assigned to Receive 2 Booster Doses of BNT162b2SA | 20.0 (7.7 to 38.6) |
An SAE was any untoward medical occurrence that occurred, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect and other important medical events. HIV positive participants were excluded.
| Percentage of participants | BNT162b2SA (30 mcg), 2 Doses |
|---|---|
| Percentage of Participants Reporting Serious Adverse Events From First Booster Dose to 5 Months After Second Booster Dose: BNT162b2 Experienced Participants Assigned to Receive 2 Booster Doses of BNT162b2SA | 3.3 (0.1 to 17.2) |
Local reactions included redness, swelling and, pain at the injection site, recorded by participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\> 2.0 to 5.0 cm), moderate (\> 5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), severe (prevents daily activity) and Grade 4 (emergency room visit or hospitalization for severe pain). HIV positive participants were excluded.
| Percentage of participants | BNT162b2SA (30 mcg) |
|---|---|
| Redness: Mild | 1.6 (0.5 to 3.7) |
| Redness: Moderate | 0.3 (0.0 to 1.8) |
| Redness: Severe | 0 (0.0 to 1.2) |
| Redness: Grade 4 | 0 (0.0 to 1.2) |
| Swelling: Mild | 1.9 (0.7 to 4.1) |
| Swelling: Moderate | 1.6 (0.5 to 3.7) |
| Swelling: Severe | 0 (0.0 to 1.2) |
| Swelling: Grade 4 | 0 (0.0 to 1.2) |
| Pain at injection site: Mild | 68.1 (62.6 to 73.2) |
| Pain at injection site: Moderate | 14.7 (11.0 to 19.1) |
| Pain at injection site: Severe | 0.3 (0.0 to 1.8) |
| Pain at injection site: Grade 4 | 0 (0.0 to 1.2) |
Local reactions included redness, swelling and, pain at the injection site, recorded by participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\> 2.0 to 5.0 cm), moderate (\> 5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), severe (prevents daily activity) and Grade 4 (emergency room visit or hospitalization for severe pain). HIV positive participants were excluded.
| Percentage of participants | BNT162b2SA (30 mcg) |
|---|---|
| Redness: Mild | 2.8 (1.3 to 5.3) |
| Redness: Moderate | 1.9 (0.7 to 4.1) |
| Redness: Severe | 0.3 (0.0 to 1.8) |
| Redness: Grade 4 | 0 (0.0 to 1.2) |
| Swelling: Mild | 2.8 (1.3 to 5.3) |
| Swelling: Moderate | 2.2 (0.9 to 4.5) |
| Swelling: Severe | 0 (0.0 to 1.2) |
| Swelling: Grade 4 | 0 (0.0 to 1.2) |
| Pain at injection site: Mild | 53.5 (47.8 to 59.1) |
| Pain at injection site: Moderate | 19.3 (15.1 to 24.1) |
| Pain at injection site: Severe | 0.3 (0.0 to 1.8) |
| Pain at injection site: Grade 4 | 0 (0.0 to 1.2) |
Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, new or worsened joint pain recorded by participants or parents/legal guardians of participants using e-diary. Fever=temperature \>=38.0 deg C categorized as \>=38.0 to 38.4, \>38.4 to 38.9, \>38.9 to 40.0 and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain graded as mild (does not interfere with activity), moderate (some interference with activity), severe (prevents daily routine activity), Grade 4 (Emergency room visit/hospitalization). Vomiting: mild (1-2 times in 24 h), moderate (\>2 times in 24 h), severe (requires IV hydration), Grade 4 (emergency room visit/hospitalization for hypotensive shock). Diarrhea: mild (2-3 loose stools in 24h), moderate (4-5 loose stools in 24 h), severe (\>=6 loose stools in 24 h) and Grade 4 (emergency room visit/hospitalization). HIV positive participants were excluded.
| Percentage of participants | BNT162b2SA (30 mcg) |
|---|---|
| Fever: 38.0°C to 38.4°C | 1.0 (0.2 to 3.8) |
| Fever: >38.4°C to 38.9°C | 0 (0.0 to 1.2) |
| Fever: >38.9°C to 40.0°C | 0 (0.0 to 1.2) |
| Fever: >40.0°C | 0 (0.0 to 1.2) |
| Fatigue: Mild | 27.8 (22.9 to 33.1) |
| Fatigue: Moderate | 21.1 (16.7 to 26.0) |
| Fatigue: Severe | 0.6 (0.1 to 2.3) |
| Fatigue: Grade 4 | 0 (0.0 to 1.2) |
| Headache: Mild | 22.0 (17.6 to 27.1) |
| Headache: Moderate | 9.9 (6.8 to 13.8) |
| Headache: Severe | 0.3 (0.0 to 1.8) |
| Headache: Grade 4 | 0 (0.0 to 1.2) |
| Chills: Mild | 4.8 (2.7 to 7.8) |
| Chills: Moderate | 1.6 (0.5 to 3.7) |
| Chills: Severe | 0.3 (0.0 to 1.8) |
| Chills: Grade 4 | 0 (0.0 to 1.2) |
| Vomiting: Mild | 1.3 (0.3 to 3.2) |
| Vomiting: Moderate | 0 (0.0 to .12) |
| Vomiting: Severe | 0 (0.0 to 1.2) |
| Vomiting: Grade 4 | 0 (0.0 to 1.2) |
| Diarrhea: Mild | 6.7 (4.2 to 10.1) |
| Diarrhea: Moderate | 1.3 (0.3 to 3.2) |
| Diarrhea: Severe | 0.3 (0.0 to 1.8) |
| Diarrhea: Grade 4 | 0 (0.0 to 1.2) |
| New or worsened muscle pain: Mild | 6.4 (3.9 to 9.7) |
| New or worsened muscle pain: Moderate | 5.8 (3.4 to 8.9) |
| New or worsened muscle pain: Severe | 0 (0.0 to 1.2) |
| New or worsened muscle pain: Grade 4 | 0 (0.0 to 1.2) |
| New or worsened joint pain: Mild | 2.9 (1.3 to 5.4) |
| New or worsened joint pain: Moderate | 1.9 (0.7 to 4.1) |
| New or worsened joint pain: Severe | 0 (0.0 to 1.2) |
| New or worsened joint pain: Grade 4 | 0 (0.0 to 1.2) |
Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, new or worsened joint pain recorded by participants or parents/legal guardians of participants using e-diary. Fever=temperature \>=38.0 deg C categorized as \>=38.0 to 38.4, \>38.4 to 38.9, \>38.9 to 40.0 and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain graded as mild (does not interfere with activity), moderate (some interference with activity), severe (prevents daily routine activity), Grade 4 (Emergency room visit/hospitalization). Vomiting: mild (1-2 times in 24 h), moderate (\>2 times in 24 h), severe (requires IV hydration), Grade 4 (emergency room visit/hospitalization for hypotensive shock). Diarrhea: mild (2-3 loose stools in 24h), moderate (4-5 loose stools in 24 h), severe (\>=6 loose stools in 24 h) and Grade 4 (emergency room visit/hospitalization). HIV positive participants were excluded.
| Percentage of participants | BNT162b2SA (30 mcg) |
|---|---|
| Fever: 38.0°C to 38.4°C | 1.6 (0.5 to 3.7) |
| Fever: >38.4°C to 38.9°C | 1.6 (0.5 to 3.7) |
| Fever: >38.9°C to 40.0°C | 0.6 (0.1 to 2.3) |
| Fever: >40.0°C | 0 (0.0 to 1.2) |
| Fatigue: Mild | 25.3 (20.6 to 30.5) |
| Fatigue: Moderate | 36.1 (30.8 to 41.6) |
| Fatigue: Severe | 4.1 (2.2 to 6.9) |
| Fatigue: Grade 4 | 0 (0.0 to 1.2) |
| Headache: Mild | 29.7 (24.8 to 35.1) |
| Headache: Moderate | 17.1 (13.1 to 21.7) |
| Headache: Severe | 0.9 (0.2 to 2.7) |
| Headache: Grade 4 | 0 (0.0 to 1.2) |
| Chills: Mild | 13.9 (10.3 to 18.2) |
| Chills: Moderate | 12.7 (9.2 to 16.8) |
| Chills: Severe | 0.9 (0.2 to 2.7) |
| Chills: Grade 4 | 0 (0.0 to 1.2) |
| Vomiting: Mild | 0.9 (0.2 to 2.7) |
| Vomiting: Moderate | 0 (0.0 to 1.2) |
| Vomiting: Severe | 0 (0.0 to 1.2) |
| Vomiting: Grade 4 | 0 (0.0 to 1.2) |
| Diarrhea: Mild | 6.0 (3.7 to 9.2) |
| Diarrhea: Moderate | 0.6 (0.1 to 2.3) |
| Diarrhea: Severe | 0 (0.0 to 1.2) |
| Diarrhea: Grade 4 | 0 (0.0 to 1.2) |
| New or worsened muscle pain: Mild | 13.0 (9.5 to 17.2) |
| New or worsened muscle pain: Moderate | 16.1 (12.3 to 20.7) |
| New or worsened muscle pain: Severe | 1.3 (0.3 to 3.2) |
| New or worsened muscle pain: Grade 4 | 0 (0.0 to 1.2) |
| New or worsened joint pain: Mild | 7.9 (5.2 to 11.5) |
| New or worsened joint pain: Moderate | 12.7 (9.2 to 16.8) |
| New or worsened joint pain: Severe | 0 (0.0 to 1.2) |
| New or worsened joint pain: Grade 4 | 0 (0.0 to 1.2) |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. HIV positive participants were excluded.
| Percentage of participants | BNT162b2SA (30 mcg) |
|---|---|
| Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: BNT162b2-Naïve Participants Who Were Enrolled to Receive BNT162b2SA | 14.2 (10.6 to 18.5) |
A SAE was any untoward medical occurrence that occurred, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect and other important medical events. HIV positive participants were excluded.
| Percentage of participants | BNT162b2SA (30 mcg) |
|---|---|
| Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: BNT162b2-Naïve Participants Who Were Enrolled to Receive BNT162b2SA | 1.2 (0.3 to 3.1) |
Local reactions included redness, swelling and, pain at the injection site, recorded by participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\> 2.0 to 5.0 cm), moderate (\> 5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), severe (prevents daily activity) and Grade 4 (emergency room visit or hospitalization for severe pain). HIV positive participants were excluded.
| Percentage of participants | BNT162b2 5 mcg Dose: 18-55 Years of Age | BNT162b2 5 mcg: >55 Years of Age | BNT162b2 10 mcg: 18-55 Years of Age | BNT162b2 10 mcg: >55 Years of Age |
|---|---|---|---|---|
| Redness: Mild | 0 (0.0 to 13.7) | 0 (0.0 to 6.8) | 0 (0.0 to 13.7) | 0 (0.0 to 7.0) |
| Redness: Moderate | 0 (0.0 to 13.7) | 1.9 (0.0 to 10.3) | 0 (0.0 to 13.7) | 0 (0.0 to 7.0) |
| Redness: Severe | 0 (0.0 to 13.7) | 0 (0.0 to 6.8) | 0 (0.0 to 13.7) | 0 (0.0 to 7.0) |
| Redness: Grade 4 | 0 (0.0 to 13.7) | 0 (0.0 to 6.8) | 0 (0.0 to 13.7) | 0 (0.0 to 7.0) |
| Swelling: Mild | 0 (0.0 to 13.7) | 1.9 (0.0 to 10.3) | 0 (0.0 to 13.7) | 3.9 (0.5 to 13.5) |
| Swelling: Moderate | 0 (0.0 to 13.7) | 0 (0.0 to 6.8) | 0 (0.0 to 13.7) | 2.0 (0.0 to 10.4) |
| Swelling: Severe | 0 (0.0 to 13.7) | 0 (0.0 to 6.8) | 0 (0.0 to 13.7) | 0 (0.0 to 7.0) |
| Swelling: Grade 4 | 0 (0.0 to 13.7) | 0 (0.0 to 6.8) | 0 (0.0 to 13.7) | 0 (0.0 to 7.0) |
| Pain at injection site: Mild | 56.0 (34.9 to 75.6) | 34.6 (22.0 to 49.1) | 48.0 (27.8 to 68.7) | 66.7 (52.1 to 79.2) |
| Pain at injection site: Moderate | 0 (0.0 to 13.7) | 1.9 (0.0 to 10.3) | 12.0 (2.5 to 31.2) | 5.9 (1.2 to 16.2) |
| Pain at injection site: Severe | 0 (0.0 to 13.7) | 0 (0.0 to 6.8) | 0 (0.0 to 13.7) | 0 (0.0 to 7.0) |
| Pain at injection site: Grade 4 | 0 (0.0 to 13.7) | 0 (0.0 to 6.8) | 0 (0.0 to 13.7) | 0 (0.0 to 7.0) |
Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, new or worsened joint pain recorded by participants or parents/legal guardians of participants using e-diary. Fever=temperature \>=38.0 deg C categorized as \>=38.0 to 38.4, \>38.4 to 38.9, \>38.9 to 40.0 and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain graded as mild (does not interfere with activity), moderate (some interference with activity), severe (prevents daily routine activity), Grade 4 (Emergency room visit/hospitalization). Vomiting: mild (1-2 times in 24 h), moderate (\>2 times in 24 h), severe (requires IV hydration), Grade 4 (emergency room visit/hospitalization for hypotensive shock). Diarrhea: mild (2-3 loose stools in 24h), moderate (4-5 loose stools in 24 h), severe (\>=6 loose stools in 24 h) and Grade 4 (emergency room visit/hospitalization). HIV positive participants were excluded.
| Percentage of participants | BNT162b2 5 mcg Dose: 18-55 Years of Age | BNT162b2 5 mcg: >55 Years of Age | BNT162b2 10 mcg: 18-55 Years of Age | BNT162b2 10 mcg: >55 Years of Age |
|---|---|---|---|---|
| Fever: 38.0°C to 38.4°C | 0 (0.0 to 13.7) | 0 (0.0 to 6.8) | 4.0 (0.1 to 20.4) | 0 (0.0 to 7.0) |
| Fever: >38.4°C to 38.9°C | 0 (0.0 to 13.7) | 0 (0.0 to 6.8) | 0 (0.0 to 13.7) | 0 (0.0 to 7.0) |
| Fever: >38.9°C to 40.0°C | 0 (0.0 to 13.7) | 0 (0.0 to 6.8) | 0 (0.0 to 13.7) | 2.0 (0.0 to 10.4) |
| Fever: >40.0°C | 0 (0.0 to 13.7) | 0 (0.0 to 6.8) | 0 (0.0 to 13.7) | 0 (0.0 to 7.0) |
| Fatigue: Mild | 20.0 (6.8 to 40.7) | 15.4 (6.9 to 28.1) | 32.0 (14.9 to 53.5) | 29.4 (17.5 to 43.8) |
| Fatigue: Moderate | 24.0 (9.4 to 45.1) | 9.6 (3.2 to 21.0) | 24.0 (9.4 to 45.1) | 19.6 (9.8 to 33.1) |
| Fatigue: Severe | 0 (0.0 to 13.7) | 1.9 (0.0 to 10.3) | 4.0 (0.1 to 20.4) | 2.0 (0.0 to 10.4) |
| Fatigue: Grade 4 | 0 (0.0 to 13.7) | 0 (0.0 to 6.8) | 0 (0.0 to 13.7) | 0 (0.0 to 7.0) |
| Headache: Mild | 20.0 (6.8 to 40.7) | 15.4 (6.9 to 28.1) | 20.0 (6.8 to 40.7) | 23.5 (12.8 to 37.5) |
| Headache: Moderate | 4.0 (0.1 to 20.4) | 7.7 (2.1 to 18.5) | 16.0 (4.5 to 36.1) | 13.7 (5.7 to 26.3) |
| Headache: Severe | 0 (0.0 to 13.7) | 0 (0.0 to 6.8) | 4.0 (0.1 to 20.4) | 0 (0.0 to 7.0) |
| Headache: Grade 4 | 0 (0.0 to 13.7) | 0 (0.0 to 6.8) | 0 (0.0 to 13.7) | 0 (0.0 to 7.0) |
| Chills: Mild | 8.0 (1.0 to 26.0) | 9.6 (3.2 to 21.0) | 12.0 (2.5 to 31.2) | 13.7 (5.7 to 26.3) |
| Chills: Moderate | 0 (0.0 to 13.7) | 1.9 (0.0 to 10.3) | 12.0 (2.5 to 31.2) | 7.8 (2.2 to 18.9) |
| Chills: Severe | 0 (0.0 to 13.7) | 0 (0.0 to 6.8) | 0 (0.0 to 13.7) | 0 (0.0 to 7.0) |
| Chills: Grade 4 | 0 (0.0 to 13.7) | 0 (0.0 to 6.8) | 0 (0.0 to 13.7) | 0 (0.0 to 7.0) |
| Vomiting: Mild | 0 (0.0 to 13.7) | 0 (0.0 to 6.8) | 0 (0.0 to 13.7) | 0 (0.0 to 7.0) |
| Vomiting: Moderate | 0 (0.0 to 13.7) | 3.8 (0.5 to 13.2) | 0 (0.0 to 13.7) | 0 (0.0 to 7.0) |
| Vomiting: Severe | 0 (0.0 to 13.7) | 0 (0.0 to 6.8) | 0 (0.0 to 13.7) | 0 (0.0 to 7.0) |
| Vomiting: Grade 4 | 0 (0.0 to 13.7) | 0 (0.0 to 6.8) | 0 (0.0 to 13.7) | 0 (0.0 to 7.0) |
| Diarrhea: Mild | 8.0 (1.0 to 26.0) | 0 (0.0 to 6.8) | 16.0 (4.5 to 36.1) | 2.0 (0.0 to 10.4) |
| Diarrhea: Moderate | 0 (0.0 to 13.7) | 3.8 (0.5 to 13.2) | 0 (0.0 to 13.7) | 0 (0.0 to 7.0) |
| Diarrhea: Severe | 0 (0.0 to 13.7) | 0 (0.0 to 6.8) | 0 (0.0 to 13.7) | 0 (0.0 to 7.0) |
| Diarrhea: Grade 4 | 0 (0.0 to 13.7) | 0 (0.0 to 6.8) | 0 (0.0 to 13.7) | 0 (0. to 07.0) |
| New or worsened muscle pain: Mild | 24.0 (9.4 to 45.1) | 11.5 (4.4 to 23.4) | 16.0 (4.5 to 36.1) | 5.9 (1.2 to 16.2) |
| New or worsened muscle pain: Moderate | 0 (0.0 to 13.7) | 1.9 (0.0 to 10.3) | 12.0 (2.5 to 31.2) | 7.8 (2.2 to 18.9) |
| New or worsened muscle pain: Severe | 0 (0.0 to 13.7) | 0 (0.0 to 6.8) | 0 (0.0 to 13.7) | 0 (0.0 to 7.0) |
| New or worsened muscle pain: Grade 4 | 0 (0.0 to 13.7) | 0 (0.0 to 6.8) | 0 (0.0 to 13.7) | 0 (0.0 to 7.0) |
| New or worsened joint pain: Mild | 4.0 (0.1 to 20.4) | 0 (0.0 to 6.8) | 8.0 (1.0 to 26.0) | 7.8 (2.2 to 18.9) |
| New or worsened joint pain: Moderate | 0 (0.0 to 13.7) | 0 (0.0 to 6.8) | 12.0 (2.5 to 31.2) | 5.9 (1.2 to 16.2) |
| New or worsened joint pain: Severe | 0 (0.0 to 13.7) | 0 (0.0 to 6.8) | 0 (0.0 to 13.7) | 0 (0.0 to 7.0) |
| New or worsened joint pain: Grade 4 | 0 (0.0 to 13.7) | 0 (0.0 to 6.8) | 0 (0.0 to 13.7) | 0 (0.0 to 7.0) |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. HIV positive participants were excluded.
| Percentage of participants | BNT162b2 5 mcg Dose: 18-55 Years of Age | BNT162b2 5 mcg: >55 Years of Age | BNT162b2 10 mcg: 18-55 Years of Age | BNT162b2 10 mcg: >55 Years of Age |
|---|---|---|---|---|
| Percentage of Participants Reporting Adverse Events From Booster Dose to 1 Month After Booster Dose: BNT162b2-Experienced Participants Who Were Rerandomized to Receive 1 Booster Dose of BNT162b2 (Lower Dose) | 11.5 (2.4 to 30.2) | 3.8 (0.5 to 13.0) | 8.0 (1.0 to 26.0) | 0.0 (0.0 to 7.0) |
A SAE was any untoward medical occurrence that occurred, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect and other important medical events. HIV positive participants were excluded.
| Percentage of participants | BNT162b2 5 mcg Dose: 18-55 Years of Age | BNT162b2 5 mcg: >55 Years of Age | BNT162b2 10 mcg: 18-55 Years of Age | BNT162b2 10 mcg: >55 Years of Age |
|---|---|---|---|---|
| Percentage of Participants Reporting Serious Adverse Events From Booster Dose to 6 Months After Booster Dose: BNT162b2-Experienced Participants Who Were Rerandomized to Receive 1 Booster Dose of BNT162b2 (Lower Dose) | 0 (0.0 to 13.2) | 1.9 (0.0 to 10.1) | 0 (0.0 to 13.7) | 0 (0.0 to 7.0) |
Occurrences of first COVID-19 infection in participants followed up based on central laboratory or locally confirmed NAAT in participants, without serological or virological evidence of prior SARS-CoV-2 infection were reported in this outcome measure. HIV positive participants were excluded from this analysis.
| Events per 1000 person-years | BNT162b2 (30 mcg) | Placebo |
|---|---|---|
| COVID-19 Incidence Based on Central Laboratory or Locally Confirmed Nucleic Acid Amplification Test (NAAT) in Participants Without Serological or Virological Evidence: Phase 2/3 | 12.326 | 141.596 |
Occurrences of first COVID-19 infection in participants followed up based on central laboratory or locally confirmed NAAT in participants, without serological or virological evidence of prior SARS-CoV-2 infection (analysis for EUA) were reported in this outcome measure.
| Events per 1000 person-years | BNT162b2 (30 mcg) | Placebo |
|---|---|---|
| COVID-19 Incidence Based on Central Laboratory or Locally Confirmed Nucleic Acid Amplification Test (NAAT) in Participants Without Serological or Virological Evidence: Phase 2/3 (Analysis for EUA) | 3.613 | 72.907 |
Occurrences of first COVID-19 infection in participants followed up based on central laboratory or locally confirmed NAAT in participants, with or without serological or virological evidence of prior SARS-CoV-2 infection were reported in this outcome measure.
| Events per 1000 person-years | BNT162b2 (30 mcg) | Placebo |
|---|---|---|
| COVID-19 Incidence Based on Central Laboratory or Locally Confirmed Nucleic Acid Amplification Test (NAAT) in Participants With or Without Serological or Virological Evidence: Phase 2/3 | 12.444 | 139.146 |
Occurrences of first COVID-19 infection in participants followed up based on central laboratory or locally confirmed NAAT in participants, with or without serological or virological evidence (analysis for EUA) of prior SARS-CoV-2 infection were reported in this outcome measure. HIV positive participants were excluded from this analysis.
| Events per 1000 person-years | BNT162b2 (30 mcg) | Placebo |
|---|---|---|
| COVID-19 Incidence Based on Central Laboratory or Locally Confirmed Nucleic Acid Amplification Test (NAAT) in Participants With or Without Serological or Virological Evidence: Phase 2/3 (Analysis for EUA) | 3.859 | 72.068 |
GMR based on geometric mean titer, comparison of 1 month after dose 2 between vaccine groups: BNT162b2-naive participants without evidence of infection up to 1 month after dose 2 were reported in this outcome measure. HIV positive participants excluded from this analysis.
| Titer | BNT162b2SA (30 mcg) | BNT162b2 (30 mcg) |
|---|---|---|
| GMR Based on Geometric Mean Titer (N1a) - Comparison of 1 Month After Dose 2 Between Vaccine Groups: BNT162b2-Naïve Participants Without Evidence of Infection (N1a) up to 1 Month After Dose 2: Phase 3 | 1358.0 (1242.2 to 1484.5) | 820.3 (745.7 to 902.3) |
Seroresponse was defined as achieving a \>=4-fold rise from baseline (before Dose 1). If the baseline measurement was below the lower limit of quantification (LLOQ), a post vaccination assay result \>=4 × LLOQ was considered a seroresponse. HIV positive participants excluded.
| Percentage of participants | BNT162b2SA (30 mcg) | BNT162b2 (30 mcg) |
|---|---|---|
| Percentage Difference of Participants Achieving Seroresponse Comparison (N1b) of 1 Month After Dose 2 Between Vaccine Groups: BNT162b2-Naïve Participants Without Evidence of Infection up to 1 Month After Dose 2: Phase 3 | 97.1 (94.3 to 98.7) | 97.3 (94.6 to 98.9) |
GMR based on geometric mean titer, comparison of 1 month after booster dose to 1 month after dose 2 for BNT162b2-experienced participants were reported in this outcome measure. HIV positive participants excluded from this analysis.
| Titer | BNT162b2SA (30 mcg) | BNT162b2 (30 mcg) |
|---|---|---|
| GMR of Neutralizing Titers (E1a) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants That Received a Booster Dose of BNT162b2: Phase 3 | 2466.0 (2202.6 to 2760.8) | 755.7 (663.1 to 861.2) |
Percentage difference of participants achieving seroresponse - comparison of 1 month after booster dose to 1 month after Dose 2 BNT162b2-experienced participants without evidence of infection up to 1 month after booster dose who were rerandomized to receive 1 booster dose were reported in this outcome measure. Seroresponse was defined as achieving a \>=4-fold rise from baseline (before Dose 1). If the baseline measurement was below the LLOQ, a postvaccination assay result \>=4 × LLOQ was considered a seroresponse. HIV positive participants excluded.
| Percentage of participants | BNT162b2 (30 mcg): 1 Month After Booster Dose | BNT162b2 (30 mcg): 1 Month After Dose 2 |
|---|---|---|
| Percentage Difference of Participants Achieving Seroresponse (E1b) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants That Received a Booster Dose of BNT162b2: Phase 3 | 99.5 (97.2 to 100.0) | 95.0 (91.0 to 97.6) |
GMR of neutralizing titers (E2a) for comparison of 1 month after booster dose to 1 month after dose 2: BNT162b2-experienced participants in Phase 3 were reported in this outcome measure. HIV positive participants were excluded from this analysis.
| Titer | BNT162b2SA (30 mcg):1 Month After Booster Dose | BNT162b2SA 30 mcg: 1 Month After Dose 2 |
|---|---|---|
| GMR of Neutralizing Titers (E2a) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants: Phase 3 | 3580.5 (3146.6 to 4074.3) | 688.3 (616.1 to 768.8) |
Percentage difference of participants achieving seroresponse - comparison of 1 month after booster dose to 1 month after Dose 2 BNT162b2-experienced participants without evidence of infection up to 1 month after booster dose who were rerandomized to receive 1 booster dose were reported in this outcome measure. Seroresponse was defined as achieving a \>=4-fold rise from baseline (before Dose 1). If the baseline measurement was below the LLOQ, a postvaccination assay result \>=4 × LLOQ was considered a seroresponse. HIV positive participants excluded.
| Percentage of participants | BNT162b2SA (30 mcg): 1 Month After Booster Dose | BNT162b2SA 30 mcg: 1 Month After Dose 2 |
|---|---|---|
| Percentage Difference of Participants Achieving Seroresponse (E2b) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants: Phase 3 | 99.1 (96.8 to 99.9) | 94.1 (90.2 to 96.8) |
GMTs of severe acute respiratory syndrome coronavirus 2 neutralizing titers were reported in this outcome measure. SARS-CoV-2 neutralization assay - NT50 and SARS-CoV-2 neutralization assay - NT90 were evaluated and reported in this outcome measure.
| Titers | BNT162b1 10 mcg Dose: 18-55 Years of Age | BNT162b1 20 mcg Dose: 18-55 Years of Age | BNT162b1 30 mcg Dose: 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b1 | BNT162b1 100 mcg Dose, 18-55 Years of Age | Placebo 18-55 Years of Age for BNT162b1 100 mcg | BNT162b2 10 mcg Dose, 18-55 Years of Age | BNT162b2 20 mcg Dose, 18-55 Years of Age | BNT162b2 30 mcg Dose, 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b2 | BNT162b1 10 mcg Dose, 65-85 Years of Age | BNT162b1 20 mcg Dose, 65-85 Years of Age | BNT162b1 30 mcg Dose, 65-85 Years of Age | Placebo, 65-85 Years of Age for BNT162b1 | BNT162b2 10 mcg Dose, 65-85 Years of Age | BNT162b2 20 mcg Dose, 65-85 Years of Age | BNT162b2 30 mcg Dose, 65-85 Years of Age | Placebo: 65-85 Years of Age for BNT162b2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NT50 titer: 7 days after dose 1 | 10.0 (10.0 to 10.0) | — | 10.0 (10.0 to 10.0) | 10.0 (10.0 to 10.0) | 10.0 (10.0 to 10.0) | 10.0 (10.0 to 10.0) | — | — | — | — | — | — | — | — | — | — | — | — |
| NT50 (titer): 21 days after dose 1 | 12.7 (9.6 to 16.8) | 12.5 (9.0 to 17.5) | 28.6 (17.1 to 47.9) | 10.0 (10.0 to 10.0) | 32.5 (17.0 to 62.4) | 10.0 (10.0 to 10.0) | 16.6 (9.8 to 27.9) | 18.9 (11.1 to 32.3) | 14.4 (10.1 to 20.4) | 10.0 (10.0 to 10.0) | 11.2 (8.7 to 14.4) | 10.0 (10.0 to 10.0) | 12.5 (9.0 to 17.4) | 10.0 (10.0 to 10.0) | 10.0 (10.0 to 10.0) | 10.0 (10.0 to 10.0) | 12.0 (9.0 to 16.0) | 10.0 (10.0 to 10.0) |
| NT50 (titer): 7 days after dose 2 | 167.9 (111.2 to 253.5) | 160.3 (80.1 to 320.9) | 267.1 (172.9 to 412.7) | 10.0 (10.0 to 10.0) | — | — | 169.0 (102.7 to 278.2) | 362.5 (256.9 to 511.6) | 360.9 (237.4 to 548.6) | 10.0 (10.0 to 10.0) | 19.9 (11.7 to 33.9) | 178.7 (94.5 to 337.7) | 100.8 (45.7 to 222.3) | 10.0 (10.0 to 10.0) | 79.3 (50.6 to 124.5) | 79.3 (40.9 to 153.5) | 155.7 (80.4 to 301.7) | 10.0 (10.0 to 10.0) |
| NT50 (titer): 14 days after dose 2 | 180.1 (107.2 to 302.5) | 202.9 (123.4 to 333.4) | 437.0 (302.6 to 631.1) | 10.0 (10.0 to 10.0) | — | — | 108.8 (54.7 to 216.5) | 292.1 (179.3 to 475.7) | 161.6 (109.3 to 238.8) | 10.0 (10.0 to 10.0) | 28.5 (13.7 to 59.2) | 104.7 (43.7 to 250.5) | 105.5 (50.0 to 222.6) | 10.0 (10.0 to 10.0) | 111.1 (81.0 to 152.3) | 73.7 (32.8 to 165.6) | 214.1 (105.9 to 433.2) | 10.0 (10.0 to 10.0) |
| NT50 (titer): 1 month after dose 2 | 68.5 (41.8 to 112.0) | 161.2 (102.5 to 253.4) | 180.5 (108.4 to 300.7) | 10.0 (10.0 to 10.0) | — | — | 105.3 (65.1 to 170.6) | 251.7 (143.5 to 441.4) | 143.6 (103.8 to 198.6) | 10.0 (10.0 to 10.0) | 22.7 (11.3 to 45.3) | 125.3 (74.7 to 210.0) | 144.7 (70.3 to 298.1) | 10.0 (10.0 to 10.0) | 69.6 (43.0 to 112.7) | 49.6 (23.1 to 106.6) | 152.3 (81.2 to 285.6) | 10.0 (10.0 to 10.0) |
| NT50 (titer): 6 months after dose 2 | — | — | — | — | — | — | — | — | 54.7 (24.7 to 121.1) | — | — | — | — | — | — | — | 29.0 (19.4 to 43.5) | — |
| NT90 (titer): 7 days after dose 1 | 10.0 (10.0 to 10.0) | — | 10.0 (10.0 to 10.0) | 10.0 (10.0 to 10.0) | 10.0 (10.0 to 10.0) | 10.0 (10.0 to 10.0) | — | — | — | — | — | — | — | — | — | — | — | — |
| NT90 (titer): 21 days after dose 1 | 10.0 (10.0 to 10.0) | 10.0 (10.0 to 10.0) | 11.9 (9.1 to 15.6) | 10.0 (10.0 to 10.0) | 15.0 (9.3 to 24.4) | 10.0 (10.0 to 10.0) | 10.9 (9.0 to 13.2) | 10.7 (9.2 to 12.5) | 10.8 (9.1 to 12.8) | 10.0 (10.0 to 10.0) | 10.0 (10.0 to 10.0) | 10.0 (10.0 to 10.0) | 10.0 (10.0 to 10.0) | 10.0 (10.0 to 10.0) | 10.0 (10.0 to 10.0) | 10.0 (10.0 to 10.0) | 10.0 (10.0 to 10.0) | 10.0 (10.0 to 10.0) |
| NT90 (titer): 7 days after dose 2 | 56.8 (35.2 to 91.4) | 67.0 (40.3 to 111.3) | 121.6 (78.8 to 187.6) | 10.0 (10.0 to 10.0) | — | — | 70.1 (42.7 to 115.0) | 142.2 (103.3 to 195.7) | 122.8 (79.2 to 190.4) | 10.0 (10.0 to 10.0) | 12.1 (9.0 to 16.3) | 73.7 (34.6 to 157.1) | 47.6 (22.1 to 102.3) | 10.0 (10.0 to 10.0) | 40.0 (26.5 to 60.3) | 33.4 (18.1 to 61.4) | 53.5 (26.1 to 109.4) | 10.0 (10.0 to 10.0) |
| NT90 (titer): 14 days after dose 2 | 76.5 (44.4 to 131.6) | 110.4 (71.4 to 170.5) | 188.1 (126.4 to 279.8) | 10.0 (10.0 to 10.0) | — | — | 46.6 (25.1 to 86.5) | 112.7 (73.9 to 171.8) | 54.3 (37.5 to 78.6) | 10.0 (10.0 to 10.0) | 16.5 (9.6 to 28.1) | 49.0 (25.0 to 95.9) | 50.3 (25.4 to 99.5) | 10.0 (10.0 to 10.0) | 56.0 (35.4 to 88.6) | 29.3 (16.3 to 52.6) | 60.3 (25.2 to 144.1) | 10.0 (10.0 to 10.0) |
| NT90 (titer): 1 month after dose 2 | 37.0 (24.6 to 55.5) | 40.1 (25.0 to 64.3) | 62.0 (35.5 to 108.3) | 10.0 (10.0 to 10.0) | — | — | 34.4 (18.4 to 64.7) | 60.0 (33.3 to 108.2) | 54.7 (41.2 to 72.6) | 10.0 (10.0 to 10.0) | 14.2 (9.0 to 22.4) | 48.4 (26.0 to 90.2) | 59.9 (30.4 to 118.0) | 10.0 (10.0 to 10.0) | 20.2 (12.1 to 33.7) | 24.6 (12.9 to 47.0) | 50.9 (28.3 to 91.6) | 10.0 (10.0 to 10.0) |
GMCs of severe acute respiratory syndrome coronavirus S1-binding and RBD-binding IgG level were reported in this outcome measure.
| Units per milliliter | BNT162b1 10 mcg Dose: 18-55 Years of Age | BNT162b1 20 mcg Dose: 18-55 Years of Age | BNT162b1 30 mcg Dose: 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b1 | BNT162b1 100 mcg Dose, 18-55 Years of Age | Placebo 18-55 Years of Age for BNT162b1 100 mcg | BNT162b2 10 mcg Dose, 18-55 Years of Age | BNT162b2 20 mcg Dose, 18-55 Years of Age | BNT162b2 30 mcg Dose, 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b2 | BNT162b1 10 mcg Dose, 65-85 Years of Age | BNT162b1 20 mcg Dose, 65-85 Years of Age | BNT162b1 30 mcg Dose, 65-85 Years of Age | Placebo, 65-85 Years of Age for BNT162b1 | BNT162b2 10 mcg Dose, 65-85 Years of Age | BNT162b2 20 mcg Dose, 65-85 Years of Age | BNT162b2 30 mcg Dose, 65-85 Years of Age | Placebo: 65-85 Years of Age for BNT162b2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S1-binding IgG level assay:7 days after Dose1 | 0.8 (0.5 to 1.1) | — | 0.9 (0.5 to 1.4) | 1.0 (0.5 to 2.2) | 0.9 (0.4 to 1.9) | 0.6 (0.6 to 0.6) | — | — | — | — | — | — | — | — | — | — | — | — |
| S1-binding IgG level assay: 21 days after Dose 1 | 294.2 (126.8 to 682.8) | 204.1 (57.5 to 723.9) | 852.7 (479.5 to 1516.4) | 0.8 (0.4 to 1.6) | 1074.4 (702.2 to 1643.9) | 0.6 (0.6 to 0.6) | 611.7 (332.0 to 1126.8) | 546.7 (346.3 to 863.1) | 1264.8 (912.6 to 1753.1) | 0.6 (0.6 to 0.6) | 34.1 (9.7 to 120.2) | 125.1 (56.2 to 278.4) | 86.3 (27.7 to 269.2) | 1.1 (0.6 to 2.3) | 172.0 (92.0 to 321.7) | 80.9 (31.7 to 206.8) | 283.2 (115.7 to 693.2) | 0.8 (0.6 to 1.2) |
| S1-binding IgG level assay:7 days after Dose 2 | 3868.2 (2052.5 to 7290.0) | 3243.1 (689.9 to 15244.1) | 23516.5 (16552.7 to 33409.8) | 1.2 (0.5 to 2.7) | — | — | 6014.0 (4061.6 to 8904.9) | 12464.0 (9249.2 to 16796.1) | 9136.4 (6385.0 to 13073.3) | 0.6 (0.6 to 0.6) | 860.7 (372.4 to 1989.3) | 10622.7 (5607.8 to 20122.3) | 6579.6 (2827.6 to 15310.2) | 1.3 (0.5 to 3.2) | 3203.3 (2314.5 to 4433.4) | 2734.2 (1211.8 to 6169.3) | 7547.9 (4224.0 to 13487.6) | 0.9 (0.6 to 1.5) |
| S1-binding IgG level assay:14 days after Dose 2 | 5120.2 (3529.2 to 7428.5) | 7480.5 (4670.8 to 11980.2) | 13940.1 (9746.7 to 19937.5) | 0.9 (0.5 to 1.9) | — | — | 4757.7 (2926.8 to 7733.9) | 7366.9 (4774.3 to 11367.4) | 7639.4 (6308.6 to 9251.1) | 0.6 (0.6 to 0.6) | 1436.6 (760.1 to 2715.0) | 6399.4 (3481.6 to 11762.3) | 4798.4 (2209.3 to 10421.9) | 0.9 (0.5 to 1.7) | 3560.2 (2282.4 to 5553.5) | 2522.7 (1182.4 to 5382.1) | 5844.0 (3620.4 to 9433.3) | 0.8 (0.6 to 1.1) |
| S1-binding IgG level assay:1Month after Dose 2 | 2530.8 (1684.3 to 3802.5) | 5329.2 (3789.4 to 7494.7) | 8095.2 (5563.4 to 11779.1) | 0.9 (0.5 to 1.7) | — | — | 3098.6 (2088.1 to 4598.0) | 5784.7 (4131.4 to 8099.8) | 5296.0 (4139.6 to 6775.4) | 0.8 (0.5 to 1.2) | 1089.8 (556.7 to 2133.4) | 5138.2 (2788.0 to 9469.5) | 4151.0 (1872.9 to 9200.2) | 1.2 (0.6 to 2.6) | 2350.5 (1787.1 to 3091.7) | 1491.5 (682.0 to 3262.0) | 4592.4 (2874.1 to 7337.9) | 0.8 (0.5 to 1.3) |
| S1-binding IgG level assay:6Months after Dose 2 | — | — | — | — | — | — | — | — | 960.8 (483.8 to 1908.1) | — | — | — | — | — | — | — | 559.6 (363.0 to 862.8) | — |
| RBD-binding IgG level assay:7 days after Dose1 | 0.9 (0.5 to 1.6) | — | 0.8 (0.5 to 1.5) | 0.9 (0.4 to 2.1) | 1.2 (0.6 to 2.6) | 0.8 (0.2 to 3.2) | — | — | — | — | — | — | — | — | — | — | — | — |
| RBD-binding IgG level assay:21 days after Dose1 | 534.4 (244.1 to 1169.6) | 362.5 (89.5 to 1468.4) | 1535.9 (938.1 to 2514.6) | 0.8 (0.5 to 1.6) | 1778.3 (1218.9 to 2594.7) | 0.9 (0.5 to 1.0) | 338.9 (172.6 to 665.4) | 347.2 (223.0 to 540.4) | 862.3 (581.2 to 1279.5) | 0.9 (0.5 to 1.6) | 61.2 (17.1 to 218.9) | 234.4 (102.9 to 533.9) | 99.2 (30.3 to 324.3) | 1.2 (0.4 to 3.6) | 83.6 (26.6 to 262.6) | 50.9 (16.7 to 155.2) | 198.6 (67.6 to 583.5) | 1.0 (0.5 to 2.1) |
| RBD-binding IgG level assay:7 days after Dose 2 | 4813.1 (2479.5 to 9343.1) | 4033.8 (832.8 to 19538.0) | 27871.8 (19430.0 to 39981.4) | 0.9 (0.5 to 1.5) | — | — | 4926.8 (3239.2 to 7493.7) | 12258.1 (8875.8 to 16929.4) | 7759.7 (5537.3 to 10874.0) | 0.9 (0.5 to 1.6) | 1283.5 (535.2 to 3078.4) | 12932.8 (7091.0 to 23587.3) | 7527.5 (3564.2 to 15897.7) | 1.4 (0.4 to 5.0) | 2521.8 (1642.3 to 3872.3) | 2567.2 (979.5 to 6728.1) | 5877.3 (3426.5 to 10080.9) | 1.1 (0.5 to 2.6) |
| RBD-binding IgG level assay:14 days after Dose 2 | 5880.4 (4249.8 to 8136.8) | 6376.7 (4314.0 to 9425.7) | 16165.9 (11013.3 to 23729.2) | 0.7 (0.5 to 1.0) | — | — | 3984.8 (2278.2 to 6969.9) | 6383.2 (4422.7 to 9212.7) | 6825.6 (5103.5 to 9129.0) | 0.9 (0.5 to 1.7) | 1771.9 (947.6 to 3313.3) | 6983.1 (3878.5 to 12573.1) | 6006.5 (2821.3 to 12787.6) | 1.4 (0.4 to 4.2) | 2941.7 (1915.7 to 4517.2) | 1734.0 (775.0 to 3879.8) | 5642.0 (3344.2 to 9518.5) | 1.0 (0.5 to 2.2) |
| RBD-binding IgG level assay:1Month after Dose 2 | 3674.2 (2595.4 to 5201.4) | 6215.2 (4312.8 to 8956.8) | 9489.6 (6258.7 to 14388.4) | 0.7 (0.4 to 1.3) | — | — | 2612.6 (1711.1 to 3989.0) | 4183.7 (3011.7 to 5811.6) | 5059.8 (3974.2 to 6442.0) | 1.0 (0.5 to 2.3) | 1495.4 (825.3 to 2709.5) | 5641.9 (3114.1 to 10221.3) | 4488.5 (2131.3 to 9452.6) | 1.2 (0.4 to 4.0) | 2214.5 (1631.6 to 3005.7) | 1272.1 (540.7 to 2993.2) | 3468.6 (1998.4 to 6020.4) | 0.9 (0.4 to 1.9) |
GMFR of SARS-CoV-2 neutralizing titers were reported in this outcome measure. HIV positive participants excluded.
| Fold rise | BNT162b1 10 mcg Dose: 18-55 Years of Age | BNT162b1 20 mcg Dose: 18-55 Years of Age | BNT162b1 30 mcg Dose: 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b1 | BNT162b1 100 mcg Dose, 18-55 Years of Age | Placebo 18-55 Years of Age for BNT162b1 100 mcg | BNT162b2 10 mcg Dose, 18-55 Years of Age | BNT162b2 20 mcg Dose, 18-55 Years of Age | BNT162b2 30 mcg Dose, 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b2 | BNT162b1 10 mcg Dose, 65-85 Years of Age | BNT162b1 20 mcg Dose, 65-85 Years of Age | BNT162b1 30 mcg Dose, 65-85 Years of Age | Placebo, 65-85 Years of Age for BNT162b1 | BNT162b2 10 mcg Dose, 65-85 Years of Age | BNT162b2 20 mcg Dose, 65-85 Years of Age | BNT162b2 30 mcg Dose, 65-85 Years of Age | Placebo: 65-85 Years of Age for BNT162b2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NT50 titer: 7 days after dose 1 | 1.0 (1.0 to 1.0) | — | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | — | — | — | — | — | — | — | — | — | — | — | — |
| NT50 (titer): 21 days after dose 1 | 1.3 (1.0 to 1.7) | 1.3 (0.9 to 1.8) | 2.9 (1.7 to 4.8) | 1.0 (1.0 to 1.0) | 3.3 (1.7 to 6.2) | 1.0 (1.0 to 1.0) | 1.7 (1.0 to 2.8) | 1.9 (1.1 to 3.2) | 1.4 (1.0 to 2.0) | 1.0 (1.0 to 1.0) | 1.1 (0.9 to 1.4) | 1.0 (1.0 to 1.0) | 1.2 (0.9 to 1.7) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 1.2 (0.9 to 1.6) | 1.0 (1.0 to 1.0) |
| NT50 (titer): 7 days after dose 2 | 16.8 (11.1 to 25.3) | 16.0 (8.0 to 32.1) | 26.7 (17.3 to 41.3) | 1.0 (1.0 to 1.0) | — | — | 16.9 (10.3 to 27.8) | 36.3 (25.7 to 51.2) | 36.1 (23.7 to 54.9) | 1.0 (1.0 to 1.0) | 2.0 (1.2 to 3.4) | 17.9 (9.5 to 33.8) | 10.1 (4.6 to 22.2) | 1.0 (1.0 to 1.0) | 7.9 (5.1 to 12.4) | 7.9 (4.1 to 15.3) | 15.6 (8.0 to 30.2) | 1.0 (1.0 to 1.0) |
| NT50 (titer): 14 days after dose 2 | 18.0 (10.7 to 30.3) | 20.3 (12.3 to 33.3) | 43.7 (30.3 to 63.1) | 1.0 (1.0 to 1.0) | — | — | 10.9 (5.5 to 21.7) | 29.2 (17.9 to 47.6) | 16.2 (10.9 to 23.9) | 1.0 (1.0 to 1.0) | 2.8 (1.4 to 5.9) | 10.5 (4.4 to 25.0) | 10.5 (5.0 to 22.3) | 1.0 (1.0 to 1.0) | 11.1 (8.1 to 15.2) | 7.4 (3.3 to 16.6) | 21.4 (10.6 to 43.3) | 1.0 (1.0 to 1.0) |
| NT50 (titer): 1 month after dose 2 | 6.8 (4.2 to 11.2) | 16.1 (10.3 to 25.3) | 18.1 (10.8 to 30.1) | 1.0 (1.0 to 1.0) | — | — | 10.5 (6.5 to 17.1) | 25.2 (14.3 to 44.1) | 14.4 (10.4 to 19.9) | 1.0 (1.0 to 1.0) | 2.3 (1.1 to 4.5) | 12.5 (7.5 to 21.0) | 14.5 (7.0 to 29.8) | 1.0 (1.0 to 1.0) | 7.0 (4.3 to 11.3) | 5.0 (2.3 to 10.7) | 15.2 (8.1 to 28.6) | 1.0 (1.0 to 1.0) |
| NT50 (titer): 6 months after dose 2 | — | — | — | — | — | — | — | — | 5.5 (2.5 to 12.1) | — | — | — | — | — | — | — | 2.9 (1.9 to 4.3) | — |
| NT90 (titer): 7 days after dose 1 | 1.0 (1.0 to 1.0) | — | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | — | — | — | — | — | — | — | — | — | — | — | — |
| NT90 (titer): 21 days after dose 1 | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 1.2 (0.9 to 1.6) | 1.0 (1.0 to 1.0) | 1.5 (0.9 to 2.4) | 1.0 (1.0 to 1.0) | 1.1 (0.9 to 1.3) | 1.1 (0.9 to 1.2) | 1.1 (0.9 to 1.3) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) |
| NT90 (titer): 7 days after dose 2 | 5.7 (3.5 to 9.1) | 6.7 (4.0 to 11.1) | 12.2 (7.9 to 18.8) | 1.0 (1.0 to 1.0) | — | — | 7.0 (4.3 to 11.5) | 14.2 (10.3 to 19.6) | 12.3 (7.9 to 19.0) | 1.0 (1.0 to 1.0) | 1.2 (0.9 to 1.6) | 7.4 (3.5 to 15.7) | 4.8 (2.2 to 10.2) | 1.0 (1.0 to 1.0) | 4.0 (2.7 to 6.0) | 3.3 (1.8 to 6.1) | 5.3 (2.6 to 10.9) | 1.0 (1.0 to 1.0) |
| NT90 (titer): 14 days after dose 2 | 7.6 (4.4 to 13.2) | 11.0 (7.1 to 17.1) | 18.8 (12.6 to 28.0) | 1.0 (1.0 to 1.0) | — | — | 4.7 (2.5 to 8.7) | 11.3 (7.4 to 17.2) | 5.4 (3.8 to 7.9) | 1.0 (1.0 to 1.0) | 1.6 (1.0 to 2.8) | 4.9 (2.5 to 9.6) | 5.0 (2.5 to 10.0) | 1.0 (1.0 to 1.0) | 5.6 (3.5 to 8.9) | 2.9 (1.6 to 5.3) | 6.0 (2.5 to 14.4) | 1.0 (1.0 to 1.0) |
| NT90 (titer): 1 month after dose 2 | 3.7 (2.5 to 5.5) | 4.0 (2.5 to 6.4) | 6.2 (3.5 to 10.8) | 1.0 (1.0 to 1.0) | — | — | 3.4 (1.8 to 6.5) | 6.0 (3.3 to 10.8) | 5.5 (4.1 to 7.3) | 1.0 (1.0 to 1.0) | 1.4 (0.9 to 2.2) | 4.8 (2.6 to 9.0) | 6.0 (3.0 to 11.8) | 1.0 (1.0 to 1.0) | 2.0 (1.2 to 3.4) | 2.5 (1.3 to 4.7) | 5.1 (2.8 to 9.2) | 1.0 (1.0 to 1.0) |
GMFR of SARS-CoV-2 S1-binding and RBD-binding IgG level assay in Phase 1 were reported in this outcome measure. HIV positive participants were excluded from this analysis.
| Fold rise | BNT162b1 10 mcg Dose: 18-55 Years of Age | BNT162b1 20 mcg Dose: 18-55 Years of Age | BNT162b1 30 mcg Dose: 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b1 | BNT162b1 100 mcg Dose, 18-55 Years of Age | Placebo 18-55 Years of Age for BNT162b1 100 mcg | BNT162b2 10 mcg Dose, 18-55 Years of Age | BNT162b2 20 mcg Dose, 18-55 Years of Age | BNT162b2 30 mcg Dose, 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b2 | BNT162b1 10 mcg Dose, 65-85 Years of Age | BNT162b1 20 mcg Dose, 65-85 Years of Age | BNT162b1 30 mcg Dose, 65-85 Years of Age | Placebo, 65-85 Years of Age for BNT162b1 | BNT162b2 10 mcg Dose, 65-85 Years of Age | BNT162b2 20 mcg Dose, 65-85 Years of Age | BNT162b2 30 mcg Dose, 65-85 Years of Age | Placebo: 65-85 Years of Age for BNT162b2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S1-binding IgG level assay:7days after dose1 | 1.0 (1.0 to 1.0) | — | 1.1 (0.8 to 1.3) | 0.8 (0.5 to 1.4) | 1.1 (0.9 to 1.5) | 1.0 (1.0 to 1.0) | — | — | — | — | — | — | — | — | — | — | — | — |
| S1-binding IgG level assay:21days after dose1 | 387.6 (182.9 to 821.1) | 271.3 (77.3 to 951.6) | 1027.5 (543.5 to 1942.4) | 0.9 (0.7 to 1.1) | 1378.3 (718.0 to 2645.9) | 1.0 (1.0 to 1.0) | 965.9 (524.4 to 1779.4) | 636.8 (296.9 to 1365.6) | 1997.4 (1441.1 to 2768.4) | 1.0 (1.0 to 1.0) | 34.4 (7.3 to 161.9) | 162.6 (81.8 to 323.1) | 124.8 (41.4 to 376.3) | 1.0 (1.0 to 1.1) | 223.5 (112.1 to 445.8) | 98.2 (36.4 to 265.2) | 447.2 (182.6 to 1094.7) | 1.0 (1.0 to 1.1) |
| S1-binding IgG level assay:7days after dose2 | 5095.8 (2819.1 to 9211.0) | 4311.2 (899.3 to 20668.6) | 28336.5 (17881.6 to 44904.3) | 1.3 (0.9 to 1.8) | — | — | 9497.1 (6413.9 to 14062.2) | 14516.5 (9188.0 to 22935.3) | 14427.7 (10082.9 to 20644.7) | 1.0 (1.0 to 1.0) | 868.3 (276.9 to 2722.5) | 13807.8 (7573.0 to 25175.6) | 9516.4 (4262.5 to 21246.3) | 1.2 (0.9 to 1.6) | 4162.5 (2679.8 to 6465.4) | 3240.5 (1349.3 to 7782.7) | 11919.3 (6670.3 to 21299.0) | 1.2 (0.9 to 1.6) |
| S1-binding IgG level assay:14days after dose2 | 6745.2 (4430.5 to 10269.0) | 9944.3 (5315.2 to 18604.8) | 16797.3 (10604.5 to 26606.6) | 1.0 (0.9 to 1.0) | — | — | 7513.2 (4621.9 to 12213.0) | 8580.1 (5164.3 to 14255.0) | 12063.8 (9962.2 to 14608.8) | 1.0 (1.0 to 1.0) | 1449.3 (521.4 to 4028.2) | 8318.2 (4793.1 to 14435.8) | 6940.3 (3323.6 to 14492.3) | 0.8 (0.6 to 1.1) | 4545.1 (2529.5 to 8166.6) | 2989.8 (1255.2 to 7121.5) | 9228.6 (5717.2 to 14896.6) | 1.0 (0.9 to 1.1) |
| S1-binding IgG level assay:1month after dose2 | 3333.9 (2382.9 to 4664.5) | 7084.4 (4443.5 to 11295.0) | 9754.4 (5820.9 to 16346.0) | 0.9 (0.8 to 1.0) | — | — | 4893.1 (3297.4 to 7261.0) | 6553.4 (3787.8 to 11338.5) | 8363.2 (6537.1 to 10699.5) | 1.2 (0.8 to 1.9) | 1099.4 (364.6 to 3314.9) | 6678.8 (3844.9 to 11601.5) | 6003.8 (2793.3 to 12904.6) | 1.1 (0.9 to 1.4) | 3054.4 (2015.9 to 4627.9) | 1767.7 (700.5 to 4460.6) | 7252.1 (4538.7 to 11587.7) | 1.0 (0.6 to 1.7) |
| S1-binding IgG level assay:6months after dose2 | — | — | — | — | — | — | — | — | 1517.2 (764.0 to 3013.2) | — | — | — | — | — | — | — | 883.7 (573.2 to 1362.5) | — |
| RBD-binding IgG level assay:7days after dose1 | 1.1 (0.8 to 1.4) | — | 1.0 (0.9 to 1.0) | 1.0 (0.6 to 1.7) | 1.3 (1.0 to 1.8) | 1.4 (0.3 to 5.6) | — | — | — | — | — | — | — | — | — | — | — | — |
| RBD-binding IgG level assay:21days after dose1 | 640.7 (321.9 to 1275.0) | 292.9 (71.9 to 1193.1) | 1763.1 (930.9 to 3339.4) | 1.1 (0.8 to 1.6) | 1966.5 (1039.6 to 3719.6) | 1.5 (0.3 to 8.7) | 516.9 (230.3 to 1160.4) | 557.1 (347.7 to 892.7) | 821.1 (456.9 to 1475.9) | 1.2 (0.7 to 1.8) | 44.4 (9.3 to 212.1) | 407.4 (178.8 to 928.2) | 159.6 (49.1 to 518.9) | 1.0 (0.9 to 1.0) | 89.6 (30.5 to 263.0) | 62.9 (17.4 to 227.0) | 316.3 (116.5 to 858.6) | 1.2 (0.7 to 2.2) |
| RBD-binding IgG level assay:7days after dose2 | 5770.9 (2945.0 to 11308.3) | 3258.8 (646.1 to 16436.3) | 31996.2 (16410.0 to 62386.2) | 1.1 (0.7 to 1.8) | — | — | 7514.3 (4609.8 to 12249.0) | 19671.3 (12848.3 to 30117.6) | 8442.8 (4885.5 to 14590.4) | 1.1 (0.6 to 2.1) | 931.4 (217.9 to 3982.1) | 22482.1 (12326.8 to 41003.5) | 12115.3 (5507.4 to 26651.4) | 1.1 (0.9 to 1.4) | 2703.3 (1629.0 to 4486.1) | 3070.3 (905.7 to 10408.5) | 9357.1 (6075.0 to 14412.3) | 1.4 (0.7 to 2.8) |
| RBD-binding IgG level assay:14days after dose2 | 7050.6 (4405.1 to 11284.8) | 5151.7 (2469.6 to 10747.0) | 18558.1 (9354.8 to 36815.6) | 0.9 (0.7 to 1.2) | — | — | 6077.6 (3328.1 to 11098.6) | 10243.4 (6509.5 to 16119.2) | 8213.0 (5507.4 to 12247.7) | 1.2 (0.8 to 1.7) | 1285.8 (329.7 to 5015.2) | 12139.3 (6742.2 to 21856.7) | 9667.2 (4456.0 to 20972.9) | 1.1 (0.8 to 1.5) | 3017.9 (1697.6 to 5364.9) | 2073.9 (698.9 to 6153.9) | 8982.5 (5966.6 to 13522.8) | 1.2 (0.6 to 2.6) |
| RBD-binding IgG level assay:1month after dose2 | 4405.3 (2727.7 to 7114.7) | 5021.3 (2410.1 to 10461.6) | 10893.9 (5125.4 to 23154.7) | 1.0 (0.8 to 1.1) | — | — | 3984.7 (2412.4 to 6581.7) | 6665.1 (4292.1 to 10350.2) | 5505.3 (3394.8 to 8927.8) | 1.3 (0.7 to 2.3) | 1085.2 (274.9 to 4283.7) | 9807.7 (5413.5 to 17768.4) | 7224.1 (3355.8 to 15551.5) | 1.0 (0.9 to 1.1) | 2373.9 (1454.3 to 3875.1) | 1521.5 (511.7 to 4523.9) | 5522.3 (3610.4 to 8446.6) | 1.3 (0.6 to 2.8) |
Percentage of participants achieving a \>= 4-fold rise from before vaccination to after vaccination: neutralizing titers in Phase 1 were reported in this outcome measure. HIV positive participants were excluded from this analysis.
| Percentage of participants | BNT162b1 10 mcg Dose: 18-55 Years of Age | BNT162b1 20 mcg Dose: 18-55 Years of Age | BNT162b1 30 mcg Dose: 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b1 | BNT162b1 100 mcg Dose, 18-55 Years of Age | Placebo 18-55 Years of Age for BNT162b1 100 mcg | BNT162b2 10 mcg Dose, 18-55 Years of Age | BNT162b2 20 mcg Dose, 18-55 Years of Age | BNT162b2 30 mcg Dose, 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b2 | BNT162b1 10 mcg Dose, 65-85 Years of Age | BNT162b1 20 mcg Dose, 65-85 Years of Age | BNT162b1 30 mcg Dose, 65-85 Years of Age | Placebo, 65-85 Years of Age for BNT162b1 | BNT162b2 10 mcg Dose, 65-85 Years of Age | BNT162b2 20 mcg Dose, 65-85 Years of Age | BNT162b2 30 mcg Dose, 65-85 Years of Age | Placebo: 65-85 Years of Age for BNT162b2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NT50 titer: 7 days after dose 1 | 0.0 (0.0 to 26.5) | — | 0.0 (0.0 to 26.5) | 0.0 (0.0 to 45.9) | 0.0 (0.0 to 26.5) | 0.0 (0.0 to 70.8) | — | — | — | — | — | — | — | — | — | — | — | — |
| NT50 (titer): 21 days after dose 1 | 0.0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 25.0 (5.5 to 57.2) | 0.0 (0.0 to 33.6) | 50.0 (21.1 to 78.9) | 0.0 (0.0 to 70.8) | 18.2 (2.3 to 51.8) | 25.0 (5.5 to 57.2) | 0.0 (0.0 to 26.5) | 0.0 (0.0 to 41.0) | 0.0 (0.0 to 28.5) | 0.0 (0.0 to 26.5) | 8.3 (0.2 to 38.5) | 0.0 (0.0 to 33.6) | 0.0 (0.0 to 26.5) | 0.0 (0.0 to 26.5) | 0.0 (0.0 to 28.5) | 0.0 (0.0 to 33.6) |
| NT50 (titer): 7 days after dose 2 | 91.7 (61.5 to 99.8) | 91.7 (61.5 to 99.8) | 100.0 (73.5 to 100.0) | 0.0 (0.0 to 33.6) | — | — | 100.0 (71.5 to 100.0) | 100.0 (73.5 to 100.0) | 100.0 (71.5 to 100.0) | 0.0 (0.0 to 41.0) | 9.1 (0.2 to 41.3) | 91.7 (61.5 to 99.8) | 75.0 (42.8 to 94.5) | 0.0 (0.0 to 33.6) | 83.3 (51.6 to 97.9) | 81.8 (48.2 to 97.7) | 90.9 (58.7 to 99.8) | 0.0 (0.0 to 33.6) |
| NT50 (titer): 14days after dose 2 | 91.7 (61.5 to 99.8) | 100.0 (73.5 to 100.0) | 100.0 (73.5 to 100.0) | 0.0 (0.0 to 33.6) | — | — | 90.9 (58.7 to 99.8) | 100.0 (73.5 to 100.0) | 100.0 (66.4 to 100.0) | 0.0 (0.0 to 41.0) | 36.4 (10.9 to 69.2) | 75.0 (42.8 to 94.5) | 83.3 (51.6 to 97.9) | 0.0 (0.0 to 33.6) | 100.0 (71.5 to 100.0) | 72.7 (39.0 to 94.0) | 100.0 (71.5 to 100.0) | 0.0 (0.0 to 33.6) |
| NT50 (titer): 1 month after dose 2 | 83.3 (51.6 to 97.9) | 100.0 (73.5 to 100.0) | 91.7 (61.5 to 99.8) | 0.0 (0.0 to 33.6) | — | — | 100.0 (71.5 to 100.0) | 100.0 (71.5 to 100.0) | 100.0 (71.5 to 100.0) | 0.0 (0.0 to 41.0) | 18.2 (2.3 to 51.8) | 91.7 (61.5 to 99.8) | 81.3 (51.6 to 97.9) | 0.0 (0.0 to 33.6) | 75.0 (42.8 to 94.5) | 54.5 (23.4 to 83.3) | 100.0 (71.5 to 100.0) | 0.0 (0.0 to 36.9) |
| NT50 (titer): 6 months after dose 2 | — | — | — | — | — | — | — | — | 60.0 (26.2 to 87.8) | — | — | — | — | — | — | — | 27.3 (6.0 to 61.0) | — |
| NT90 (titer): 7 days after dose 1 | 0.0 (0.0 to 26.5) | — | 0.0 (0.0 to 26.5) | 0.0 (0.0 to 45.9) | 0.0 (0.0 to 26.5) | 0.0 (0.0 to 70.8) | — | — | — | — | — | — | — | — | — | — | — | — |
| NT90 (titer): 21 days after dose 1 | 0.0 (0.0 to 26.5) | 0.0 (0.0 to 26.5) | 0.0 (0.0 to 26.5) | 0.0 (0.0 to 33.6) | 16.7 (2.1 to 48.4) | 0.0 (0.0 to 70.8) | 0.0 (0.0 to 28.5) | 0.0 (0.0 to 26.5) | 0.0 (0.0 to 26.5) | 0.0 (0.0 to 41.0) | 0.0 (0.0 to 28.5) | 0.0 (0.0 to 26.5) | 0.0 (0.0 to 26.5) | 0.0 (0.0 to 33.6) | 0.0 (0.0 to 26.5) | 0.0 (0.0 to 26.5) | 0.0 (0.0 to 28.5) | 0.0 (0.0 to 33.6) |
| NT90 (titer): 7 days after dose 2 | 83.3 (51.6 to 97.9) | 81.8 (48.2 to 97.7) | 91.7 (61.5 to 99.8) | 0.0 (0.0 to 33.6) | — | — | 81.8 (48.2 to 97.7) | 100.0 (73.5 to 100.0) | 100.0 (71.5 to 100.0) | 0.0 (0.0 to 41.0) | 0.0 (0.0 to 28.5) | 66.7 (34.9 to 90.1) | 58.3 (27.7 to 84.8) | 0.0 (0.0 to 33.6) | 41.7 (15.2 to 72.3) | 45.5 (16.7 to 76.6) | 63.6 (30.8 to 89.1) | 0.0 (0.0 to 33.6) |
| NT90 (titer): 14 days after dose 2 | 83.3 (51.6 to 97.9) | 91.7 (61.5 to 99.8) | 100.0 (73.5 to 100.0) | 0.0 (0.0 to 33.6) | — | — | 45.5 (16.7 to 76.6) | 91.7 (61.5 to 99.8) | 66.7 (29.9 to 92.5) | 0.0 (0.0 to 41.0) | 18.2 (2.3 to 51.8) | 58.3 (27.7 to 84.8) | 63.6 (30.8 to 89.1) | 0.0 (0.0 to 33.6) | 81.8 (48.2 to 97.7) | 27.3 (6.0 to 61.0) | 60.0 (26.2 to 87.8) | 0.0 (0.0 to 33.6) |
| NT90 (titer): 1 month after dose 2 | 41.7 (15.2 to 72.3) | 54.5 (23.4 to 83.3) | 63.6 (30.8 to 89.1) | 0.0 (0.0 to 33.6) | — | — | 45.5 (16.7 to 76.6) | 81.8 (48.2 to 97.7) | 72.7 (39.0 to 94.0) | 0.0 (0.0 to 41.0) | 9.1 (0.2 to 41.3) | 66.7 (34.9 to 90.1) | 66.7 (34.9 to 90.1) | 0.0 (0.0 to 33.6) | 16.7 (2.1 to 48.4) | 27.3 (6.0 to 61.0) | 63.6 (30.8 to 89.1) | 0.0 (0.0 to 36.9) |
Percentage of participants achieving a \>= 4-fold rise from before vaccination to after vaccination: S1-binding and RBD-binding IgG level assay in Phase 1 were reported in this outcome measure. HIV positive participants were excluded from this analysis.
| Percentage of participants | BNT162b1 10 mcg Dose: 18-55 Years of Age | BNT162b1 20 mcg Dose: 18-55 Years of Age | BNT162b1 30 mcg Dose: 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b1 | BNT162b1 100 mcg Dose, 18-55 Years of Age | Placebo 18-55 Years of Age for BNT162b1 100 mcg | BNT162b2 10 mcg Dose, 18-55 Years of Age | BNT162b2 20 mcg Dose, 18-55 Years of Age | BNT162b2 30 mcg Dose, 18-55 Years of Age | Placebo: 18-55 Years of Age for BNT162b2 | BNT162b1 10 mcg Dose, 65-85 Years of Age | BNT162b1 20 mcg Dose, 65-85 Years of Age | BNT162b1 30 mcg Dose, 65-85 Years of Age | Placebo, 65-85 Years of Age for BNT162b1 | BNT162b2 10 mcg Dose, 65-85 Years of Age | BNT162b2 20 mcg Dose, 65-85 Years of Age | BNT162b2 30 mcg Dose, 65-85 Years of Age | Placebo: 65-85 Years of Age for BNT162b2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S1-binding IgG level assay:7days after dose1 | 0.0 (0.0 to 26.5) | — | 0.0 (0.0 to 26.5) | 0.0 (0.0 to 45.9) | 8.3 (0.2 to 38.5) | 0.0 (0.0 to 70.8) | — | — | — | — | — | — | — | — | — | — | — | — |
| S1-binding IgG level assay:21days after dose1 | 100.0 (73.5 to 100.0) | 91.7 (61.5 to 99.8) | 100.0 (73.5 to 100.0) | 0.0 (0.0 to 33.6) | 100.0 (73.5 to 100.0) | 0.0 (0.0 to 70.8) | 100.0 (71.5 to 100.0) | 100.0 (73.5 to 100.0) | 100.0 (73.5 to 100.0) | 0.0 (0.0 to 41.0) | 72.7 (39.0 to 94.0) | 100.0 (73.5 to 100.0) | 91.7 (61.5 to 99.8) | 0.0 (0.0 to 33.6) | 100.0 (73.5 to 100.0) | 91.7 (61.5 to 99.8) | 100.0 (71.5 to 100.0) | 0.0 (0.0 to 33.6) |
| S1-binding IgG level assay:7days after dose2 | 100.0 (73.5 to 100.0) | 91.7 (61.5 to 99.8) | 100.0 (73.5 to 100.0) | 0.0 (0.0 to 33.6) | — | — | 100.0 (71.5 to 100.0) | 100.0 (73.5 to 100.0) | 100.0 (71.5 to 100.0) | 0.0 (0.0 to 41.0) | 100.0 (71.5 to 100.0) | 100.0 (73.5 to 100.0) | 100.0 (73.5 to 100.0) | 0.0 (0.0 to 33.6) | 100.0 (73.5 to 100.0) | 100.0 (71.5 to 100.0) | 100.0 (71.5 to 100.0) | 0.0 (0.0 to 33.6) |
| S1-binding IgG level assay:14days after dose2 | 100.0 (73.5 to 100.0) | 100.0 (73.5 to 100.0) | 100.0 (73.5 to 100.0) | 0.0 (0.0 to 33.6) | — | — | 100.0 (71.5 to 100.0) | 100.0 (73.5 to 100.0) | 100.0 (66.4 to 100.0) | 0.0 (0.0 to 41.0) | 100.0 (71.5 to 100.0) | 100.0 (73.5 to 100.0) | 100.0 (73.5 to 100.0) | 0.0 (0.0 to 33.6) | 100.0 (71.5 to 100.0) | 100.0 (71.5 to 100.0) | 100.0 (71.5 to 100.0) | 0.0 (0.0 to 33.6) |
| S1-binding IgG level assay:1month after dose2 | 100.0 (73.5 to 100.0) | 100.0 (73.5 to 100.0) | 100.0 (73.5 to 100.0) | 0.0 (0.0 to 33.6) | — | — | 100.0 (71.5 to 100.0) | 100.0 (71.5 to 100.0) | 100.0 (71.5 to 100.0) | 0.0 (0.0 to 41.0) | 100.0 (71.5 to 100.0) | 100.0 (73.5 to 100.0) | 100.0 (73.5 to 100.0) | 0.0 (0.0 to 33.6) | 100.0 (73.5 to 100.0) | 100.0 (71.5 to 100.0) | 100.0 (71.5 to 100.0) | 0.0 (0.0 to 36.9) |
| S1-binding IgG level assay:6months after dose2 | — | — | — | — | — | — | — | — | 100.0 (69.2 to 100.0) | — | — | — | — | — | — | — | 100.0 (71.5 to 100.0) | — |
| RBD-binding IgG level assay:7days after dose1 | 0.0 (0.0 to 26.5) | — | 0.0 (0.0 to 26.5) | 0.0 (0.0 to 45.9) | 8.3 (0.2 to 38.5) | 0.0 (0.0 to 70.8) | — | — | — | — | — | — | — | — | — | — | — | — |
| RBD-binding IgG level assay:21days after dose1 | 100.0 (73.5 to 100.0) | 91.7 (61.5 to 99.8) | 100.0 (73.5 to 100.0) | 0.0 (0.0 to 33.6) | 100.0 (73.5 to 100.0) | 0.0 (0.0 to 70.8) | 100.0 (71.5 to 100.0) | 100.0 (73.5 to 100.0) | 100.0 (73.5 to 100.0) | 0.0 (0.0 to 41.0) | 72.7 (39.0 to 94.0) | 100.0 (73.5 to 100.0) | 100.0 (73.5 to 100.0) | 0.0 (0.0 to 33.6) | 91.7 (61.5 to 99.8) | 83.3 (51.6 to 97.9) | 100.0 (71.5 to 100.0) | 11.1 (0.3 to 48.2) |
| RBD-binding IgG level assay:7days after dose2 | 100.0 (73.5 to 100.0) | 91.7 (61.5 to 99.8) | 100.0 (73.5 to 100.0) | 0.0 (0.0 to 33.6) | — | — | 100.0 (71.5 to 100.0) | 100.0 (73.5 to 100.0) | 100.0 (71.5 to 100.0) | 0.0 (0.0 to 41.0) | 100.0 (71.5 to 100.0) | 100.0 (73.5 to 100.0) | 100.0 (73.5 to 100.0) | 0.0 (0.0 to 33.6) | 100.0 (73.5 to 100.0) | 100.0 (71.5 to 100.0) | 100.0 (71.5 to 100.0) | 11.1 (0.3 to 48.2) |
| RBD-binding IgG level assay:14days after dose2 | 100.0 (73.5 to 100.0) | 100.0 (73.5 to 100.0) | 100.0 (73.5 to 100.0) | 0.0 (0.0 to 33.6) | — | — | 100.0 (71.5 to 100.0) | 100.0 (73.5 to 100.0) | 100.0 (66.4 to 100.0) | 0.0 (0.0 to 41.0) | 100.0 (71.5 to 100.0) | 100.0 (73.5 to 100.0) | 100.0 (73.5 to 100.0) | 0.0 (0.0 to 33.6) | 100.0 (71.5 to 100.0) | 100.0 (71.5 to 100.0) | 100.0 (71.5 to 100.0) | 11.1 (0.3 to 48.2) |
| RBD-binding IgG level assay:1month after dose2 | 100.0 (73.5 to 100.0) | 100.0 (73.5 to 100.0) | 100.0 (73.5 to 100.0) | 0.0 (0.0 to 33.6) | — | — | 100.0 (71.5 to 100.0) | 100.0 (71.5 to 100.0) | 100.0 (71.5 to 100.0) | 0.0 (0.0 to 41.0) | 100.0 (71.5 to 100.0) | 100.0 (73.5 to 100.0) | 100.0 (73.5 to 100.0) | 0.0 (0.0 to 33.6) | 100.0 (73.5 to 100.0) | 100.0 (71.5 to 100.0) | 100.0 (71.5 to 100.0) | 12.5 (0.3 to 52.7) |
GMR based on reference strain NT, comparison of participants 12 to 15 years of age to participants 16 to 25 years of age of participants without evidence of infection up to 1 month after dose 2 in Phase2/3 were reported in this outcome measure. HIV positive participants were excluded from this analysis.
| Titer | BNT162b2 (30 mcg): 12-15 Years of Age | BNT162b2 (30 mcg): 16-25 Years of Age |
|---|---|---|
| GMR Based on Reference Strain NT - Comparison of Participants 12 to 15 Years of Age to Participants 16 to 25 Years of Age- Participants Without Evidence of Infection up to 1 Month After Dose 2 - Dose 2 Evaluable Immunogenicity Population: Phase2/3 | 1239.5 (1095.5 to 1402.5) | 705.1 (621.4 to 800.2) |
Incidence of asymptomatic SARS-CoV-2 infection per 1000 person years follow-up without serological or virological evidence (up to start of asymptomatic surveillance period) of past infection were reported in this outcome measure.
| Events per 1000 person-years | BNT162b2 (30 mcg) | Placebo |
|---|---|---|
| Incidence of Asymptomatic SARS-CoV-2 Infection Per 1000 Person Years Follow-up Without Serological or Virological Evidence (Up to Start of Asymptomatic Surveillance Period) of Past Infection: Phase 3 | 62.663 | 100.000 |
Incidence of asymptomatic SARS-CoV-2 infection per 1000 person years follow-up without serological or virological evidence of past infection based on N-binding antibody seroconversion were reported in this outcome measure.
| Events per 1000 person-years | BNT162b2 (30 mcg) | Placebo |
|---|---|---|
| Incidence of Asymptomatic SARS-CoV-2 Infection Per 1000 Person Years Follow-up Without Serological or Virological Evidence of Past Infection Based on N-binding Antibody Seroconversion: Phase 3 | 44.220 | 93.813 |
COVID-19 incidence per 1000 person years follow-up with or without the evidence of infection were reported in this outcome measure.
| Events per 1000 person-years | BNT162b2 (30 mcg) | Placebo |
|---|---|---|
| COVID-19 Incidence Per 1000 Person-Years of Follow-up With or Without Evidence of Infection 7 Days After Second Dose of BNT162b2 Based on CDC-Defined Symptoms (Analysis for EUA): Phase 3 | 3.863 | 73.410 |
COVID-19 incidence per 1000 person years follow-up with or without the evidence of infection were reported in this outcome measure.
| Events per 1000 person-years | BNT162b2 (30 mcg) | Placebo |
|---|---|---|
| COVID-19 Incidence Per 1000 Person-Years of Follow-up With or Without Evidence of Infection 14 Days After Second Dose of BNT162b2 Based on CDC-Defined Symptoms (Analysis for EUA): Phase 3 | 4.034 | 73.256 |
COVID-19 incidence per 1000 person years follow-up without the evidence of infection (analysis for EUA) were reported in this outcome measure.
| Events per 1000 person-years | BNT162b2 (30 mcg) | Placebo |
|---|---|---|
| COVID-19 Incidence Per 1000 Person-Years of Follow-up Without Evidence of Infection: 7 Days After Dose 2 Based on CDC Defined Symptoms (Analysis for EUA): Phase 3 | 3.615 | 74.324 |
COVID-19 incidence per 1000 person years follow-up without the evidence of infection were reported in this outcome measure.
| Events per 1000 person-years | BNT162b2 (30 mcg) | Placebo |
|---|---|---|
| COVID-19 Incidence Per 1000 Person-Years of Follow-up Without Evidence of Infection: 14 Days After Dose 2 Based on CDC Defined Symptoms (Analysis for EUA): Phase 3 | 4.242 | 74.564 |
Severe COVID-19 incidence per 1000 person years follow-up with or without the evidence of infection were reported in this outcome measure.
| Events per 1000 person-years | BNT162b2 (30 mcg) | Placebo |
|---|---|---|
| Severe COVID-19 Incidence Per 1000 Person-Years of Follow-up With or Without Evidence of Infection: 7 Days After Dose 2: Phase 3 | 0.153 | 3.279 |
Severe COVID-19 incidence per 1000 person years follow-up with or without the evidence of infection (analysis for EUA) were reported in this outcome measure.
| Events per 1000 person-years | BNT162b2 (30 mcg) | Placebo |
|---|---|---|
| Severe COVID-19 Incidence Per 1000 Person-Years of Follow-up With or Without Evidence of Infection: 14 Days After Dose 2 (Analysis for EUA): Phase 3 | 0.504 | 1.495 |
Severe COVID-19 incidence per 1000 person years follow-up without the evidence of infection were reported in this outcome measure.
| Events per 1000 person-years | BNT162b2 (30 mcg) | Placebo |
|---|---|---|
| Severe COVID-19 Incidence Per 1000 Person-Years of Follow-up Without Evidence of Infection: 7 Days After Dose 2: Phase 3 | 0.160 | 3.431 |
Severe COVID-19 incidence per 1000 person years follow-up without the evidence of infection (analysis for EUA) were reported in this outcome measure.
| Events per 1000 person-years | BNT162b2 (30 mcg) | Placebo |
|---|---|---|
| Severe COVID-19 Incidence Per 1000 Person-Years of Follow-up Without Evidence of Infection: 14 Days After Dose 2 (Analysis for EUA): Phase 3 | 0.530 | 1.578 |
COVID-19 incidence per 1000 person years follow-up with or without the evidence of infection (analysis for EUA) were reported in this outcome measure.
| Events per 1000 person-years | BNT162b2 (30 mcg) | Placebo |
|---|---|---|
| COVID-19 Incidence Per 1000 Person-Years of With or Without Evidence of Infection: 14 Days After Dose 2 (EUA Analysis): Phase 3 | 4.032 | 72.180 |
COVID-19 incidence per 1000 person years follow-up without the evidence of infection (analysis for EUA) were reported in this outcome measure.
| Events per 1000 person-years | BNT162b2 (30 mcg) | Placebo |
|---|---|---|
| COVID-19 Incidence Per 1000 Person-Years of Follow-up Without Evidence of Infection: 14 Days After Dose 2 (EUA Analysis): Phase 3 | 4.240 | 73.428 |
Seroresponse was defined as achieving a \>=4-fold rise from baseline (before Dose 1). If the baseline measurement was below the lower limit of quantification (LLOQ), a post vaccination assay result \>=4 × LLOQ was considered a seroresponse. HIV positive participants were excluded from this analysis.
| Percentage of participants | BNT162b2SA (30 mcg) | BNT162b2 (30 mcg) |
|---|---|---|
| Percentage Difference of Participants Achieving Seroresponse (Reference Strain) 1 Month After Second Dose in BNT162b2-Naive Participants: Phase 3 | 84.8 (71.1 to 93.7) | 97.3 (94.6 to 98.9) |
GMR based on GMT (Reference Strain) 1 month after second dose of BNT162b2SA and 1 month after the second dose of BNT162b2 in BNT162b2-naive participant were reported in this outcome measure.
| Titer | BNT162b2SA (30 mcg) | BNT162b2 (30 mcg) |
|---|---|---|
| GMR Based on Geometric Mean Titer (Reference Strain) 1 Month After Second Dose in BNT162b2-Naive Participants: Phase 3 | 356.7 (260.9 to 487.6) | 820.3 (745.7 to 902.3) |
GMR based on geometric mean titer of SA NT 1 Month after second dose of BNT162b2SA to 1 Month after the second dose (N2a) of BNT162b2 naive participants of Phase 3 were reported in this outcome measure.
| Titer | BNT162b2SA (30 mcg) | BNT162b2 (30 mcg) |
|---|---|---|
| GMR Based on Geometric Mean Titer of SA NT 1 Month After Second Dose of BNT162b2SA to 1 Month After the Second Dose (N2a) of BNT162b2 Naive Participants: Phase 3 | 1358.0 (1242.0 to 1484.0) | 273.1 (245.6 to 303.7) |
Seroresponse was defined as achieving a \>=4-fold rise from baseline (before Dose 1). If the baseline measurement was below the LLOQ, a postvaccination assay result \>=4 × LLOQ was considered a seroresponse.
| Percentage of participants | BNT162b2SA (30 mcg) | BNT162b2 (30 mcg) |
|---|---|---|
| Percentage Difference of Participants Achieving Seroresponse (N2b) Comparison of 1 Month After Dose 2 Between Vaccine Groups: BNT162b2-Naïve Participants Without Evidence of Infection up to 1 Month After Dose 2: Phase 3 | 97.1 (94.3 to 98.7) | 57.6 (51.8 to 63.2) |
GMR of neutralizing titers (E3a) - comparison of 1 month after booster dose to 1 month after dose 2: BNT162b2-experienced participants of Phase 3 were reported in this outcome measure.
| Titer | BNT162b2 (30 mcg): 1 Month After Booster Dose | BNT162b2 (30 mcg): 1 Month After Dose 2 |
|---|---|---|
| GMR of Neutralizing Titers (E3a) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants That Received a Booster Dose of BNT162b2: Phase 3 | 2562.1 (2284.9 to 2872.8) | 745.7 (656.5 to 847.1) |
Percentage difference of participants achieving seroresponse (E3b) - comparison of 1 month after booster dose to 1 month after dose 2 BNT162b2-experienced participants without evidence of infection up to 1 month after booster dose who were rerandomized to receive 1 booster dose were reported in this outcome measure.
| Percentage of participants | BNT162b2 (30 mcg): 1 Month After Booster Dose | BNT162b2 (30 mcg): 1 Month After Dose 2 |
|---|---|---|
| Percentage Difference of Participants Achieving Seroresponse (E3b) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants That Received a Booster Dose of BNT162b2: Phase 3 | 100.0 (98.2 to 100.0) | 95.2 (91.3 to 97.7) |
GMR of neutralizing titers (E4a) - comparison of 1 month after booster dose to 1 month after dose 2: BNT162b2-experienced participants of Phase 3 were reported in this outcome measure.
| Titer | BNT162b2SA (30 mcg):1 Month After Booster Dose | BNT162b2SA 30 mcg: 1 Month After Dose 2 |
|---|---|---|
| GMR of Neutralizing Titers (E4a) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants: Phase 3 | 1676.0 (1496.2 to 1877.3) | 686.0 (612.0 to 769.0) |
Percentage difference of participants achieving seroresponse (E4b) - comparison of 1 month after booster dose to 1 month after dose 2 BNT162b2-experienced participants without evidence of infection up to 1 month after booster dose who were rerandomized to receive 1 booster dose were reported in this outcome measure.
| Percentage of participants | BNT162b2SA (30 mcg): 1 Month After Booster Dose | BNT162b2SA 30 mcg: 1 Month After Dose 2 |
|---|---|---|
| Percentage Difference of Participants Achieving Seroresponse (E4b) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants: Phase 3 | 99.5 (97.4 to 100.0) | 94.0 (89.9 to 96.7) |
Percentage difference of participants achieving seroresponse for SA variant NT comparison of 1 Month after second booster dose to 1 Month after Dose 2 of BNT162b2 in participants assigned to receive 2 booster doses of BNT162b2SA of Phase 3 were reported in this outcome measure.
| Percentage of participants | BNT162b2 (30 mcg): 1 Month After Second Booster Dose | BNT162b2 (30 mcg): 1 Month After Dose 2 |
|---|---|---|
| Percentage Difference of Participants Achieving Seroresponse for SA Variant NT Comparison of 1 Month After Second Booster Dose to 1 Month After Dose 2 of BNT162b2 in Participants Assigned to Receive 2 Booster Doses of BNT162b2SA: Phase 3 | 100.0 (87.2 to 100.0) | 100.0 (87.2 to 100.0) |
GMR of SA variant NT 1 month after second booster dose to 1 month after dose 2 of BNT162b2 in participants assigned to receive 2 booster doses of BNT1612b2SA were reported in this outcome measure.
| Titer | BNT162b2 (30 mcg): 1 Month After Second Booster Dose | BNT162b2 (30 mcg): 1 Month After Dose 2 |
|---|---|---|
| GMR of SA Variant NT 1 Month After Second Booster Dose to 1 Month After Dose 2 of BNT162b2 in Participants Assigned to Receive 2 Booster Doses of BNT1612b2SA: Phase 3 | 4981.2 (3690.8 to 6722.8) | 1076.5 (854.5 to 1356.1) |
Percentage difference of participants achieving seroresponse for SA variant NT: BNT162b2-experienced participants without evidence of infection up to 1 month after booster dose who were rerandomized to receive 1 booster dose were reported in this outcome measure.
| Percentage of participants | BNT162b2SA (30 mcg) | BNT162b2 (30 mcg) |
|---|---|---|
| Percentage Difference of Participants Achieving Seroresponse for SA Variant NT: BNT162b2-Experienced Participants Without Evidence of Infection up to 1 Month After Booster Dose Who Were Rerandomized to Receive 1 Booster Dose: Phase 3 | 99.2 (97.3 to 99.9) | 99.6 (97.7 to 100.0) |
GMR of SA Variant NT: BNT162b2-experienced participants without evidence of infection up to 1 month after booster dose who were rerandomized to receive 1 booster dose were reported in this outcome measure.
| Titer | BNT162b2SA (30 mcg) | BNT162b2 (30 mcg) |
|---|---|---|
| GMR of SA Variant NT: BNT162b2-Experienced Participants Without Evidence of Infection up to 1 Month After Booster Dose Who Were Rerandomized to Receive 1 Booster Dose: Phase 3 | 3536.4 (3131.3 to 3994.0) | 2453.0 (2190.0 to 2747.7) |
Collected over AEs: From Dose 1 to 1 Month after each dose (up to a maximum of 2 years); SAEs: From Dose 1 to 6 Months after each dose (up to a maximum of 2 years); Local reactions/systemic events: Within 7 days after each dose. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PC Fup Period - Ph1 - BNT162b1 10 mcg | 0/24 (0%) | 0/24 (0%) | 23/24 (95.8%) |
| PC Fup Period - Ph1 - BNT162b1 20 mcg | 0/24 (0%) | 0/24 (0%) | 23/24 (95.8%) |
| PC Fup Period - Ph1 - BNT162b1 30 mcg | 0/24 (0%) | 0/24 (0%) | 23/24 (95.8%) |
| PC Fup Period - Ph1 - BNT162b1 100 mcg | 0/12 (0%) | 0/12 (0%) | 12/12 (100%) |
| PC Fup Period - Ph1 - BNT162b2 10 mcg | 0/24 (0%) | 0/24 (0%) | 18/24 (75%) |
| PC Fup Period - Ph1 - BNT162b2 20 mcg | 0/24 (0%) | 1/24 (4.2%) | 22/24 (91.7%) |
| PC Fup Period - Ph1 - BNT162b2 30 mcg | 0/24 (0%) | 1/24 (4.2%) | 23/24 (95.8%) |
| OL Fup Period - Ph1 - Placebo/BNT162b2 30 mcg | 0/35 (0%) | 0/35 (0%) | 7/35 (20%) |
| PC Fup Period - Ph1 - Placebo | 0/39 (0%) | 0/39 (0%) | 24/39 (61.5%) |
| PC Fup Period - Ph2/3 Sub >=16 YOA (Final) - Placebo | 23/22,012 (0.1%) | 293/22,012 (1.3%) | 3,848/22,012 (17.5%) |
| PC Fup Period - Ph2/3 Sub >=16 YOA (Final) - BNT162b2 (30 mcg) | 61/22,010 (0.3%) | 430/22,010 (2%) | 9,587/22,010 (43.6%) |
| OL Fup Period - Ph2/3 Sub >=16 YOA (Final) - Pla/B2 (30 mcg) | 38/20,357 (0.2%) | 354/20,357 (1.7%) | 5,446/20,357 (26.8%) |
| PC Fup Period - Ph3 Sub 12-15 YOA - Placebo | 0/1,129 (0%) | 2/1,129 (0.2%) | 760/1,129 (67.3%) |
| PC Fup Period - Ph3 Sub 12-15 YOA - BNT162b2 (30 mcg) | 0/1,131 (0%) | 13/1,131 (1.1%) | 1,091/1,131 (96.5%) |
| OL Fup Period - Ph3 Sub 12-15 YOA - Placebo/BNT162b2 (30 mcg) | 1/1,014 (0.1%) | 13/1,014 (1.3%) | 238/1,014 (23.5%) |
| Ph2/3 - Subjects Who Are Part of PA 18 - BNT162b2 (30 mcg) | 47/23,403 (0.2%) | 69/23,403 (0.3%) | 3,326/23,403 (14.2%) |
| Add Booster for 1 Booster Dose Sub - BNT162b2 (30 mcg) | 0/381 (0%) | 1/381 (0.3%) | 27/381 (7.1%) |
| Add Booster for 2 Booster Doses Sub - BNT162b2 (30 mcg) | 0/15 (0%) | 0/15 (0%) | 1/15 (6.7%) |
| Add Booster for Low Dose Booster Sub - BNT162b2 (30 mcg) | 0/71 (0%) | 0/71 (0%) | 1/71 (1.4%) |
| Naive Sub Received Booster Dose (PA 18) - BNT162b2 (30 mcg) | 0/242 (0%) | 0/242 (0%) | 23/242 (9.5%) |
| Sub Assigned to 2 Booster Doses - BNT162b2SA (30 mcg, 2 Doses) | 0/30 (0%) | 1/30 (3.3%) | 26/30 (86.7%) |
| Sub Rerand to 1 Booster Dose - BNT162b2 (30 mcg) | 0/306 (0%) | 2/306 (0.7%) | 263/306 (85.9%) |
| Sub Rerand to Receive 1 Booster Dose - BNT162b2SA (30 mcg) | 0/318 (0%) | 2/318 (0.6%) | 270/318 (84.9%) |
| BNT162b2-Naive Subjects / BNT162b2SA (30 mcg) | 0/330 (0%) | 4/330 (1.2%) | 309/330 (93.6%) |
| Sub Rerand to Receive 1 Booster Dose - BNT162b2 (5 mcg) | 0/79 (0%) | 1/79 (1.3%) | 47/79 (59.5%) |
| Sub Rerand to Receive 1 Booster Dose - BNT162b2 (10 mcg) | 0/76 (0%) | 0/76 (0%) | 64/76 (84.2%) |
| PC Fup Period - Ph2 - BNT162b2 (30 mcg) | 2/180 (1.1%) | 1/180 (0.6%) | 166/180 (92.2%) |
| PC Fup Period - Ph2 - Placebo | 0/180 (0%) | 0/180 (0%) | 100/180 (55.6%) |
| Event | PC Fup Period - Ph1 - BNT162b1 10 mcg | PC Fup Period - Ph1 - BNT162b1 20 mcg | PC Fup Period - Ph1 - BNT162b1 30 mcg | PC Fup Period - Ph1 - BNT162b1 100 mcg | PC Fup Period - Ph1 - BNT162b2 10 mcg | PC Fup Period - Ph1 - BNT162b2 20 mcg | PC Fup Period - Ph1 - BNT162b2 30 mcg | OL Fup Period - Ph1 - Placebo/BNT162b2 30 mcg | PC Fup Period - Ph1 - Placebo | PC Fup Period - Ph2/3 Sub >=16 YOA (Final) - Placebo | PC Fup Period - Ph2/3 Sub >=16 YOA (Final) - BNT162b2 (30 mcg) | OL Fup Period - Ph2/3 Sub >=16 YOA (Final) - Pla/B2 (30 mcg) | PC Fup Period - Ph3 Sub 12-15 YOA - Placebo | PC Fup Period - Ph3 Sub 12-15 YOA - BNT162b2 (30 mcg) | OL Fup Period - Ph3 Sub 12-15 YOA - Placebo/BNT162b2 (30 mcg) | Ph2/3 - Subjects Who Are Part of PA 18 - BNT162b2 (30 mcg) | Add Booster for 1 Booster Dose Sub - BNT162b2 (30 mcg) | Add Booster for 2 Booster Doses Sub - BNT162b2 (30 mcg) | Add Booster for Low Dose Booster Sub - BNT162b2 (30 mcg) | Naive Sub Received Booster Dose (PA 18) - BNT162b2 (30 mcg) | Sub Assigned to 2 Booster Doses - BNT162b2SA (30 mcg, 2 Doses) | Sub Rerand to 1 Booster Dose - BNT162b2 (30 mcg) | Sub Rerand to Receive 1 Booster Dose - BNT162b2SA (30 mcg) | BNT162b2-Naive Subjects / BNT162b2SA (30 mcg) | Sub Rerand to Receive 1 Booster Dose - BNT162b2 (5 mcg) | Sub Rerand to Receive 1 Booster Dose - BNT162b2 (10 mcg) | PC Fup Period - Ph2 - BNT162b2 (30 mcg) | PC Fup Period - Ph2 - Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AppendicitisInfections and infestations | 0/24 | 0/24 | 0/24 | 0/12 | 0/24 | 1/24 | 0/24 | 0/35 | 0/39 | 9/22012 | 17/22010 | 1/20357 | 2/1129 | 1/1131 | 2/1014 | 3/23403 | 0/381 | 0/15 | 0/71 | 0/242 | 1/30 | 0/306 | 0/318 | 0/330 | 0/79 | 0/76 | 0/180 | 0/180 |
| NeuritisNervous system disorders | 0/24 | 0/24 | 0/24 | 0/12 | 0/24 | 0/24 | 1/24 | 0/35 | 0/39 | 0/22012 | 0/22010 | 0/20357 | 0/1129 | 0/1131 | 0/1014 | 0/23403 | 0/381 | 0/15 | 0/71 | 0/242 | 0/30 | 0/306 | 0/318 | 0/330 | 0/79 | 0/76 | 0/180 | 0/180 |
| Back painMusculoskeletal and connective tissue disorders | 0/24 | 0/24 | 0/24 | 0/12 | 0/24 | 0/24 | 0/24 | 0/35 | 0/39 | 0/22012 | 1/22010 | 1/20357 | 0/1129 | 0/1131 | 0/1014 | 1/23403 | 0/381 | 0/15 | 0/71 | 0/242 | 0/30 | 0/306 | 0/318 | 0/330 | 1/79 | 0/76 | 0/180 | 0/180 |
| Adenocarcinoma gastricNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/24 | 0/24 | 0/24 | 0/12 | 0/24 | 0/24 | 0/24 | 0/35 | 0/39 | 0/22012 | 1/22010 | 0/20357 | 0/1129 | 0/1131 | 0/1014 | 0/23403 | 0/381 | 0/15 | 0/71 | 0/242 | 0/30 | 0/306 | 0/318 | 0/330 | 0/79 | 0/76 | 1/180 | 0/180 |
| Suicidal ideationPsychiatric disorders | 0/24 | 0/24 | 0/24 | 0/12 | 0/24 | 0/24 | 0/24 | 0/35 | 0/39 | 2/22012 | 0/22010 | 5/20357 | 0/1129 | 4/1131 | 1/1014 | 1/23403 | 0/381 | 0/15 | 0/71 | 0/242 | 0/30 | 0/306 | 0/318 | 0/330 | 0/79 | 0/76 | 0/180 | 0/180 |
| Acute myocardial infarctionCardiac disorders | 0/24 | 0/24 | 0/24 | 0/12 | 0/24 | 0/24 | 0/24 | 0/35 | 0/39 | 3/22012 | 13/22010 | 6/20357 | 0/1129 | 0/1131 | 0/1014 | 0/23403 | 0/381 | 0/15 | 0/71 | 0/242 | 0/30 | 1/306 | 0/318 | 0/330 | 0/79 | 0/76 | 0/180 | 0/180 |
| Ovarian cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/24 | 0/24 | 0/24 | 0/12 | 0/24 | 0/24 | 0/24 | 0/35 | 0/39 | 0/22012 | 0/22010 | 1/20357 | 0/1129 | 0/1131 | 0/1014 | 0/23403 | 0/381 | 0/15 | 0/71 | 0/242 | 0/30 | 1/306 | 0/318 | 0/330 | 0/79 | 0/76 | 0/180 | 0/180 |
| Kidney infectionInfections and infestations | 0/24 | 0/24 | 0/24 | 0/12 | 0/24 | 0/24 | 0/24 | 0/35 | 0/39 | 0/22012 | 0/22010 | 1/20357 | 0/1129 | 0/1131 | 0/1014 | 0/23403 | 0/381 | 0/15 | 0/71 | 0/242 | 0/30 | 0/306 | 1/318 | 0/330 | 0/79 | 0/76 | 0/180 | 0/180 |
| Deep vein thrombosisVascular disorders | 0/24 | 0/24 | 0/24 | 0/12 | 0/24 | 0/24 | 0/24 | 0/35 | 0/39 | 4/22012 | 4/22010 | 4/20357 | 0/1129 | 0/1131 | 0/1014 | 0/23403 | 0/381 | 0/15 | 0/71 | 0/242 | 0/30 | 0/306 | 1/318 | 0/330 | 0/79 | 0/76 | 0/180 | 0/180 |
| Eosinophilic oesophagitisGastrointestinal disorders | 0/24 | 0/24 | 0/24 | 0/12 | 0/24 | 0/24 | 0/24 | 0/35 | 0/39 | 0/22012 | 0/22010 | 0/20357 | 0/1129 | 0/1131 | 0/1014 | 0/23403 | 0/381 | 0/15 | 0/71 | 0/242 | 0/30 | 0/306 | 0/318 | 1/330 | 0/79 | 0/76 | 0/180 | 0/180 |
| Event | PC Fup Period - Ph1 - BNT162b1 10 mcg | PC Fup Period - Ph1 - BNT162b1 20 mcg | PC Fup Period - Ph1 - BNT162b1 30 mcg | PC Fup Period - Ph1 - BNT162b1 100 mcg | PC Fup Period - Ph1 - BNT162b2 10 mcg | PC Fup Period - Ph1 - BNT162b2 20 mcg | PC Fup Period - Ph1 - BNT162b2 30 mcg | OL Fup Period - Ph1 - Placebo/BNT162b2 30 mcg | PC Fup Period - Ph1 - Placebo | PC Fup Period - Ph2/3 Sub >=16 YOA (Final) - Placebo | PC Fup Period - Ph2/3 Sub >=16 YOA (Final) - BNT162b2 (30 mcg) | OL Fup Period - Ph2/3 Sub >=16 YOA (Final) - Pla/B2 (30 mcg) | PC Fup Period - Ph3 Sub 12-15 YOA - Placebo | PC Fup Period - Ph3 Sub 12-15 YOA - BNT162b2 (30 mcg) | OL Fup Period - Ph3 Sub 12-15 YOA - Placebo/BNT162b2 (30 mcg) | Ph2/3 - Subjects Who Are Part of PA 18 - BNT162b2 (30 mcg) | Add Booster for 1 Booster Dose Sub - BNT162b2 (30 mcg) | Add Booster for 2 Booster Doses Sub - BNT162b2 (30 mcg) | Add Booster for Low Dose Booster Sub - BNT162b2 (30 mcg) | Naive Sub Received Booster Dose (PA 18) - BNT162b2 (30 mcg) | Sub Assigned to 2 Booster Doses - BNT162b2SA (30 mcg, 2 Doses) | Sub Rerand to 1 Booster Dose - BNT162b2 (30 mcg) | Sub Rerand to Receive 1 Booster Dose - BNT162b2SA (30 mcg) | BNT162b2-Naive Subjects / BNT162b2SA (30 mcg) | Sub Rerand to Receive 1 Booster Dose - BNT162b2 (5 mcg) | Sub Rerand to Receive 1 Booster Dose - BNT162b2 (10 mcg) | PC Fup Period - Ph2 - BNT162b2 (30 mcg) | PC Fup Period - Ph2 - Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Injection site pain (PAIN)General disorders | 19/24 | 23/24 | 23/24 | 12/12 | 15/24 | 19/24 | 23/24 | 0/35 | 8/39 | 861/22012 | 4200/22010 | 0/20357 | 341/1129 | 1023/1131 | 0/1014 | 0/23403 | 0/381 | 0/15 | 0/71 | 0/242 | 23/30 | 240/306 | 250/318 | 285/330 | 33/79 | 52/76 | 156/180 | 26/180 |
| Headache (HEADACHE)Nervous system disorders | 15/24 | 18/24 | 21/24 | 9/12 | 11/24 | 10/24 | 13/24 | 0/35 | 8/39 | 1741/22012 | 2836/22010 | 0/20357 | 506/1129 | 854/1131 | 0/1014 | 0/23403 | 0/381 | 0/15 | 0/71 | 0/242 | 18/30 | 140/306 | 158/318 | 190/330 | 18/79 | 29/76 | 95/180 | 54/180 |
| Chills (CHILLS)General disorders | 7/24 | 15/24 | 14/24 | 10/12 | 3/24 | 8/24 | 10/24 | 0/35 | 3/39 | 389/22012 | 1723/22010 | 0/20357 | 159/1129 | 557/1131 | 0/1014 | 0/23403 | 0/381 | 0/15 | 0/71 | 0/242 | 14/30 | 84/306 | 110/318 | 102/330 | 8/79 | 17/76 | 61/180 | 9/180 |
| Fatigue (FATIGUE)General disorders | 14/24 | 18/24 | 20/24 | 10/12 | 8/24 | 14/24 | 15/24 | 0/35 | 17/39 | 1779/22012 | 3217/22010 | 0/20357 | 538/1129 | 876/1131 | 0/1014 | 0/23403 | 0/381 | 0/15 | 0/71 | 0/242 | 22/30 | 184/306 | 209/318 | 248/330 | 25/79 | 41/76 | 117/180 | 67/180 |
| Myalgia (MUSCLE PAIN)Musculoskeletal and connective tissue disorders | 9/24 | 16/24 | 14/24 | 7/12 | 6/24 | 7/24 | 11/24 | 0/35 | 3/39 | 706/22012 | 1997/22010 | 0/20357 | 196/1129 | 477/1131 | 0/1014 | 0/23403 | 0/381 | 0/15 | 0/71 | 0/242 | 14/30 | 113/306 | 115/318 | 121/330 | 13/79 | 14/76 | 76/180 | 15/180 |
| Pyrexia (FEVER)General disorders | 1/24 | 8/24 | 15/24 | 6/12 | 0/24 | 1/24 | 5/24 | 0/35 | 0/39 | 0/22012 | 758/22010 | 0/20357 | 17/1129 | 275/1131 | 0/1014 | 0/23403 | 0/381 | 0/15 | 0/71 | 0/242 | 5/30 | 25/306 | 28/318 | 15/330 | 0/79 | 2/76 | 27/180 | 0/180 |
| Arthralgia (JOINT PAIN)Musculoskeletal and connective tissue disorders | 8/24 | 10/24 | 6/24 | 3/12 | 2/24 | 1/24 | 4/24 | 0/35 | 2/39 | 453/22012 | 1245/22010 | 0/20357 | 107/1129 | 229/1131 | 0/1014 | 0/23403 | 0/381 | 0/15 | 0/71 | 0/242 | 13/30 | 73/306 | 68/318 | 75/330 | 1/79 | 12/76 | 34/180 | 13/180 |
| Injection site swelling (SWELLING)General disorders | 1/24 | 6/24 | 8/24 | 5/12 | 2/24 | 0/24 | 0/24 | 0/35 | 0/39 | 0/22012 | 554/22010 | 0/20357 | 13/1129 | 104/1131 | 0/1014 | 0/23403 | 0/381 | 0/15 | 0/71 | 0/242 | 0/30 | 23/306 | 20/318 | 23/330 | 1/79 | 3/76 | 21/180 | 0/180 |
| Injection site erythema (REDNESS)General disorders | 0/24 | 1/24 | 4/24 | 4/12 | 0/24 | 0/24 | 1/24 | 0/35 | 0/39 | 0/22012 | 491/22010 | 0/20357 | 18/1129 | 97/1131 | 0/1014 | 0/23403 | 0/381 | 0/15 | 0/71 | 0/242 | 0/30 | 17/306 | 15/318 | 23/330 | 1/79 | 0/76 | 14/180 | 1/180 |
| Diarrhoea (DIARRHEA)Gastrointestinal disorders | 3/24 | 3/24 | 3/24 | 4/12 | 0/24 | 1/24 | 1/24 | 0/35 | 2/39 | 674/22012 | 766/22010 | 0/20357 | 106/1129 | 141/1131 | 0/1014 | 0/23403 | 0/381 | 0/15 | 0/71 | 0/242 | 4/30 | 25/306 | 29/318 | 42/330 | 4/79 | 5/76 | 41/180 | 29/180 |
Safety Analysis Set included randomized participants who received at least 1 dose of the study intervention.
| Age, Customized(Participants) | Phase 1: BNT162b1 10 mcg Dose: 18-85 Years of Age | Phase 1: BNT162b1 20 mcg Dose:18-85 Years of Age | Phase 1: BNT162b1 30 mcg Dose:18-85 Years of Age | Phase 1: BNT162b1 100 mcg Dose:18-55 Years of Age | Phase 1: Placebo: 18-85 Years of Age | Phase 1: BNT162b2 10 mcg Dose: 18-85 Years of Age | Phase 1: BNT162b2 20 mcg Dose: 18-85 Years of Age | Phase 1: BNT162b2 30 mcg Dose: 18-85 Years of Age | Phase 2/3: BNT162b2 (30 mcg): >=16 Years of Age | Phase 2/3: Placebo: >=16 Years of Age | Phase 2/3: BNT162b2 30mcg: 12-15 Years of Age | Phase 2/3: Placebo: 12-15 Years of Age | Phase 3: BNT162b2 SA 30 mcg: 18-55 Years of Age | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 378 | 377 | 1134 | 1130 | 0 | 3019 |
| Between 18 and 65 years | 12 | 12 | 12 | 12 | 21 | 12 | 12 | 12 | 17130 | 17141 | 0 | 0 | 333 | 34709 |
| >=65 years | 12 | 12 | 12 | 0 | 18 | 12 | 12 | 12 | 4563 | 4553 | 0 | 0 | 0 | 9206 |
| Sex: Female, Male(Participants) | Phase 1: BNT162b1 10 mcg Dose: 18-85 Years of Age | Phase 1: BNT162b1 20 mcg Dose:18-85 Years of Age | Phase 1: BNT162b1 30 mcg Dose:18-85 Years of Age | Phase 1: BNT162b1 100 mcg Dose:18-55 Years of Age | Phase 1: Placebo: 18-85 Years of Age | Phase 1: BNT162b2 10 mcg Dose: 18-85 Years of Age | Phase 1: BNT162b2 20 mcg Dose: 18-85 Years of Age | Phase 1: BNT162b2 30 mcg Dose: 18-85 Years of Age | Phase 2/3: BNT162b2 (30 mcg): >=16 Years of Age | Phase 2/3: Placebo: >=16 Years of Age | Phase 2/3: BNT162b2 30mcg: 12-15 Years of Age | Phase 2/3: Placebo: 12-15 Years of Age | Phase 3: BNT162b2 SA 30 mcg: 18-55 Years of Age | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 13 | 11 | 14 | 7 | 22 | 17 | 13 | 15 | 10724 | 10952 | 564 | 544 | 160 | 23056 |
| Male | 11 | 13 | 10 | 5 | 17 | 7 | 11 | 9 | 11347 | 11119 | 570 | 586 | 173 | 23878 |
| Ethnicity (NIH/OMB)(Participants) | Phase 1: BNT162b1 10 mcg Dose: 18-85 Years of Age | Phase 1: BNT162b1 20 mcg Dose:18-85 Years of Age | Phase 1: BNT162b1 30 mcg Dose:18-85 Years of Age | Phase 1: BNT162b1 100 mcg Dose:18-55 Years of Age | Phase 1: Placebo: 18-85 Years of Age | Phase 1: BNT162b2 10 mcg Dose: 18-85 Years of Age | Phase 1: BNT162b2 20 mcg Dose: 18-85 Years of Age | Phase 1: BNT162b2 30 mcg Dose: 18-85 Years of Age | Phase 2/3: BNT162b2 (30 mcg): >=16 Years of Age | Phase 2/3: Placebo: >=16 Years of Age | Phase 2/3: BNT162b2 30mcg: 12-15 Years of Age | Phase 2/3: Placebo: 12-15 Years of Age | Phase 3: BNT162b2 SA 30 mcg: 18-55 Years of Age | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 5716 | 5710 | 132 | 130 | 42 | 11735 |
| Not Hispanic or Latino | 23 | 24 | 22 | 12 | 38 | 23 | 23 | 24 | 16281 | 16261 | 1000 | 997 | 288 | 35016 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 74 | 100 | 2 | 3 | 3 | 183 |
| Race (NIH/OMB)(Participants) | Phase 1: BNT162b1 10 mcg Dose: 18-85 Years of Age | Phase 1: BNT162b1 20 mcg Dose:18-85 Years of Age | Phase 1: BNT162b1 30 mcg Dose:18-85 Years of Age | Phase 1: BNT162b1 100 mcg Dose:18-55 Years of Age | Phase 1: Placebo: 18-85 Years of Age | Phase 1: BNT162b2 10 mcg Dose: 18-85 Years of Age | Phase 1: BNT162b2 20 mcg Dose: 18-85 Years of Age | Phase 1: BNT162b2 30 mcg Dose: 18-85 Years of Age | Phase 2/3: BNT162b2 (30 mcg): >=16 Years of Age | Phase 2/3: Placebo: >=16 Years of Age | Phase 2/3: BNT162b2 30mcg: 12-15 Years of Age | Phase 2/3: Placebo: 12-15 Years of Age | Phase 3: BNT162b2 SA 30 mcg: 18-55 Years of Age | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 222 | 217 | 4 | 3 | 0 | 446 |
| Asian | 3 | 0 | 4 | 1 | 1 | 1 | 0 | 2 | 951 | 947 | 72 | 71 | 26 | 2079 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 53 | 31 | 3 | 0 | 0 | 87 |
| Black or African American | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 2098 | 2121 | 52 | 57 | 40 | 4372 |
| White | 20 | 22 | 20 | 11 | 38 | 23 | 24 | 21 | 18090 | 18103 | 973 | 963 | 261 | 38569 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 580 | 540 | 24 | 29 | 4 | 1177 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 77 | 112 | 6 | 7 | 2 | 204 |
Showing the first 100 of 175 sites across 6 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2020 to primary completion in Feb 2023, 33 months.
Results were first posted in Mar 2026, 3 years 1 month after primary completion.
Of 73 industry-sponsored phase 2/3 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's 33 months is above that.
Counting every sponsor, half of 168 studies reached it within 11 months; a quarter within 5 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BNT162 Vaccine